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Human pluripotent stem cells (hPSC), including human embryonic stem cells 
(hESC) and human induced pluripotent stem cells (hiPSC), have the ability to 
self-renew and under appropriate conditions differentiate into all three germ 
layers. The potential use of hPSC for regenerative medicine has been 
promising because of successful in vitro differentiation to lineage-specific cell 
types and more recently, approval for clinical trials. However, a major concern 
is the risk of teratoma formation from residual hPSC. Several strategies have 
been reported to eliminate residual hPSC, including cell sorting using specific 
antibodies, transgenic fluorescent markers, and physical properties such as cell 
adherence or density gradient centrifugation; and retrospective approaches 
with genetic manipulation like gene interference or introduction of “suicide 
gene”. However, none is capable of completely precluding residual hPSC. Our 
group previously reported the first hESC-specific cytotoxic monoclonal 
antibody (mAb), mAb84. Subsequently, others reported the use of cytotoxic 
small molecules inhibiting oleate synthesis or anti-apoptotic factors. However, 
these small molecules may have non-specific effects on differentiated cell. 
More recently, we identified another hESC-specific cytotoxic mAb, TAG-A1 
(A1). A1 is cytotoxic to hPSC but not differentiated cells and its cytotoxicity 
and killing kinetics on hPSC is comparable to mAb84. However, unlike 
mAb84 which is an IgM, A1 is an IgG and thus have better penetration 
efficiency into embryoid bodies (EB). Additional characterization revealed 
that A1 kills hPSC within 5 minutes in a dosage-dependent manner and must 
be minimally bivalent to exert its effect.  A1 binds to an O-linked glycan 





 A1 molecules per hESC.  In SCID mouse models, treatment of hESC in 
vitro or in vivo with A1 prevented/delayed teratoma formation up to 10 weeks 
post-injection unlike non-treated mice which formed grade 3 teratomas by 
week 6. Moreover, in vitro treatment with F(ab)2_A1 also prevented/delayed 
teratoma formation, suggesting that killing is independent of the Fc region. 
Mechanistically, A1 kills hPSC via oncosis and not apoptosis. Hallmarks of 
oncosis include rapid killing rate, cell and mitochondria swelling, and severe 
plasma membrane damage.  By scanning electron microscopy, membrane 
pores were observed following A1 treatment and A1 was predominantly 
localised on fused debris of microvilli and damaged plasma membrane.  
Hence, we proposed that A1 kills via receptor dimerization-initiated signalling 
pathway where the microvilli are likely the signal initiating sites. 
In addition, A1-treated hPSC exhibited microvilli degradation, homotypic 
adhesion, and actin re-organization. More importantly, excess reactive oxygen 
species (ROS), specifically superoxide, was produced upon A1 treatment and 
critical for inducing hPSC death. The source of ROS was nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase, most likely Nox2 isoform 
and this occurs downstream of microvilli degradation and homotypic 
adhesion, but upstream of massive actin re-organization, mitochondria 
impairment and plasma membrane damage. Taken together, we presented A1 
as an effective tool to increase the safety of hPSC-based therapy and proposed 
for the first time a mechanistic model of antibody-induced oncosis on hESC 
revealing a previously unrecognized role for NADPH oxidase-derived ROS in 
mediating oncotic hESC death.  
XI 
 
LIST OF TABLES 
Table 2-1: Overview of methods to prevent hPSC tumorigenicity. .......................................... 13 
Table 2-2: Hallmarks of apoptosis and their respective assays. ............................................... 18 
Table 2-3: Hallmarks of oncosis and their respective assays. ................................................... 20 
Table 2-4: Cytotoxic antibodies induced cell death. .................................................................. 20 
Table 3-1: Sequences of specific primers used in qRT-PCR for markers of pluripotency, 
endoderm, mesoderm and ectoderm. .......................................................................................... 52 
Table 6-1: Different hallmarks of apoptosis and oncosis. ......................................................... 94 






LIST OF FIGURES 
Figure 2-1: Derivation of a hESC line, and differentiation into various cell types
35
. ............... 5 
Figure 2-2: Reprogrammed hiPSC from differentiated somatic cells
37
. .................................... 6 
Figure 2-3: Schematic view of the relationship between apoptosis, oncosis and necrosis
83
. .. 16 
Figure 2-4: Extrinsic (ligand-receptor mediated) and intrinsic (mitochondria-mediated) 
apoptotic pathways
90
. ................................................................................................................... 17 
Figure 2-5: Antibody-induced apoptosis via TNF receptor activation
102
. ............................... 23 
Figure 2-6: RE2-induced T cell oncosis
71
. .................................................................................. 24 
Figure 2-7: Anti-Porimin-induced Jurkat cells oncosis
72
. ......................................................... 25 
Figure 2-8: RAV12-induced COLO 205 colon tumour cells oncosis
77
. .................................... 26 
Figure 2-9: Anti-NGcGM3 14F7-induced L1210 murine tumour cell oncosis
79
. .................... 28 
Figure 2-10: mAb84-induced human embryonic stem cell (hESC) oncosis
34
. ......................... 29 
Figure 2-11: Involvement of microvilli in GA101-induced B lymphoma cells homotypic 
adhesion
74
. ..................................................................................................................................... 30 
Figure 2-12: GA101-induced B lymphoma cell oncosis
75,76
. ...................................................... 31 
Figure 3-1: Equation to calculate the number of A1 molecules per hESC from the mass 
of unbound A1. ............................................................................................................................. 40 
Figure 4-1: Generation of monoclonal antibodies against hESC surface markers by 
hybridoma formation. .................................................................................................................. 56 
Figure 4-2: A1 binds to and kills both undifferentiated hESC and hiPSC. ............................. 57 
Figure 4-3: A1 loss binding and cytotoxicity on hESC-derived EB. ........................................ 59 
Figure 4-4: A1 loss binding and cytotoxicity on differentiated hESC via FGF-2 
starvation. ..................................................................................................................................... 60 
Figure 4-5: A1 cytotoxicity on hESC is dosage-dependent. ...................................................... 61 
Figure 4-6: A1 kill hESC rapidly within 5 minutes of incubation. ........................................... 61 
Figure 4-7: kinetics of A1 cytotoxicity on hESC is not dosage-dependent. ............................. 62 
Figure 4-8: A1 binds to multiple glycoproteins on hESC.......................................................... 64 
Figure 4-9: A1 recognizes O-linked glycans on target antigens from hESC lysate. ............... 66 
Figure 4-10: Partial inhibition of N-glycosylation and O-glycosylation by tunicamycin 
and Benzyl-α-GalNac treatment. ................................................................................................ 67 
Figure 4-11: Expression of pluripotency marker, Oct3/4, was verified upon inhibitors 
treatment. ...................................................................................................................................... 68 
XIII 
 
Figure 4-12: A1 binding to hESC was down-regulated upon B-GalNac treatment ................ 69 
Figure 4-13: A1 cytotoxicity on hESC was down-regulated upon B-GalNac treatment ........ 70 
Figure 4-14: There is no difference in the relative RNA expression level of listed markers 
between DMSO control and B-GalNac treatment. .................................................................... 71 
Figure 4-15: Structures of the nine sugars used in the sugar inhibition assay
121
. ................... 72 
Figure 4-16: A1 binding on hESC was blocked by LNFP1, H1 and LewisB. .......................... 73 
Figure 4-17: Binding profile of sugar-blocked A1 on hESC. .................................................... 73 
Figure 4-18: A1 cytotoxicity on hESC was blocked by LNFP1, H1 and LewisB. ................... 74 
Figure 4-19: Differences in the CDRs amino acids sequences between A1 and mAb84. ........ 75 
Figure 4-20: There is no competitive inhibition between A1 and mAb84. .............................. 76 
Figure 4-21: A1 showed better penetration efficiency into hESC-derived EB than mAb84.
 ........................................................................................................................................................ 77 
Figure 4-22: Brief illustration of the ELISA working principle. .............................................. 78 
Figure 4-23: The standard curve of ELISA. .............................................................................. 79 
Figure 4-24: A1 binding and killing on hESC at different initial concentration. ................... 79 
Figure 4-25: The relationship between the amount of unbound A1 and bound A1 in the 
stoichiometry assay and corresponding A1 killing on hESC at different initial amount of 
A1. .................................................................................................................................................. 80 
Figure 4-26: Determination of pore size with 40 kDa, 70 kDa and 2000 kDa dextran 
beads respectively. ........................................................................................................................ 81 
Figure 4-27: Sites of cleavage to generate Fab and F(ab)2 by papain and IdeS 
respectively
130
 ................................................................................................................................ 83 
Figure 4-28: Size of digested antibody fragments. ..................................................................... 84 
Figure 4-29: Fc_A1 in the digestion mixture does not bind to hESC ....................................... 85 
Figure 4-30: Bivalency of A1 is essential for its cytotoxicity on hESC, but not binding ........ 86 
Figure 5-1: Prevented or delayed teratoma formation with in vitro A1 treatment. ................ 90 
Figure 5-2: Prevented or delayed teratoma formation with in vivo A1 treatment. ................. 92 
Figure 6-1: Degree of DNA fragmentation measured in TUNEL assay by flow cytometry. .. 95 
Figure 6-2: Measured caspases activity and cell death by flow cytometry. ............................. 96 
Figure 6-3: Dynamics of A1-treated hESC in culture under Confocal Microscopy. .............. 98 
Figure 6-4: Morphology of a non-treated hESC under TEM. .................................................. 99 
Figure 6-5: Morphological changes of A1-treated hESC under TEM. .................................. 100 
Figure 6-6: Morphology of non-treated hESC under SEM. ................................................... 101 
XIV 
 
Figure 6-7: Morphological changes of A1-treated hESC at stage 1 under SEM. ................. 102 
Figure 6-8: Morphological changes of A1-treated hESC at stage 2 under SEM. ................. 102 
Figure 6-9: Morphological changes of A1-treated hESC at stage 3 under SEM. ................. 103 
Figure 6-10: Morphological changes of A1-treated hESC at stage 2 under SEM. ............... 104 
Figure 6-11: Non-treated hESC under immuno-SEM. ........................................................... 106 
Figure 6-12: A1 binding pattern was not correlated with plasma membrane damage. ....... 107 
Figure 6-13: Correlation between A1 aggregates and membrane debris. ............................. 108 
Figure 6-14: A1 bound to surface microvilli of hESC. ............................................................ 109 
Figure 6-15: Bivalent A1 and F(ab)2_A1 can induce hESC homotypic adhesion. ................ 110 
Figure 6-16: A1 treatment induced reduction of actin-associated proteins. ......................... 111 
Figure 6-17: Association between actin polymerization and A1 cytotoxicity on hESC. ....... 112 
Figure 6-18: Re-distribution of F-actin and G-actin in A1-treated hESC. ............................ 113 
Figure 6-19: A1-induced ROS production measured via HE staining by flow cytometry. .. 115 
Figure 6-20: A1-induced ROS production measured via carboxy-H2DCFDA staining by 
fluorescence microscopy. ........................................................................................................... 116 
Figure 6-21: A1-induced hESC death and ROS production were directly correlated. ........ 116 
Figure 6-22: ROS scavengers partially blocked A1-induced hESC death. ............................ 117 
Figure 6-23: Depletion of ROS production was directly correlated with decreased A1-
induced hESC death. .................................................................................................................. 118 
Figure 6-24: Isoforms of NADPH oxidases
168
. ......................................................................... 119 
Figure 6-25: Assembly and activation of Nox2-NADPH oxidase
164
 ....................................... 120 
Figure 6-26: Increased NADPH oxidase activity in A1-treated hESC. .................................. 121 
Figure 6-27: Inhibitors of NADPH oxidase can partially block A1-induced hESC death. .. 122 
Figure 6-28: Inhibition of ROS production was directly correlated with decreased A1-
induced hESC death. .................................................................................................................. 123 
Figure 6-29: Nox2 expression was partially down-regulated with siNox2. ............................ 124 
Figure 6-30: Expression of pluripotency marker Tra-1-60 of hESC was maintained upon 
siNox2 transfection. .................................................................................................................... 125 
Figure 6-31: A1 binding was not affected upon Nox2 knockdown. ........................................ 125 
Figure 6-32: A1 cytotoxicity on hESC was down-regulated upon Nox2 knockdown. .......... 126 
Figure 6-33: Expression of Nox1 and Nox3 in hESC. .............................................................. 127 
XV 
 
Figure 6-34: Nox3 was partially knockdown in hESC while hESC pluripotency was 
maintained. ................................................................................................................................. 127 
Figure 6-35: A1 cytotoxicity on hESC was not affected upon Nox3 knockdown. ................. 128 
Figure 6-36: A1 induced hESC mitochondrial impairment. ................................................... 129 
Figure 6-37: Mitochondrial depolarization was down-regulated upon Nox2 knockdown. .. 130 
Figure 6-38: ROS production occurs downstream of microvilli degradation, but 
upstream of severe plasma membrane damage. ...................................................................... 132 
Figure 6-39: ROS depletion by Tiron did not prevent A1-induced homotypic adhesion. .... 133 
Figure 6-40: Actin inhibitors treatment did not prevent A1 cytotoxicity on hESC in 
addition to Tiron treatment. ...................................................................................................... 133 
Figure 6-41: Treatment with actin inhibitors did not affect A1-induced ROS production. 134 
Figure 6-42: Mechanistic model of A1-induced hESC death. ................................................. 136 
Figure 7-1: Three well-studied pathways of Nox2-NADPH oxidase activation. ................... 146 
Figure 7-2: Role of phagocytosis and endocytosis in formation of endosomal and 
lysosomal membrane
194






LIST OF ABBREVIATIONS 
hPSC Human pluripotent stem cells 
hESC Human embryonic stem cells 
hiPSC Human induced pluripotent stem cells 
EB Embryoid bodies 
RPE Retinal pigment epithelium 
mAb Monoclonal antibody 
SCID Severe combined immunodeficient 
A1 mAb TAG-A1 
IgM Immunoglobulin M 
IgG Immunoglobulin G 
Fc Fragment, crystallisable 
ADCC Antibody-dependent cell-mediated cytotoxicity 
CDC Complement-dependent cytotoxicity 
Fab Fragment antigen-binding 
FGF-2 Fibroblast growth factor-2 
PD Parkinson’s disease 
FDA Food and Drug Administration 
SCD1 Stearoyl-coA desaturase 
FAC Fluorescence-activated cell sorting 
MAC Magnetic-activated cell sorting 
SSEA-5 Stage-specific embryonic antigen-5 
RA Retinoic acid 
PODXL Podocalyxin 
TK Thymidine kinase 
HPC Hematopoietic progenitor cells 
TNF Tumor necrosis factor 
FADD Fas associated death domain 
Apaf-1 Apoptosis protease activating factor  
SEM Scanning electron microscopy 
TEM Transmission electron microscopy 
TUNEL 
Terminal deoxynucleotidyl transferase mediated dUTP Nick 
End Labelling  
PI Propidium iodide 
EGFR Epidermal growth factor receptor 
SHH Sonic hedgehog 
SCCHN Squamous cell carcinoma of the head and neck  
MAP Mitogen activated protein  
APO-1 Apoptosis antigen 1 
NGcGM3 N-glycolyl GM3 ganglioside 
HA Homotypic adhesion 




NEAA Nonessential amino acids 
FBS Fetal bovine serum 
ELISA Enzyme-Linked ImmunoSorbent Assay 
OPD o-phenylenediamine dihydrochloride 
DPI Diphenyleneiodonium chloride 
APO Acetovanillone or Apocynin 




ESIMR90 human fetal lung fibroblasts-derived iPS cells 
MS Mass spectrometry 
ConA Concanavalin A 
B-GalNac Benzyl-α-GalNac 
LNFP1 Lacto-N-fucopentaose I 
H1 Type-1 H 
H2 Type-2 H 
bgA Type-1 A 
bgB  Type-1 B 
UV Ultra-violet 
SEM Standard error of mean 
OGT O-GlcNAc 
CDR Complementarity determining regions 
qRT-PCR Quantitative real-time PCR 
HSV Herpes simplex virus 
IM Intramuscular  
IV Intravenous 
FcRn Neonatal Fc receptor 
SOD Superoxide dismutase 
GEF Guanine nucleotide exchange factor 
GPCR G-protein coupled receptor 
RTK Receptor tyrosine kinase 
LMP Lysosome membrane permeabilization 








1 CHAPTER 1 INTRODUCTION 
1.1 Background 
Human pluripotent stem cells (hPSC), namely human embryonic stem cells 
(hESC) and human induced-pluripotent stem cells (hiPSC), are characterized 
by their unique abilities to replicate indefinitely (self-renewal) and under the 
appropriate conditions differentiate into derivatives of all three germ layers 
(pluripotency)
1,2
. Mounting studies have reported the successful differentiation 
of hPSC into embryoid bodies (EB)
3
















, and retinal pigment 
epithelium (RPE)
23,24
. Their successes demonstrate the great potential of hPSC 
in tissue engineering and regenerative medicine to treat various diseases such 
as diabetes, heart failure, Parkinson’s disease, degenerative eye diseases, and 
skeletal tissue injuries. Since 2009, several clinical trials have been approved 
to transplant hESC-derived oligodendrocytes, RPE, or beta cells for the 
treatment of spinal cord-injured patients
25
, Stargardt’s Macular Dystrophy and 







respectively. However, formation of teratomas or teratocarcinomas due to 
residual undifferentiated hPSC remains a major safety concern and can 
potentially impede the progress of hPSC-based therapies
29–31
.  
Previously, our group was the first to demonstrate the successful use of hESC-
specific cytotoxic monoclonal antibody (mAb), mAb84, in preventing 
teratoma formation in severe combined immunodeficient (SCID) mice
32
. 
However, since mAb84 is an IgM pentamer, its relatively large molecule size 
2 
 
may impede its penetration efficiency into tumour mass. Subsequently, the 
variable genes of mAb84 was cloned and reformatted as a single-chain Fv 
dimer, scFv84-HTH. The recombinant scFv84-HTH retained the binding 
properties of mAb84 but more importantly had improved penetration
33
. 
However, to achieve the same level of cytotoxicity on hESC, the amount of 
scFv84-HTH required is 20 times more than mAb84. Nevertheless, since 
mAb84 and scFv84-HTH are either multivalent or bivalent, the author 
speculated that antibody cytotoxicity is associated with its valency. 
Interestingly, from a subsequent panel of mAbs raised against hESC, another 
hESC-specific cytotoxic antibody, mAb TAG-A1 (A1), was discovered by our 
group. Unlike mAb84, A1 is an IgG monomer hence the penetration issue may 
be alleviated.  
Antibody-induced cell death has been widely used to eliminate undesired 
cells. Antibodies can induce cell death via various routes, including antibody-
dependent cell-mediated cytotoxicity (ADCC), complement-dependent 
cytotoxicity (CDC), and direct cell death via apoptosis or oncosis. Previously, 
our group has demonstrated that mAb84 kills hESC via oncosis
34
. However, 
unlike ADCC, CDC, and apoptosis, the understanding about antibody-induced 
cell oncosis is limited.  
1.2 Thesis objectives 
As we discussed, A1 is potentially a better alternative to mAb84 in eliminating 
tumorigenicity for hPSC-based therapy especially if the differentiated cells are 
in an aggregated state. A1 was generated as part of the antibody discovery 
platform in BTI. My project aimed to characterize A1, benchmark it to mAb84 
and investigate the mechanism of action for A1-induced cell death, so that to 
3 
 
facilitate the effective use of A1 in hPSC-based transplantation and to 
understand the regulation of hPSC death. Hence, there are three objectives for 
this thesis: 
(1) In vitro characterization of A1 
(2) In vivo characterization of A1 
(3) Elucidation of A1-induced hESC death mechanism 
1.2.1 In vitro characterization of A1 
First, the specificity of A1 cytotoxicity will be determined against 
undifferentiated hESC, hiPSC and spontaneously differentiated hESC. Next, 
studies will be carried out to identify the antigen target of A1 on hESC. Many 
antigens on the cell surface are glycoproteins; hence the characterisation will 
include both the core proteins and post-translational modifications, namely O-
glycosylation and N-glycosylation. Subsequently, A1 will be benchmarked to 
mAb84 in terms of amino acid sequences in variable regions, competitive 
binding on hESC, penetration efficiency into EB, dosage efficiency, and 
killing kinetics. We will also exam the stoichiometry between A1 and hESC, 
as well as the association between A1 cytotoxicity, bivalency and the Fc-
domain.   
1.2.2 In vivo characterization of A1 
The ultimate goal of cytotoxic A1 is to eliminate residual undifferentiated 
hPSC from differentiated cells and therefore prevent teratoma formation. 
Hence this chapter will investigate whether A1 can prevent teratoma formation 




1.2.3 Elucidation of A1-induced hESC death mechanism 
First, the mode of A1-induced hESC death, namely oncosis or apoptosis, will 
be determined by examining the features of A1 killing, via apoptosis assay and 
morphological observations under confocal microscopy, scanning electron 
microscopy and transmission electron microscopy. Subsequently, functional 
studies will be carried out to identify events that occur in A1-induced hESC 
death. Last but not the least, a mechanistic model of A1-induced hESC death 
will be proposed with the key mediator of the cell death pathway and 
delineated order of observed events.  
1.3 Thesis organization  
This thesis consists of seven chapters. 
Chapter 1 describes the background and objectives of this research. 
Chapter 2 is relevant literature review which covers (1) the potential of 
hPSC-based therapies and the major safety concern: teratoma formation; (2) 
current methods to prevent teratoma formation; (3) applications of cytotoxic 
antibody-induced cell death; (4) phases and modes of cell death, and (5) 
studies on cytotoxic antibody-induced cell death.   
Chapter 3 provides the detailed materials and methods of this research. 
Chapter 4 presents results on the in vitro characterization of A1.  
Chapter 5 presents results on the in vivo characterization of A1.  
Chapter 6 elucidates the mechanism of A1-induced hESC death.  
Chapter 7 summaries the results of this research and discuss the direction of 
future works.      
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2 CHAPTER 2 LITERATURE REVIEW 
2.1 Origin of human pluripotent stem cells (hPSC) 
Human embryonic stem cells (hESC) and human-induced pluripotent stem cell 
(hiPSC) are the two sources of human pluripotent stem cells (hPSC). Human 
ESC are derived from the inner cell mass of an early stage human embryo
1
. 
They are pluripotent stem cells with unique abilities to replicate indefinitely 
(self-renewal) and under the appropriate conditions differentiate into 
derivatives of all three germ layers (pluripotency) (Figure 2-1). Thus, hESC 
can potentially be the single source of cells to provide replacement for the lost 
to damage or disease. 
 
Figure 2-1: Derivation of a hESC line, and differentiation into various cell types
35
. 
An embryonic stem cell line is derived from the inner cell mass of an early-stage human 
blastocyst and cultured in the presence of feeder cells or in feeder-free media, which can be 
differentiated into cell types of all three germ layers and germ cells by using methods such as 





In 2007, an alternative source of hPSC, human induced-pluripotent stem cells 
(hiPSC) were generated by reprogramming human dermal fibroblasts with 
transient over-expression of four transcription factors: Oct3/4, Sox2, Klf4, and 
c-Myc
2
. Reprogramed cells have the ability to differentiate into derivatives of 
the three germ layers in vitro and in teratomas, and are similar to hESC in 
morphology, proliferation, surface antigens, gene expression, epigenetic status 




Figure 2-2: Reprogrammed hiPSC from differentiated somatic cells
37
.  
Human induced pluripotent stem cells (hiPSC) can be reprogrammed from differentiated 
somatic cells (fibroblasts) with retroviral over-expression of the four factors Oct4, Sox2, Klf4 
and c-Myc, and potentially differentiate into all somatic cell types. 
 
 
The generation of hiPSC might alleviate two concerns of hESC usage: 
immunogenicity upon transplantation
38
 and ethical controversy in the 
destruction of human embryos for medical research
39
. However, to use hiPSC 
in humans, safety concerns regarding the usage of viruses for reprogramming 
and expression of oncogenes should be addressed. 
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2.2 Applications of human pluripotent stem cells 
Differentiating hPSC into various types of lineage-specific derivatives for cell 
replacement therapies has attracted substantial interest from the scientific 
community over the last decade. The first success was reported about a decade 
ago for hESC-derived cardiomyocyte lineage. With improved differentiation 
protocols, a recent study demonstrated that hESC-derived cardiomyocytes can 
be produced at a clinical scale, cryopreserved with good viability and 
delivered via intra-myocardial to regenerate non-human primate hearts
6
. Their 
success holds a great promise for the treatment of human heart failure. 
Another promising hPSC-derived lineage is dopamine-producing neurons for 
the treatment of Parkinson’s disease (PD). Recently, a preclinical assessment 
of hESC-derived midbrain dopamine neurons in a rat PD model showed long-
term survival with functionality restoring long-distance, target-specific 
neurotransmission in the host brain, comparable to fetal neurons
10
. In another 
study, transplantation of autologous hiPSC-derived dopamine neurons 
provided functional recovery of motor deficits for at least 2 years in a non-
human primate model
11
. These animal models provide a strong support for the 
clinical translation of hPSC-derived neurons. Researchers have also been 
seeking solutions from hPSC-based renal regeneration to overcome the 
prevalence of end-stage renal disease because there are no postnatal stem cells 
to replace lost nephrons. In vitro formation of a self-organizing kidney with 
nephron formation was recently achieved by directed differentiation of hESC 
under a fully chemically-defined monolayer culture condition
13
.  
On the other hand, hESC- or hiPSC-derived hepatocyte-like cells are 
predominantly used in the field of toxicology for drug discovery and 
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cytotoxicity screening in the early phase of pharmaceutical development
40
. For 
example, hiPSC-derived hepatocyte-like cells was used to host an in vitro 
assay of liver-stage malaria infection to allow the assessment of donor-specific 
drug response
8
. Current challenge is to control the maturity of hepatocytes 
while maintaining functional and stable hepatic functions, including high 
activity levels of the cytochrome P450 enzymes
9
.  
Encouragingly, several hPSC-derived lineages have been approved for clinical 
trials by the US Food and Drug Administration (FDA). In 2009, the first 
clinical trial of hPSC was approved for the transplantation of hESC-derived 
oligodendrocytes into spinal cord-injured patients
25
. With the observation of 
microscopic cysts, this trial was placed on clinical hold due to safety concern 
of teratoma formation. In 2013, Asterias bought over this project and the first 
interim result in Aug 2015 showed that the first patient has progressed well in 
the injury treatment and two other patients have been successfully dosed with 
the same stem cells
41,42
. With the publication of initial safety data, Asterias 
plans to expand the enrolment from 13 patients up to 40 patients in the Phase 
1/2a clinical trial. Another two clinical trials involving hESC-derived retinal 
pigment epithelial (RPE) cells were approved in 2010 to establish the safety 
and tolerability of sub-retinal transplantation for the treatment of Stargardt’s 
Macular Dystrophy and Dry Age-Related Macular Degeneration
26
. 
Preliminary results were promising as no signs of hyper-proliferation, 
tumorigenicity, ectopic tissue formation, or apparent rejection were observed 
after 4 months
43
. Subsequently, in 2013, transplantation of hESC-derived RPE 
cells for the treatment of severe myopia was approved for phase I/II clinical 
trials
27
. Most recently, a phase I clinical trial initiated by Viacyte using hESC-
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derived beta cells delivered in immune-protective capsules was approved for 
the treatment of diabetes
28
.  
2.3 Tumorigenicity: the major safety concern of hPSC-based therapies 
In any hPSC-based therapies, hPSC need to be differentiated into the desired 
lineage-specific derivatives under a controlled environment. However, since 
the differentiation is not 100% efficient, there are usually undifferentiated or 
partially differentiated hPSC remaining in the differentiated cell products, 
which poses the risk of tumorigenicity. Over the last decade, two prominent 
safety hurdles of hESC-based therapies are immunogenicity and 
tumorigenicity
29
. Progressively, immunogenicity of hESC can almost be 
resolved by one or combinations of methods, such as transplanting cells into 
immune-privileged sites, generating patient-specific hESC, producing HLA 
isotypes-matched hESC-line banks, and the use of autologous derivatives from 
hiPSC
31,38
. However, strategies to solve the tumorigenicity of hPSC remain 
elusive.  
Briefly, tumorigenicity of hPSC refers to either the formation of teratomas 
(benign tumours) or teratocarcinomas (malignant tumours) in the 
differentiated cell products due to the presence of residual undifferentiated 
hPSC. Currently, in vivo teratoma formation is considered as the most 
definitive assay to evaluate hPSC pluripotency and determine the 
tumorigenicity of their therapeutic derivatives
44
. The purity of differentiated 
cell products is not trivial. A titration experiment of undifferentiated hPSC in 
severe combined Immunodeficient (SCID) mice demonstrated that as few as 2 
colonies of undifferentiated hPSC or less than 250 single-cell undifferentiated 










 in SCID mice due to residual undifferentiated hESC 
after transplantation. The first report described engraftment of hESC-derived 
neural precursor cells into the sub-retinal space where formation of severe 
intraocular teratomas was observed after long-term survival
46
. Another study 
involving the transplantation of hESC-derived insulin expressing cells into 
mice also resulted in the failure of treatment for Type I diabetes due to 
teratoma formation
47
. Though teratomas are benign tumours, they can still 
exert a mass effect and transform to teratocarcinomas
53
. Teratocarcinomas are 
usually characterized as containing both undifferentiated malignant embryonal 
carcinoma cells and somatic tissues
50
. Formation of malignant germ cell–like 
tumours was reported in a study on in vivo differentiation of partially 
reprogrammed hiPSC in SCID mice
52
. Another study showed that hESC are 
prone to generate primitive, undifferentiated teratocarcinomas, instead of 
teratomas, in engrafted human fetal tissues, namely thymus, lung and 
pancreas, in SCID mice
49
. These observations raise urgent safety concerns 
about the therapeutic applications of hPSC.  
2.4 Solutions: methods to prevent tumorigenicity of hPSC 
Methods to eliminate residual hPSC fall into two categories: negative or 
positive cell sorting based on specific antibodies
54
, transgenic fluorescent 
markers
55,56
, or physical properties
57
; or genetic manipulation by gene 
interference
58
 or introduction of “suicide gene”59,60. These methods are applied 
in three different stages
29,31
. First, in the pre-transplantation stage, hPSC can 
either be terminally differentiated into the desired cell types or 
undifferentiated cells can be removed from differentiated cells products by 
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various sorting techniques. Second, in the early post-transplantation stage, 
tumour progression can be interrupted with methods such as genetic 
manipulation or cytotoxic drugs. Third, in the late post-transplantation stage, 
detected tumours carrying an engineered “suicide gene” can be eliminated by 
drugs. Various methods to eliminate undifferentiated hPSC or tumour 
formation at different stages, as well as their advantages and disadvantages are 
summarized in Table 2-1.  
In general, prospective removal in the pre-transplantation stage is considered 
to be superior to retrospective removal in the two later stages because of the 
risks of genetic modification and metastatic transformation
61
. In the pre-
transplantation stage, undifferentiated hPSC are mostly purified by positive or 
negative cell sorting with marker-specific antibodies. Positive selection can 
provide a higher purity of cells than negative selection, though the yield is 
compromised. In a more recent development, our group, for the first time, 
demonstrated the specific killing of undifferentiated hESC by a cytotoxic 
monoclonal antibody (mAb), mAb84.  Injection of hESC after treatment with 
mAb84 for 45 minutes in vitro, prevented teratoma formation in SCID mice
32
. 
Subsequently, similar methods using cytotoxic small molecules were also 
proposed
62,63
. A small molecule, PluriSIn#1, was reported to selectively 
eliminate hPSC while sparing a large array of progenitor and differentiated 
cells. PluriSIn#1 was reported to inhibit the biosynthesis of MUFA oleate by 
stearoyl-coA desaturase (SCD1), which is a vital process in hPSC. This 
consequently leads to the induction of ER stress, protein synthesis attenuation 
and eventually apoptosis
62
. Another group reported the hPSC-specific anti-
apoptotic factor to remove residual hPSC based on a unique hESC signature of 
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pro- and anti-apoptotic gene expression profile
63
. However, according to the 
mechanism of action, both the dependence on SCD1 and anti-apoptotic profile 
might not be limited to hPSC. Therefore, it is unclear whether there will be 
any potential side effects on differentiated cells. Recently, our group continued 
to generate new panels of mAbs against hESC leading to the discovery of 
another hESC-specific cytotoxic antibody, mAb TAG-A1 (A1). Similar to 




Table 2-1: Overview of methods to prevent hPSC tumorigenicity. 
 
Stage Principle Advantages Disadvantages Examples  Ref 
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2.5 Applications of cytotoxic antibodies 
Applications of cytotoxic antibodies are diverse. Firstly, antibody-induced cell 
death can be used as a cell model to study molecular and cellular functions. In 
1995, Bazil et al. generated mAb MEM-59, which recognizes the surface 
adhesion molecule CD43 on human hematopoietic progenitor cells (HPC) and 
directly kills HPC via cross-linking of CD43
70
. With MEM-59 induced-HPC 
death, CD43 was identified as a negative regulator of early hematopoietic 
events.  
Secondly, cytotoxic antibodies can be used to identify novel pathways of cell 
death and to characterize cell death. Matsuoka et al. generated mAb RE2, 
which could induce a novel type of cell death in activated interleukin 2-
dependent T cells
71
. Zhang et al. also found a cytotoxic antibody, anti-
Porimin, targeting Jurkat cells
72
. In this study, they reported the very first cell 
surface receptor-mediated oncosis as well as some unique features of cellular 
response upon cell death, such as cell aggregate, plasma membrane 
permeabilization and membrane blebs.  
Thirdly, as mentioned in the previous section, cytotoxic antibodies have been 
used intensively to eliminate undesired cells, such as the treatment of cancers. 
Rituximab, a mAb targeting the CD20 antigen on B-lymphocytes, was the first 
cytotoxic antibody approved to treat B-cell malignancies, such as non-
Hodgkin's lymphoma, in combination with chemotherapy
73
. To overcome the 
rituximab-resistance in some patients, many next-generation anti-CD20 
cytotoxic antibodies have been generated
74–76
. There are also other cytotoxic 
antibodies such as RAV12 that induces recurrent adenocarcinoma cell death
77
 





Although all these antibodies can induce cell death, the modes of cell death 
and mechanism of action is different.  
2.6 Phases and Modes of Cell Death 
The terminology of cell death is complicated and sometimes confusing. One 
way to distinguish different types of cell death is to define it by cellular 




a) Reversible “pre-mortal phase”; 
b) Irreversible cell death, “point-of-no-return”; 
c) Post-mortal autolytic and degradative changes. 
In the pre-mortal phase, there are two major modes of cell death: apoptosis 
and oncosis. In developmental biology, programmed cell death was introduced 
to describe that cells in a particular location are scheduled to die for 
embryologic development and organ differentiation. For a very long-time, 
programmed cell death has been used synonymously with apoptosis and 
oncosis has been considered as accidental cell death. However, this concept 
was proved not to be always true
81
, where oncosis can also be a route of 
programmed cell death. In fact, with the pre-existence of relevant genetic 
information and cell death factors, every cell may experience “programmed” 
cell death upon an appropriate stimulus, whereas the route (apoptosis or 
oncosis) differs among cell types and the stimulus
80,82
. On the contrary, most 
of post-mortal cellular changes should be termed as “necrosis”80, which is an 
ancient word describing cellular changes after cell death. A schematic view of 







Figure 2-3: Schematic view of the relationship between apoptosis, oncosis and necrosis
83
. 
1A: swelling; 1B: vacuolization, blebbing, and increased permeability; 1C: necrotic changes 
such as coagulation, shrinkage and karyolysis. 2A: Shrinkage and pyknosis; 2B: budding; 2C: 
necrotic changes such as break up into clusters of apoptotic bodies. 
 
2.6.1 Apoptosis 
Apoptosis was first proposed by Kerr et al. in 1972 to describe a pattern of 
controlled cell deletion. In the regulation of normal development and cell 
population, apoptosis was thought to play a complementary but opposite role 
to mitosis
84
. Dysregulation of apoptosis would result in many diseases such as 
cancer, Alzheimer’s and autoimmune diseases85,86. The process of apoptosis is 
tightly controlled and organized. It usually begins with the activation of 
caspases 12 to 24 hours after a trigger event. In general, there are two major 
pathways to apoptosis activation: extrinsic caspase-8 activation via receptor-
ligand binding, and intrinsic caspase-9 activation via mitochondria
87
.  
2.6.1.1 Ligand-receptor mediated apoptosis via caspase-8 activation 
Apoptosis can be initiated by binding of a ligand to a surface receptor. Well-
characterized pathways include death receptors from the tumour necrosis 
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factor (TNF) receptors superfamily, such as Fas (CD95) receptor. Upon ligand 
binding, Fas receptors form trimers and their clustered cytoplasmic death 
domains then recruit adaptor molecules such as Fas-associated death domain 
(FADD). FADD in turn recruits procaspases-8 and converts it into active 
caspase-8. Activated caspase-8 continues to convert procaspases-3 into 
effector caspase-3 and eventually apoptosis
88
.  
2.6.1.2 Mitochondria-mediated apoptosis via caspase-9 activation 
Non-receptor mediated stimuli, such as radiation, hypoxia, hyperthermia, viral 
infections, and free radicals, can also trigger apoptosis via a mitochondria-
mediated pathway. Stimuli cause mitochondrial impairment and release of 
sequestered pro-apoptotic protein, cytochrome c, into the cytosol. Cytochrome 
c in turn binds to apoptosis protease activating factor (Apaf-1) and 
procaspases-9 to form an apoptosome, which activates procaspases-9 to 











Upon activation, caspases breakdown certain plasma membrane proteins and 
cytoskeleton proteins, which in turn leads to membrane budding. Organelles in 
the cytoplasm become tightly packed and chromatin undergoes condensation, 
known as pyknosis. Subsequently, the cell breaks apart into apoptotic bodies 
enclosing DNA fragments and cell organelles by intact plasma membrane
84,89
. 
Apoptotic bodies with phosphatidylserine expressed on the outer membrane 
are recognized and engulfed by the neighbouring cells, in particular, 
macrophages and endothelial cells. Eventually, cell debris is cleared out from 
the tissue to avoid inflammatory response
89
.  
Apoptosis can be recognized by a set of well-characterized hallmarks 
including morphological changes such as cellular shrinkage and budding of 
plasma membrane (apoptotic bodies), and biochemical changes such as 
activation of caspases, patterned DNA fragmentation and exposure of 
phosphatidylserine on the outer membrane surface
91
. Assays to identify the 
different hallmarks of apoptosis are summarized in Table 2-2.  
Table 2-2: Hallmarks of apoptosis and their respective assays. 
Hallmarks Assays 
Cell death time: hours  
Cell shrinkage and apoptotic body formation 
Scanning/ transmission Electron 
microscope (TEM or SEM) 
Caspase activation Measure caspase activity 
Phosphatidylserine externalization Annexin V detection 
DNA fragmentation 
Terminal deoxynucleotidyl transferase 





Oncosis was first proposed by Von Rechkling-hausen in 1910 to describe cell 
death with swelling and was subsequently used to describe ischemic cell death 
distinct from apoptosis
83
. Though oncosis is the older term, apoptosis has been 
better elucidated and used to represent programmed cell death. In the recent 
literature, there are increasing numbers of reports on oncosis, including 
bacteria-induced macrophage death, toxin or radiation-induced cell death, and 
cell death due to ischemic heart disease and stroke
92
. Compared to the 
understanding of apoptosis, the activation pathway of oncosis is still under 
investigation. Some studies have shown that failure in the ionic pumps of the 




Upon stimulation, oncosis can be triggered within seconds to minutes 
followed by marked cell shape and volume alteration in the early stage
80
. It 
was characterized by several morphological and biochemical changes such as 
apparent swelling of cell and organelles, gross vacuolization, plasma 
membrane damage and cytoskeleton proteins degradation
80,83
. Buja et al. have 
postulated that plasma membrane damage in oncosis undergoes in three 
stages
82,93
. At stage 1, oncosis stimuli induce selective membrane injury 
leading to cell swelling without generalized increase in cell membrane 
permeability. At stage 2, plasma membrane damage becomes irreversible with 
non-selective membrane permeability to propidium iodide (PI) and trypan blue. 
At stage 3, the cell membrane eventually breaks down, leading to the necrotic 
phase. Based on the current understanding, the hallmarks of oncosis and the 
relevant assays for identification are summarized in Table 2-3.  
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Table 2-3: Hallmarks of oncosis and their respective assays. 
Hallmarks Assays 
Rapid cell death (within minutes)  
Plasma membrane damage 
Uptake of trypan blue/propidium iodide/dextran 
beads; 
Scanning electron microscope (SEM) 
Apparent swelling of cell and 
organelles 
Transmission electron microscope (TEM) 
Cytoskeleton proteins degradation Western Blot 
 
2.7 Studies on Cytotoxic Antibody-Induced Cell Death 
Besides antibody-dependent cell-mediated cytotoxicity (ADCC) and 
complement-dependent cytotoxicity (CDC), antibodies can induce direct cell 
death via apoptosis or oncosis. Some examples of antibody-induced direct cell 
death are summarized in Table 2-4 and will be discussed in greater detail in 
this section.  
















Rituximab  Non-Hodgkin’s lymphoma CD20 Apoptosis 
Anti-APO-1 B-cell lymphoblastoma Fas receptor Apoptosis 
TRA-8 
Primary hepatocellular 
carcinoma cells and liver 
cancer cells 
DR5 receptor  Apoptosis  
RE2 
Interleukin  2-dependent T 
cell 
n.d. Oncosis 
Anti-Porimin Jurkat cell Porimin Oncosis 
RAV12 Adenocarcinoma RAAG12 Oncosis 
Anti-NeuGcGM3 
14F7 





Lung tumour cells NeuGcGM3 Oncosis 
mAb84 Human embryonic stem cells PODXL Oncosis 
GA101 Non-Hodgkin’s lymphoma CD20 Oncosis 
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2.7.1 Antibody-induced apoptosis 
Antibodies can induce apoptosis via three different pathways. First, antibodies 
targeting growth factor receptors can antagonize ligand–receptor signalling 
and lead to cell apoptosis. In tumour cells, overexpression of growth factor 
receptors leads to uncontrolled cell proliferation. Antibodies have been 
developed to modulate growth factor signalling in tumours, such as cetuximab 
against epidermal growth factor receptor (EGFR), and trastuzumab 
(Herceptin) against HER2. The EGFR pathway is known to regulate cell 
survival and inhibit apoptosis through the PI3K/Akt pathway. Cetuximab 
binds to EGFR with high affinity and specificity and blocks ligand-binding 
induced tyrosine kinase-dependent phosphorylation and subsequent 
downstream signalling. Increased levels of the proapoptotic factor Bax as well 
as activity of caspases (caspase 3, 8, and 9) were reported in cetuximab-treated 
DiFi tumour cells
94
. In addition, cetuximab-mediated inactivation of anti-
apoptotic protein, Bcl-2, was demonstrated in breast carcinoma
95
 and 
squamous cell carcinoma of the head and neck (SCCHN)
96
. In trastuzumab-
induced breast cancer cell apoptosis, inhibition of PI3K/Akt activity as well as 
down-regulation of Bcl-2 was observed
97
.   
Second, antibodies can induce apoptosis via antigen crosslinking. In 1995, 
mAb MEM-59 was reported to recognize a highly sialylated glycoprotein, 
CD43, and induce cytokine-dependent apoptosis in hematopoietic progenitor 
cells (HPC)
70
. Cytokine-induced proliferation of HPC was markedly 
suppressed by immobilized MEM-59 in a dosage-dependent manner. 
Apoptotic features including cellular shrinkage, DNA fragmentation, and 
membrane blebbing were observed. MEM-59 induced-apoptosis requires 
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crosslinking of at least three CD43 molecules and the presence of cytokines. 
However, it is unclear how signals leading to apoptosis were transduced upon 
crosslinking of CD43. Rituximab-induced apoptosis has been applied to 
improve the clinical efficacy in the treatment of non-Hodgkin’s lymphomas 
since lacking of tumour-associated effector cells can lead to rituximab failure 
in treatments based on ADCC. Crosslinking of CD20 by rituximab upon 
binding can induce strong and sustained phosphorylation of mitogen activated 
protein (MAP) kinases, p38. Inhibition of p38 leads to significant reduction in 
rituximab-induced apoptosis
98
. DNA fragmentation, phosphatidylserine 
exposure, and increase in caspase-3 activity were detected
73
. However, the 
precise mechanism how CD20-crosslinking leads to phosphorylation remains 
to be elucidated.  
Third, apoptosis can be triggered upon agonist antibodies binding to surface 
receptors that transduce proapoptotic signals, such as death receptors of 
tumour necrosis factor (TNF) receptor family
99
. In 1989, a mAb, anti-APO-1, 
was reported to induce rapid apoptosis of human B-cell lymphoblastoma cells 
by selectively binding to apoptosis antigen 1 (APO-1), later identified as Fas 
receptor
100
. Subsequently, another mAb, TRA-8, was developed as an agonist 
of the DR5 receptor to induce apoptosis in primary hepatocellular carcinoma 
cells and liver cancer cells
101
. Binding of anti-APO-1 to Fas receptor and 
TRA-8 to DR5 receptor triggers the activation of procaspases and the 




Figure 2-5: Antibody-induced apoptosis via TNF receptor activation
102
.   
 
 
2.7.2 Antibody-induced oncosis 
Pathways of antibody-induced oncosis remain to be elucidated. Nevertheless, 
the mechanism of action has been better understood with increasing studies to 
characterize the features of antibody-induced oncosis.  
In 1995, mAb RE2 (IgG) was reported to directly kill interleukin 2-dependent 
T cells in a non-apoptotic, complement-independent manner
71
. Cross-linking 
of cell surface molecules is required for RE2 cytotoxicity since Fab_RE2 has 
no cytolytic activity whereas cross-linked Fab RE2 by anti-rat 
immunoglobulin can recapitulate the cytotoxicity (Figure 2-6A). RE2 





C, and no cytotoxicity at 0
o
C (Figure 2-6A). Involvement of cytoskeleton-
dependent active progress was postulated since treatment with cytochalasin D 




2-6B). Under scanning electron microscopy, giant holes (>1 μm) were 
observed on cell plasma membrane (Figure 2-6C). In fact, cell swelling upon 
RE2 treatment was also apparent. 
 
Figure 2-6: RE2-induced T cell oncosis
71
.  
(A) Kinetics of cytotoxicity effect (measured by trypan blue) of RE2 mAb on T cell clone at 
different temperatures, and in different formats. (B) Effect of cytochalasin D on cytotoxicity 
of RE2 at various times when cytochalasin was added (ο) and at the end of the assay (). (C) 
Giant pore formation on cell membrane.  
 
 
In 1998, by immunizing mice with apoptotic cells, mAb anti-Porimin (IgM) 
was generated and found to directly kill Jurkat cells within 20 minutes of 
incubation in an oncosis-like manner72. Anti-Porimin binds to a 110-kDa type 
I transmembrane protein with extensive O- and N-linked glycans, designated 
as Porimin (pro-oncosis receptor inducing membrane injury). Porimin was 
localised on the plasma membrane surface of Jurkat cells under immuno-TEM 





Jurkat cells was detected by propidium iodide uptake. Oncosis features, such 
as cell aggregate and rapid pore formation on the cell membrane were 
visualized under SEM (Figure 2-7A).  
 
Figure 2-7: Anti-Porimin-induced Jurkat cells oncosis
72
.  
(A) Cell aggregate and pore formation on plasma membrane were observed in anti-Porimin-
treated Jurkat cells. (B) Localisation of the Porimin receptor (arrows) on the surface of plasma 
membrane of the cell.  
 
 
In 2007, chimeric antibody RAV12 (IgG1) was generated based on mAb KID3 
to induce oncosis in adenocarcinoma tumour cells 
77
. RAV12 was 
demonstrated to recognize N-linked carbohydrate antigen (RAAG 12) on 
multiple antigens, which is heavily expressed in adenocarcinoma tumours 





authors concluded that RAV12-binding site on RAAG12 consists minimally 
of Galβ1-3GlcNAcβ1-3Gal.  
 
Figure 2-8: RAV12-induced COLO 205 colon tumour cells oncosis
77
.  
(A) RAV12 recognizes RAAG12, an N-linked carbohydrate epitope on multiple proteins. (B) 
Reduced extracellular sodium protects COLO 205 cells from KID3 cytotoxicity. (C) RAV12 
treatment rapidly induces cell swelling and disrupts actin cytoskeleton.  
 
 
Intriguingly, similar to RE2, RAV12-mediated cytotoxicity also required 
cross-linking of surface antigens as cross-linking Fab_RAV12 with a 
secondary antibody restored the lost cytotoxicity when RAV12 was presented 
as a monovalent Fab_RAV12. Attenuation of KID3-induced cell death was 
correlated to the reduced extracellular sodium concentration (Figure 2-8B), 
which supports the previously suggested role of membrane ion channel failure 
in oncosis. Rapid cell swelling and disruption of F-actin cytoskeleton were 





In 2008, mAb 14F7 (IgG1) against N-glycolyl GM3 ganglioside (NGcGM3) 
was reported to induce L1210 murine tumour cell death via oncosis. Similar to 
previous studies, cellular swelling and membrane pore formation were 
observed under SEM. Only the bivalent F(ab)2_14F7 and not the monovalent 
Fab_14F7 retained the cytotoxic capacity of the whole mAb (Figure 2-9A), 
indicating cross-linking of target antigens is required for the cytotoxicity. In 
addition, by depleting cellular ganglioside and subsequently incorporating 
exogenous ganglioside, the authors demonstrated that expression of NGcGM3 
ganglioside at the plasma membrane is necessary but not sufficient for 14F7-
induced cell death (Figure 2-9B). Re-arrangement of actin cytoskeleton was 
again identified in this study. Cytochalasin B treatment inhibited 14F7 
cytotoxicity in a dosage-dependent manner (Figure 2-9C). Moreover, a linker 
protein that mediates actin cytoskeleton to the plasma membrane, ezrin, was 
shown to have increased phosphorylation upon 14F7 treatment (Figure 2-9D). 
Similar to 14F7, a subsequent study identified another anti-NGcGM3 mAb, 





Figure 2-9: Anti-NGcGM3 14F7-induced L1210 murine tumour cell oncosis
79
.  
(A) F(ab)2_14F7 but not Fab_14F7 retained the cytotoxic capacity of the whole mAb. (B) 
Expression of NGcGM3 ganglioside at the plasma membrane is necessary but not sufficient 
for 14F7-induced cell death. D-PDMP depletes cellular ganglioside. NGcGM3 in the figure 
represents exogenous NGcGM3. (C) Treatment of cytochalasin B inhibits 14F7 cytotoxicity. 
(D) 14F7 treatment leads to increased level of phosphor-ezrin.  
 
 
Previously, our group has also investigated mAb84 (IgM)-induced human 
embryonic stem cell (hESC) oncosis34. Oncotic features including rapid cell 
death, formation of cell aggregates, and membrane pore formation were 
observed. Role of actin cytoskeleton re-organization was confirmed by the 
degradation of actin cytoskeleton-associated proteins: talin, α-actinin, and 
paxillin, as well as co-localisation of paxillin with mAb84 at the peripheral 
membrane. mAb84 binds to a highly glycosylated protein, podocalyxin 
(PODXL). Aggregation of PODXL was detected at the plasma membrane 
under immuno-SEM (Figure 2-10A). Hence, it was proposed that mAb84 





which in turn leads to pore formation throughout the plasma membrane 
(Figure 2-10B). Subsequent studies with antibody fragments of mAb84 
suggested that mAb84 cytotoxicity is affected by the valency and the linker 
construction of the antibody33.   
 
Figure 2-10: mAb84-induced human embryonic stem cell (hESC) oncosis
34
. 
(A) Aggregation of antigens upon incubation with mAb84 was observed under immuno-SEM. 
(B) Proposed model for mAb84-mediated oncosis.  
 
 
Recently, studies on type II anti-CD20 antibody, GA101 (IgG), have provided 
more insights to understand antibody-induced oncosis74–76. Consistent with 





cell death featured cell aggregate/homotypic adhesion (HA), actin re-
organization, and membrane pore formation. Under TEM, early stage of HA 
revealed that the initial cell-cell contact was established by microvilli (Figure 
2-11).  
 






Upon GA101 treatment, lysosomal membrane impairment (Figure 2-12A) and 
the subsequent release of cathepsin (Figure 2-12B) was discovered
75
. 







Figure 2-12: GA101-induced B lymphoma cell oncosis
75,76
.  
(A) Lysosomal membrane impairment detected by lysotracker green was correlated with 
annexin V measured cell death. (B) GA101 treatment induced the release of lysosomal 
enzyme, cathepsin. (C) GA101-induced ROS production was detected by dihydroethidium 
(HE) staining, and correlated to cell death. (D) ROS scavenger, Tiron, can partially block 
GA101 cytotoxicity.  
 
 
In conclusion, all the published examples of antibody-induced oncosis exhibit 
similar hallmarks namely rapid cell death, cell swelling, membrane pore 
formation and cytoskeleton protein reduction. In addition, studies so far have 






linking of antigens, formation of cell aggregate/homotypic adhesion, 
lysosomal membrane impairment, and ROS production. However, a more 
detailed mechanistic pathway remains to be elucidated.  
2.8 Summary 
Human pluripotent stem cells (hPSC) hold great potential in regenerative 
medicine and tissue engineering. However, the risk of teratoma formation due 
to residual undifferentiated hPSC in hPSC-derived products has become the 
major safety hurdle for hPSC-based therapies. Currently, there are no available 
methods to completely preclude teratoma formation. Cytotoxic mAbs such as 
mAb84 and A1 can be used to directly eliminate residual undifferentiated 
hPSC from differentiated cell products. Two major modes of cell death, 
namely apoptosis and oncosis, were reviewed in this chapter. Moreover, 
studies on antibody-induced cell death were discussed. In this thesis, to 
facilitate the application of A1, we aimed to characterize A1 benchmarking to 




3 CHAPTER 3 MATERIALS AND METHODS 
3.1 Cell culture 
3.1.1 Human embryonic stem cells (hESC) 
Human embryonic stem cell line, HES-3 was obtained from ES Cell 
International (ESI, Singapore, http://escellinternational). The cells were 
cultured at 37
o
C, 5% CO2 on matrigel-coated culture dishes supplemented 
daily with conditioned media (CM) from immortalized mouse feeders, ΔE-
MEF
103
. The media used for culturing hESC was KNOCKOUT (KO) media 
which contained 85% KO–DMEM (DMEM, Dulbecco’s modified Eagle’s 
medium) supplemented with 15% KO serum replacer, 1 mM L-glutamine, 25 
U/ml penicillin, 25 U/ml streptomycin, 1% non-essential amino acids (NEAA), 
0.1 mM 2-mercaptoethanol, and 5 ng/mL of recombinant human fibroblast 
growth factor-2 (FGF-2) (Invitrogen, Carlsbad, CA, 
http://www.invitrogen.com). To passage hESC, briefly, once the culture 
reached confluency, the cells were mechanically cut with cell cutter 
(Invitrogen) into small square cell sheets, scraped from the culture dish using 
cell scraper and transferred to a fresh matrigel-coated culture dish. Culture 
dishes were pre-incubated with matrigel (Becton Dickinson and Company, 
Franklin Lakes, NJ, http://www.bd.com) at 4
o
C overnight or at room 
temperature for at least 4 hours. Cells are passaged at a ratio of 1:6 or 1:8 
depending on the confluency.  
3.1.2 Human induced pluripotent stem cells (hiPSC) 
Human iPSC, ESIMR90, reprogrammed from fetal lung fibroblast
104
, were 
cultured as above described for hESC; with the exception that 100 ng/ml 
instead of 5 ng/ml of FGF-2 was supplemented to the CM.  
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3.1.3 Spontaneous differentiation of hESC 
To induce hESC differentiation in vitro, hESC were mechanically cut and 
harvested as clumps and cultured as embryoid bodies (EB) for 7 days in EB 
media (80% KO-DMEM, 20% fetal bovine serum (FBS), 25 U/ml penicillin, 
25 μg/ml streptomycin, 2 mM L-glutamine, 0.1 mM NEAA, and 0.1 mM 2-
mercaptoethanol) on non-adherent suspension culture dishes (Corning). 
Subsequently, EB were dissociated with trypsin, plated on gelatinized culture 
dishes
105
 and passaged every 7 days at a 1:4 ratio. EB media was replaced 
once every two days.  
For benzyl-α-GalNac experiment, EB were harvested on day 7 and day 14 for 
mRNA extraction. For penetration studies, EB were harvested on day 5 or day 
6. Alternatively, hESC differentiation was induced by FGF-2 starvation. Here, 
FGF-2 was not supplemented to daily harvested CM.  
3.1.4 Mouse embryonic fibroblast and conditioned media (CM) 
Monolayers of immortalized mouse embryonic fibroblast, ΔE-MEF, were 
grown to confluency in T-flasks and treated with 10 μg/ml mitomycin-C for 3 
hours.  Following treatment, cells were detached with 0.25% trypsin, seeded 




 and incubated overnight to 
facilitate adhesion. Feeders were then equilibrated in fresh KO media and CM 
was collected every 24 hours. The CM was clarified by filtration (0.22 μm) 
and supplemented with an additional 5 ng/ml of FGF-2 prior to addition to 
hESC cultures. 
3.2 Penetration studies into EB 
Purified A1 and mAb84 were conjugated to FITC (Fluorescein) using LYNX 
Rapid conjugation kit (AbD Serotec) according to the manufacturer’s 
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instructions. Briefly, 150 μg of A1 or mAb84 were incubated with Fluorescein 
solution overnight at room temperature and stopped with the provided 
quencher. Conjugation efficiency was verified with immuno-fluorescent 
staining on hESC. Spontaneously differentiated EB spheres were washed with 
1% BSA/PBS- and incubated with either 20 μg of FITC-conjugated A1 or 
FITC-conjugated mAb84 at 4°C for 4 hours. After incubation, excess 
antibodies were washed off with 1% BSA/PBS- and EB were pelleted for 
cryo-embedding and sectioning.  
EB were placed into embedding mould covered with dry ice and 2-
methylbutane. After removing any excess liquid around the EB, O.C.T. 
(optimal cutting temperature, water-soluble glycols and resins) compound 
were added into the mould to cover the EB. Subsequently, the mould was 
placed into dry ice/methyl butane mixture to freeze the O.C.T. Frozen blocks 
were either sectioned 5 minutes after frozen or stored at -80 °C for future 
sectioning. Each block was sectioned into 10 μm thick slides and kept at -80 
°C for future imaging.  
3.3 SDS-PAGE and Western Blot 
In general, protein lysates were obtained in two ways. For attached hESC on 
culture plate, cells were scraped off from the surface of the dish in 2% Triton-
100/PBS- and lysed for 30 minutes in a centrifuge tube or falcon tube on a 
rotor. Alternatively, after A1 treatment, cells in suspension were pelleted and 
lysed in 2% Triton-100/PBS- for 30 minutes in a centrifuge tube on a rotor. 
Protein lysates were collected in supernatant after 30 minutes centrifugation at 
10,000xg. Protein quantification was performed with Pierce protein 
quantification kit using standards from BSA Protein Assay (Bio-Rad 
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Laboratories) and read by 96-well Plate Reader (Sunrise Absorbance Reader, 
TECAN).  
Protein lysates (20 μg/well) were separated by SDS-PAGE (NuPAGE 4-12% 
gradient gel, Invitrogen) under reducing (15% β-mercaptoethanol) or non-
reducing conditions followed by western blotting, silver staining or Coomassie 
staining. For western blotting, resolved proteins were transferred onto PVDF 
membrane (Millipore) at 100 V for 90 minutes and immunoblotted with 
appropriately diluted antibodies in PBS- containing 2.5% BSA and 0.05% 
Tween-20, followed by HRP-conjugated antibodies (1:10000 dilution, DAKO) 
or near-infrared fluorescence antibodies (1:1000 dilution, Li-cor). Protein 
bands were detected with either chemiluminescence from chemical reaction 
with ECL Prime (Amersham) using Medical X-ray processor 2000 (Kodak) or 
Odyssey fluorescence scanner (Li-cor) respectively. Silver staining was 
performed using SilverQuest silver staining kit (Invitrogen) according to the 
manufacturer’s protocol and the protein bands corresponding to that on the 
western blotting membrane were manually excised for mass spectrometry 
analysis. For Coomassie staining, the gel with resolved proteins was removed 
from the SDS-PAGE (NuPAGE 4-12% gradient gel, Invitrogen) cassette and 
stained in sufficient amount of Coomassie stain solution (1 g Coomassie R250, 
100 ml acetic acid, 400 ml methanol and 500 ml ddH2O) for 1 hour. After 
staining, the gel was washed and hydrated with ddH2O twice followed by 
overnight distaining in sufficient amount of distain solution (200 ml methanol, 
100 ml acetic acid and 700 ml ddH2O). Gel with visible protein bands was 
scanned by Odyssey fluorescence scanner (Li-Cor) for further analysis. 
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For cytoskeleton reduction assay, hESC were incubated with A1 for 45 
minutes, pelleted and lysed with NP40 buffer consisting of 150 mM sodium 
chloride, 1% IGEPAL (Sigma-Aldrich) and 50 mM Tris with pH 8.0. The 
antibodies used for immuno-blotting were anti-β-GAPDH, anti-α-actinin, anti-
paxillin, anti-talin and anti-vinculin (Millipore).  
For Nox families, antibodies used for immuno-blotting were rabbit polyclonal 
to Nox1, anti-Nox2/gp91phox antibody, and anti-Nox3 antibody (Abcam).  
For periodate treatment experiment, after transferring the resolved proteins to 
PVDF membrane, the membrane was incubated with 2 mM sodium 
metaperiodate at 37
o
C for 45 minutes. The membrane was then washed twice 
with 0.1 M bicarbonate buffer and incubated with 1 mM sodium borohydride 
at room temperature for 30 minutes. Thereafter, the membrane was washed 
twice with PBS- and immunoblotted with the appropriately diluted antibodies 
in PBS- containing 2.5% BSA and 0.05% Tween-20, followed by near-
infrared fluorescence antibodies (1:1000 dilutions, Li-cor). Protein bands were 
detected with Odyssey fluorescence scanner (Li-cor). 
3.4 Immuno-precipitation (IP) 
Protein lysates in 2% Triton-100/PBS- were used for immuno-precipitation on 
the automated MEA system (PhyNexus Inc). Briefly, A1 (~100 μg) was 
directly captured onto Protein G PhyTip® columns (5 μl resin bed, 
PhyNexus Inc). After washing away the unbound proteins with PBS-, 
clarified cell lysate was passed through the column functionalized with 
A 1 . The column was further washed with PBS- after which bound 
proteins were eluted at low pH with Elution Buffer (200 mM NaH2PO4/140 
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mM NaCl, pH2.5) and neutralized immediately with 1 M Tris-Cl pH 9.0. 




C for further analysis. 
3.5 Mass Spectrometry Analysis 
The excised silver-staining gel bands were soaked overnight at 4
o
C in washing 
solution (2.5 mM ammonium bicarbonate in Acetonitrile) followed by 20 
minutes incubation at 37
o
C after a change in washing buffer. The gel was then 
subjected to in-gel proteolysis with trypsin following reduction and s-
alkylation of cysteine residues with iodoacetamide. Extracted peptides were 
subjected to analysis using mass spectrometry on an Orbitrap Velos LC/MS 
(Thermo Scientific). In Orbitrap Velos, peptide ions are injected tangentially 
into the electric field between the electrodes and trapped because their 
electrostatic attraction to the inner electrode is balanced by centrifuge force. 
Ions of a specific mass-to-charge ratio move in rings that oscillate along the 
central spindle. The frequency of these harmonic oscillations is independent of 
the ion velocity and is inversely proportional to the square root of the mass-to-
charge ratio (m/z or m/q). By sensing the ion oscillation, peptide sequence can 
be determined. Protein IDs were identified by mapping against the Homo 
sapiens subset of the Uniprot database. Antigen candidates were selected with 
the following filter setting: match score above 4, peptide coverage above 5, 
unique number of peptides above 1, and membrane proteins.  
3.6 Removal of Sialic Acid and N-linked Glycans 
Antigens immunoprecipitated by A1 (as described above) were then treated 
with sialidase and PNGase F to remove sialic acid and N-linked glycans 
respectively (New England Biolabs). Removal of terminal sialic acid is also 
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necessary to expose certain N-linked or O-linked glycans
106
. IP eluate (40 μg) 
was first denatured in 1x glycoprotein Denaturing Buffer (New England 
Biolabs) at 95
o
C for 10 minutes. Denatured proteins were then incubated with 
1 μl sialidase at 37oC overnight. Subsequently, 1x G7 Reaction Buffer (New 
England Biolabs) and 10% NP-40 (New England Biolabs) was added and 
incubated with 2 μl of PNGase F at 37oC overnight. Digested proteins were 
subsequently resolved on SDS-PAGE and transferred to Western blot before 
the removal of O-linked glycans by β-elimination. 
3.7 Removal of O-linked Glycan 
After sialidase and PNGase F treatment, proteins were separated by SDS-
PAGE and transferred to PVDF membrane as described above. Removal of O-
linked glycans was achieved by β-elimination. Briefly, PVDF membrane with 
resolved proteins was incubated with 5 mM NaOH at 42
o
C overnight.  
3.8 Fragmentation of A1  
Papain digestion of IgG produces Fab fragments in the presence of reducing 
agent. In the experiments, 50 µl of 2 mg/ml purified IgG A1 in PBS- was 
incubated with 100 µl of 0.1 mg/ml papain (Sigma-Aldrich) in freshly made 
digestion buffer (PBS- containing 0.02 M EDTA, 0.02 M cysteine) for 1 hour 
in a 37°C water bath. After which, the mixture was removed from the water 
bath and the digestion reaction terminated by adding 20 µl of 0.3 M 
iodoacetamide in PBS- and vortexing. The reaction mixture was then dialyzed 
using VIVASPIN 500 (Sartorius Stedim Biotech) with membrane pore size of 
30 kDa. F(ab)2 fragments of A1 were produced using IdeS Protease 
(Promega). Purified A1 was mixed with IdeS Protease in the ratio of 1 µg of 
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antibody to 1 unit of IdeS Protease in digestion buffer. Mixture was incubated 
at 37°C for 45 minutes. The efficiency of enzyme digestion as well as the size 
of different fragments was verified on SDS-PAGE with Coomassie blue 
staining and/or western blotting.  
3.9 Stoichiometry assay between A1 and hESC 
Stoichiometry assay was performed to investigate the number of A1 molecules 
bound per hESC under saturated binding or unsaturated binding conditions. 
Briefly, different amounts of A1 (0 μg -12 μg) were incubated with 2 x 105 
hESC at 4
o
C for 45 minutes. After incubation, unbound A1 in the supernatant 
were separated from A1 bound to hESC by centrifugation. The concentration 
of unbound A1 in the supernatant was measured by ELISA (Enzyme-Linked 
ImmunoSorbent Assay) and used to calculate the mass of unbound A1. 
Subsequently, the number of A1 molecules per hESC was estimated based on 
the equation below (Figure 3-1). At the same time, the cell viability in the 
pellet was estimated by PI uptake via flow cytometry. 
 
Figure 3-1: Equation to calculate the number of A1 molecules per hESC from the mass 
of unbound A1. 
 
3.10 Enzyme-Linked ImmunoSorbent Assay (ELISA) 
ELISA was performed to estimate the concentration of unbound A1 in the 
supernatant after binding with hESC. Capture antibody (goat anti-human IgG1, 
heavy-chain specific, 5 μg/ml in bicarbonate buffer, 100 μl, Sigma) was 
coated onto 96-well plate (NUNC MaxiSorp) and incubated for 2 hours at 
37
o
C. The plate was then washed three times with 0.1% Tween/PBS- and 
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blocked by 3% BSA/PBS- for 1 hour at 37
o
C. After washing, serial diluted 
standard antibody (human Fc, chimeric IgG1 A1 with known concentration) 
and serial diluted unbound A1 (human Fc, chimeric IgG1 A1 with unknown 
concentration) were added to the plate correspondingly. After 1-hour 
incubation at 37
o
C, the plate was washed again and incubated with secondary 
antibody (goat anti-human IgG, Fc specific, peroxidase conjugated, 1:5000 in 
bicarbonate buffer, Sigma) for 1 hour at 37
o
C. Subsequently, unbound 
secondary antibodies were washed away and o-phenylenediamine 
dihydrochloride (OPD, Pierce) was used as the soluble substrate for 
development of the colorimetric assay. Due to the enzyme (peroxidase) 
reaction with H2O2, an oxidized product will be formed which reacts with the 
colourless, chromogenic substrate (OPD) to form an orange coloured product. 
After 4 minutes, the reaction was stopped by denaturation of the enzyme with 
hydrochloric acid (100 μl, 3 M). The absorbance value of the oxidized product 
was read by the 96-well Plate Reader (Sunrise Absorbance Reader, TECAN) 
at 492 nm with a reference wavelength of 620 nm. Absorbance values of all 
samples were normalized against the blank value and the relative absorbance 
of the standards were then plotted against their corresponding concentrations 
to generate a standard curve. Based on the equation of regression line, the 
concentration of unbound A1 was calculated.  
3.11 Antibody and inhibitors treatment 
For mAb treatment experiments, single-cell suspension were harvested and 
resuspended in 1% BSA/PBS-. Cells (2 x 10
5
) were treated with 5 μg of A1, 
PBS- as buffer control, for 45 minutes at 4°C in the volume of 100 μl, and 
then proceed for flow cytometry analysis.  
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In sugar blocking assay, 5 μg of A1 was pre-incubated with nine different 
sugars in the concentration of 2 mM in PBS- (Type-1 H (H1), Type-2 H (H2), 
Lacto-N-fucopentaose I (LNFP1), Type-1 A (bgA), Type-1 B (bgB), LewisA, 
LewisB, LewisX and LewisY, Dextra Laboratories Ltd) separately prior to the 
addition to hESC.  
For other inhibitor assays, where appropriate, hESC were pre-incubated with 
the actin polymerization inhibitors: Latrunculin A (4 μg, Sigma-Aldrich), 
cytochalasin B (4 μg, Sigma-Aldrich), and cytochalasin D (4 μg, Sigma-
Aldrich) for 5 minutes before mAb treatment; or the ROS scavengers: Tiron 
(4,5-Dihydroxy-1,3-benzenedisulfonic acid disodium salt monohydrate, 50 
mM, Sigma-Aldrich) or Tempol (4-Hydroxy-2,2,6,6-tetramethylpiperidine 1-
oxyl, 120 mM, Sigma-Aldrich) for 1 hour before mAb treatment; or the 
NADPH oxidase inhibitors: DPI (Diphenyleneiodonium chloride, 240 μM, 
Sigma-Aldrich) or Apo (Acetovanillone or Apocynin, 40 mM, Sigma-Aldrich), 
or MPA (Mycophenolic acid, 3.12 mM, Sigma-Aldrich) for 1 hour before 
mAb treatment. For in-culture glycan inhibitor treatment, tunicamycin (5 
μg/ml, Sigma-Aldrich) and Benzyl 2-acetamido-2-deoxy-α-D-
galactopyranoside (Benzyl-α-GalNac, 4 mM, Sigma-Aldrich) were spiked into 
hESC culture in 6-well flat-bottom plate (Falcon) 4 days after passaging. After 
24-hour treatment, hESC were harvested for flow cytometry analysis to check 
pluripotency, down-regulation of glycosylation as well as A1 binding and 
killing of hESC. Besides Tiron and Tempol, all other inhibitors were 
reconstituted in DMSO. Therefore, for negative control, hESC were treated 
with the same volume of DMSO as the inhibitors treatment.  
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3.12 SCID mouse teratoma model: in vitro treatment 
HES-3 were cultured at 37
o
C, 5% CO2 on matrigel-coated culture dishes 
supplemented daily with CM from immortalized mouse feeders, ΔE-MEF. On 
day 5, the cells were pre-washed 3 times with PBS- and incubated with PBS- 
for 1.5-2 hours at 37
o
C, 5% CO2. Subsequently, cells were harvested into 
single-cell suspension by gentle pipetting. Single-cell suspension (5 x 10
6
 
cells/per mouse in 30 μl fresh KO media were mixed with 125 μg of IgG1 A1 
(30 μl in HEPES), and matrigel (30 μl), and immediately injected into the 
quadriceps of the right hind leg of a female SCID mouse. As a negative 
control, cells were mixed with 30 μl of HEPES. As an isotype control, cells 
were mixed with 125 μg of IgG1 A19 (30 μl in HEPES). To demonstrate the 
cytotoxicity is independent of ADCC, the single-cell suspension of hESC (5 x 
10
6
 cells/per mouse in a 30 μl KO media) were mixed with F(ab)2_A1 digested 
from 125 μg IgG1 A1 (30 μl in HEPES). Each condition has 3 SCID mice. 
Animal experiments were performed in accordance with NIH and NACLAR 
guidelines. Teratoma formation was monitored visually and measured by 
caliper using a previously established grading system
34
: grade 0 = no visible 
teratoma (6.32 mm average maximal hind leg diameter), grade 1 = teratoma 
just detectable (10.55 mm average), grade 2 = teratoma obvious (13.2 mm 
average), and grade 3 = teratoma impedes locomotion (14.52 mm average).  
3.13 SCID mouse teratoma model: in vivo treatment 
Cell on day 5 were harvested via the same method as described above. Single-
cell suspension of hESC (5 x 10
6
 cells/per mouse in a 30 μl KO media) were 
mixed with matrigel (30 μl) and directly injected into the quadriceps of the 
right hind leg of a female SCID mouse. Subsequently, 125 μg of A1 (30 μl in 
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HEPES) were injected at approximately the same site to “hunt” previously 
injected hESC. Similar to in vitro treatment, mice in another condition were 
injected with F(ab)2_A1 digested from 125 μg IgG1 A1 (30 μl in HEPES). 
Each condition has 3 SCID mice. 
3.14 Light and fluorescence microscopy imaging 
Light and fluorescence imaging of cryo-sectioned slides in penetration studies, 
detection of ROS production and homotypic adhesion upon A1 treatment were 
performed using an Olympus IX71 inverted microscope (Olympus). Detection 
of ROS production and homotypic adhesion upon A1 treatment was performed 
in 96-well plates (CellStar). Fluorescence imaging of F-actin and G-actin upon 
A1 treatment was acquired using Spinning Disk Confocal (PerkinElmer) in µ-
Dish
35 mm high 
(ibidi). F-actin was labelled with Alexa Fluor 488 Phalloidin 
(Life Technologies), nucleus was stained by Hoechst blue (Life Technologies), 
and G-actin was labelled with Deoxyribonuclease I, Alexa Fluor 594 
Conjugate (Life Technologies).  
3.15 Transmission Electron Microscopy 
Cells after treatment were fixed with 4% paraformaldehyde and 2.5% 
glutaraldehyde in 0.1 M cacodylate buffer (pH 7.3) for a first 15 minutes at 
room temperature and then overnight with fresh fixatives at 4
o
C; and post-
fixed by 1% OsO4 in 0.1 M cacodylate buffer (pH 7.3) for 1-2 hours at 4
o
C. 
Fixed cells were dehydrated in a graded series of ethanol from 30% to 100% 
and propylene oxide. Subsequently, dehydrated cells were embedded in Spurr 
resin (SPI-CHEM, Low Viscosity Spurr Kit). Silver to gold ultra-thin sections 
were cut with ultra-microtome (Leica Ultracut UCT) and stained in 1% uranyl 
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acetate for 15 minutes and lead citrate for 10 minutes. Stained sections were 
examined with a transmission electron microscope (JEOL JEM 2010F TEM, 
200kV, FEG). 
3.16 Scanning Electron Microscopy 
After A1 treatment, unbound A1 were washed away and cells were primarily 
fixed by 4% paraformaldehyde and 2.5% glutaraldehyde in PBS- (pH 7.3) for 
15 minutes at room temperature. Fixed cells were then washed and 
resuspended with deionized water and loaded onto poly-L-lysine-coated 
coverslips (20 mm in diameter). Cells were allowed to settle down for 10-15 
minutes. Subsequently, cells were fixed with 4% paraformaldehyde and 2.5% 
glutaraldehyde (pH 7.3, in PBS-) for 3-5 hours. Fixed cells were dehydrated in 
a graded series of ethanol from 30% to 100%. Subsequently, dehydrated cells 
were dried by Critical Point Dryer (Tousimis Autosamdri-815) and surface 
coated with Platinum (40 seconds, 40 mA, JEOL JFC-1600 Fine Coater). 
Coated samples were examined with a scanning electron microscope (Helios 
NanoLab DualBeam, FEI) and cell morphology was observed under secondary 
electron mode. For ROS depletion experiment, cells were firstly pre-incubated 
with ROS scavenger Tiron prior to A1 treatment. For immuno-SEM, cells 
were primarily fixed with only 4% paraformaldehyde for 15 minutes. After 
primary fixation, un-reacted aldehyde was blocked away with 100 mM glycine. 
After 3 times wash with 1% BSA/PBS-, cells were incubated with 100 μl 
gold-conjugated secondary antibody (25 nm, goat anti-human, IgG, EMS) for 
1 hour. Cells were then washed and fixed with 4% paraformaldehyde and 2.5% 
glutaraldehyde in PBS- (pH 7.3) for 2 hours before loaded to poly-L-lysine-
coated coverslips (10 mm in diameter). After dehydration and critical point 
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drying as describe above, cells on coverslips were surface coated with carbon. 
Coated samples were examined with a scanning electron microscope (JEOL 
JSM-6701F, FEG). Cell morphology was observed under secondary electron 
mode, gold particles were detected under backscatter mode, and a combined 
mode is available to overlay cell morphology with gold particles.  
3.17 Induction of apoptosis via Ultra-violet (UV) irradiation 
Confluent hESC cultures were exposed to 200 mJ of UV using a UV cross-
linker (UV Stratalinker 1800, Stratagene) to induce apoptosis
34
. After UV 
exposure, the cells were maintained at 37
o
C/5% CO2 for 20 hours before 
harvesting for apoptotic assays.  
3.18 Caspases assay 
Guava Caspase3/7-FAM kit and Caspase9-SR kit (Millipore) were used to 
measure caspase 3/7/9 activity. The Guava Caspase Assays employ a FLICA 
(Fluorescent Labelled Inhibitor of Caspase) reagent that specifically identifies 
active caspases. Each FLICA is comprised of three subunits: an active site 
binding peptide to confer specificity (DEVD for caspase 3/7, and LEHD for 
caspase 9); a covalent crosslinking agent (FMK); and a green (FAM) or 
orange-red fluorescent probe (SR). In this assay, the membrane integrity and 
cell viability were simultaneously evaluated using 7-AAD. Cells (non-treated, 
UV-treated, A1-treated) were resuspended in 100 μl PBS- at a concentration 
of 2 x 10
6 
cells/ml and incubated with 10 μl of caspase reagent for 1 hour at 
37
o
C in a CO2 incubator. At the end of incubation, cells were washed twice 
with provided washing buffer, resuspended in 200 μl of 7-AAD working 
solution and incubated for 10 minutes at room temperature. After incubation, 
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cells were washed twice and analysed by flow cytometer (Guava EasyCyte, 
Millipore).  
3.19 TUNEL assay 
TUNEL assay measures the extent of DNA fragmentation upon cell death
107
. 
APO-DIRECT TUNEL Kit (Millipore) was used. UV-treated hESC was used 
as a positive control since UV crosslinking is reported to induce apoptosis in 
hESC
34
. Cells (non-treated, UV-treated, A1-treated) were fixed in 1% 
paraformaldehyde in PBS- (pH 7.4) at a concentration of 1-2 x 10
6
 cells/ml 
and the suspension was placed on ice for 30-60 minutes. After cells were 
washed twice with PBS-, they were resuspended in 70% ethanol at a 
concentration of 1-2 x 10
6
 cells/ml and incubated for 1 hour on ice. 
Subsequently, cells were washed three times and resuspended in 50 μl of 
staining solution (10 μl of TdT reaction buffer, 0.75 μl of TdT enzyme, 8 μl of 
fluorescein-dUTP and 32.25 μl of distilled H2O). Cells were then incubated for 
1 hour at 37
o
C and resuspended every 15 minutes. After incubation, cells were 
washed with rinsing buffer, resuspended in 0.5 ml of the Propidium 
Iodide/RNaseA solution, incubated in the dark for 30 minutes at room 
temperature, and analysed by flow cytometer (FACScan, Becton Dickinson 
FACS Calibur).   
3.20 Detection of ROS  
ROS production was detected with HE staining (Dihydroethidium, Sigma-
Aldrich). HE is a cell-permeable ﬂuorogenic probe that reacts with ROS to 
form ethidium. Ethidium intercalates within double-stranded DNA in the 
nucleus and emits red ﬂuorescence. Cells after pre-incubation with ROS 
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scavengers and A1 treatment were resuspended in 200 μl 1% BSA/PBS- with 
25 μM HE and incubated for 30 minutes in the dark at room temperature. 
After incubation, the intensity of red fluorescence was directly analysed on a 
Guava InCyte Flow Cytometer (Merck Millipore) with detection emission in 
the Red-HLog channel. Alternatively, 2 x 10
5 
hESC were pre-incubated with 
30 μM carboxy-H2DCFDA (Life Technologies) in 100 μl 1%BSA/PBS- for 
10 minutes at 37°C, and transferred into a flat-bottomed 96-well plate (BD 
Science). Carboxy-H2DCFDA is oxidized in the presence of ROS to carboxy-
DCF, which emits green ﬂuorescence. Cells were imaged before and after 
treatment with 5 μg of A1. 
3.21 Assessment of homotypic adhesion formation 




were pre-incubated with 50 mM Tiron or PBS- in 100 μl 
1% BSA/PBS- in a flat-bottomed 96-well plastic plate (BD Science) for 1 hour 
at 4
o
C. After pre-incubation, cells were treated with 5 μg of A1 or F(ab)2_A1 
or Fab_A1 or PBS- for 45 minutes at 4
o
C. Subsequently, cells were viewed 
using light microscopy imaging. 
3.22 Flow cytometry analysis-cytotoxicity assay 
Cytotoxicity of A1 or digested A1 fragments after papain treatment on hESC, 
or spontaneously differentiated hESC, or hESC after pre-treatment with 
inhibitors was evaluated using propidium iodide (PI) exclusion assays via flow 
cytometry analysis. PI (1.25 mg/ml) were directly added into cell suspension 
after treatment with A1 or digested A1 fragments and analysed on a Guava 
InCyte Flow Cytometer (Merck Millipore) with detection emission in the Red-
HLog channel or on a FACScan (Becton Dickinson FACS Calibur) with 
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detection emission in the FL-3 channel. To demonstrate the correlation 
between ROS production and cell death, cells were stained with 25 μM HE as 
previously described for 10 minutes first and together with 1.5 pM Sytox 
green dead-cell stain (Life Technologies) for another 20 minutes. After 
incubation, cells were analysed on a Guava InCyte Flow Cytometer (Merck 
Millipore) with detection emission in the Red-HLog channel for HE and 
Green-HLog channel for Sytox green. All incubations were performed at 4
o
C 
unless otherwise indicated. 
3.23 Flow cytometry analysis-binding assay 
To evaluate the pluripotency-associated markers of hESC, cells at a 
concentration of 2 x 10
6
 cells/ml were incubated with mAb to Oct3/4 (2.5 μg, 
Santa Cruz) or mAb to Tra-1-60 (Millipore) in 100 μl 1% BSA/PBS- for 30 
minutes. Cells were then washed with cold 1% BSA/PBS-, and further 
incubated for 15 minutes with FITC-conjugated goat anti-mouse secondary 
antibody (1:500 dilutions, DAKO) or APC-Conjugated rabbit anti-mouse 
secondary antibody (1:500 dilution, DAKO). After incubation, cells were 
again washed and resuspended in 1% BSA/PBS- for analysis on a FACScan 
(Becton Dickinson FACS Calibur) with detection emission in the FL-1 
channel for FITC signal and FL-4 channel for APC signal, or on a Guava 
InCyte Flow Cytometer (Merck Millipore) with detection emission in the 
Green-HLog channel for FITC signal and Red2-HLog channel for APC signal. 
As controls, cells were only incubated with secondary antibody (FITC-
conjugated antibody or APC-conjugated antibody). To evaluate the binding of 
A1 to hESC or hESC after pre-treatment with inhibitors, cells were incubated 
with goat anti-human FITC secondary antibody (1:700 dilutions, DAKO) for 
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15 minutes and washed twice before Flow cytometry analysis. To evaluate the 
binding of papain or IdeS protease digested A1 fragments or undigested A1 to 
hESC, cells were incubated with anti-human Fc specific primary antibody 
conjugated with biotin (1:2000 dilutions, Sigma-Aldrich) for 30 minutes and 
followed by 15 minutes incubation with FITC-conjugated streptavidin (1:100 
dilutions, DAKO), or cells were incubated with kappa-light chain specific 
FITC-conjugated antibody (1:100 dilutions, Sigma-Aldrich). To evaluate the 
down-regulation of N-glycosylation after tunicamycin treatment, hESC or 
hESC after tunicamycin treatment was incubated with biotin-conjugated 
Concanavalin A (4 μg/ml in DMSO, Vector Labs) for 30 minutes. After 
washing, cells were incubated with streptavidin-FITC (1:100 dilutions, DAKO) 
for 15 minutes before Flow cytometry analysis. All incubations were 
performed at 4
o
C unless otherwise indicated.  
3.24 Measurement of NADPH oxidase activity 
Human ESC with or without A1 treatment were washed and pelleted with 2 x 
10
6
 cells in a micro-centrifuge tube for NADP/NADPH Assay (Abcam). Total 
NADP/NADPH was extracted from each sample according to the 
manufacturer’s protocol. NADPH was obtained by decomposing the NADP 
component with heat. To quantify the concentration of total NADP/NADPH 
or NADPH, a standard curve was generated with provided NADPH standards. 
The average absorbance of the duplicates for each standard or sample was 
determined and normalized against the mean absorbance value of the blank. 
Based on the trend line equation of the standard curve, the concentration of 
total NADP/NADPH or NADPH of the samples was obtained. The 
concentration of NADP was obtained by subtracting the concentration of 
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NADPH from that of total NADP/NADPH. Therefore, the ratio of 
NADP/NADPH was obtained.  
3.25 Knockdown of Nox2/gp91 and Nox3 using small interfering RNA 
Human ESC maintained either with daily change of CM or mTeSR (StemCell 
Technologies), were passaged weekly by cutting into small clumps. On the 
day of transfection, healthy and exponentially growing cells (70%-90% 
confluence on day 5 after passaging) were fed with mTeSR (8 ml/6 cm plate) 
6-8 hour prior to transfection. Cells were then incubated with ROCK Inhibitor 
Y-27632 (Calbiochem, 10 μM) for 1 hour. These steps are necessary to 
preserve cell viability after transfection. At the same time, transfection 
solution was prepared. 80 pmol to 120 pmol of target siRNA or scramble 
siRNA (Silencer Select, Life Technologies) or 5 μl of Lipofectamine 
RNAimax were mixed separately in OPTI-MEMI (Invitrogen) in the volume 
of 50 μl; and incubated at room temperature for 5 minutes. The contents of the 
two tubes were combined by gentle pipetting and incubated at room 
temperature for 30-50 minutes. The resulting transfection solution (100 μl) 
was used to resuspend the cell pellet produced after Accutase dissociation. 
After incubation, cells were then dissociated into single-cell suspension using 
Accutase (STEMCELLPRO) (3 ml/6 cm plate, 18 minutes at 37
o
C), and 
neutralized by 4 ml of mTeSR. Cells were then pelleted by centrifugation 
(25xg, 3 minutes). Cells (1 x 10
6
 to 2 x 10
6
) were equally allocated to each 
condition. Cell pellet was resuspended in 100 μl of siRNA/Lipofectamine 
transfection solution and incubated at room temperature for 10-15 minutes. At 
the end of the incubation, 1.5 ml of pre-warmed fresh growth media (mTeSR 
containing ROCK inhibitor at a final concentration of 10 μM) was added and 
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the suspension was transferred into a Matrigel-coated well of a six-well plate, 
followed by overnight incubation at 37
o
C, 5% CO2. Transfected cells were 
maintained with daily change of mTeSR and harvested for various assays 4-5 
days after transfection. Knockdown efficiency was assessed by western 
blotting and qRT-PCR.  
3.26 RNA extraction, reverse transcription, and qRT-PCR 
Total mRNAs were extracted from cell pellets using RNeasy® MiniKit 
(Qiagen) according to the manufacturer's instructions. Then, cDNAs were 
produced using Oligo dT (Life Technologies) and M-MLV reverse 
transcription kit (Promega) according to the manufacturer's protocol. 
Quantitative real-time polymerase chain reaction (qRT-PCR) was performed 
using Fast SYBR green (Applied Biosystems) or TaqMan Fast Advanced 
Master Mix (Life Technologies) with 7500 Fast Real time PCR system 
(Applied Biosystems). For Nox2 and Nox3 knockdown experiment, TaqMan 
Gene Expression Assay containing specific primers and probes was used 
(Nox2: Hs00166163_m1, Nox3: Hs01098883_m1, and GAPDH: 
Hs02758991_g1). For markers of pluripotency, endoderm, mesoderm and 
ectoderm, specific primers sequences are listed in Table 3-1.  
Table 3-1: Sequences of specific primers used in qRT-PCR for markers of pluripotency, 




Gene name Primer sequences (F) Primer sequences (R)
Pluripotency 
Oct4 F: 5'-GGCCGCAGCTTACACATGTT-3' R: 5'-AACGACCATCTGCCGCTTT-3'
Nanog F: 5'-GAAAAACAACTGGCCGAAGAAT-3' R: 5'-GGTGCTGAGGCCTTCTGC-3'
Endoderm
AFP F: 5'-TCCCTCCTGCATTCTCTGATG-3' R: 5'-CCTGAGCTTGGCACAGATCC-3'
GATA6 F: 5'-GCGGCTTGGATTGTCCTGT-3' R: 5'-TGCGCCATAAGGTGGTAGTTG-3'
Mesoderm
Hand1 F: 5'-TTCTTCGAATCGTGGTGGTTT-3' R: 5'-CAGGAAGTGCAGCGACAAAA-3'
Nkx2.5 F: 5'-TCCCCTGGATTTTGCATTCA-3' R: 5'-AGGATCACTCATTGCACGCTG-3'
Ectoderm
Pax6 F: 5’-CCAGCTTCACCATGGCAAAT-3’ R: 5’-GGCAGCATGCAGGAGTATGAG-3’
Msx1 F: 5'-GCCATGTCTCCTGCATAGCTT-3' R: 5'-CGCTTTTCTTGCCTGGTGTC-3'
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3.27 Mitochondrial membrane permeability assay 
The membrane-permeable JC-1 dye (Molecular Probes) was used to assess 
mitochondrial membrane permeability. JC-1 dye accumulation in 
mitochondria is potential-dependent. JC-1 monomers emit green fluorescence 
(~529 nm) whist JC-1 aggregates emit red fluorescence (~590 nm). 
Mitochondrial depolarization is indicated by a decrease in the red/green 
fluorescence intensity ratio. After A1 treatment, cells with or without Nox2 
knockdown were washed and incubated with JC-1 dye (1:100 dilutions) at 
37
o
C for 30 minutes. After incubation, red and green fluorescence changes 
were monitored with flow cytometry analysis.   
3.28 Statistics  
Error bars represent the standard error of mean (SEM) of at least 3 
independent experiments unless otherwise stated. Significance in difference 
between the experimental groups was calculated using unpaired, 2-tailed t test. 
The degree of statistical significance was represented by the number of 
asterisks displayed on the figures determined by P values as follows: * < .05, 




4 CHAPTER 4 IN VITRO CHARACTERIZATION OF A1 
4.1 Discovery of mAb TAG-A1 (A1) 
A panel of monoclonal antibodies (mAb) against hESC surface markers was 
generated by immunizing BALB/c mice with undifferentiated hESC (Figure 
4-1). Briefly, viable undifferentiated hESC were injected into BALB/c mice 
over a period of 5 weeks. Serum was drawn from immunized mice and 
screened for the presence of antibodies that bind to hESC. The positive mice 
were then sacrificed to harvest the spleens. The spleenocytes were 
subsequently fused with Sp2/0 myeloma cells and colonies of hybridomas 
were isolated after hypoxanthine-aminopterin-thymidine (HAT) selection. 
Specificity of the mAbs produced from the hybridomas was first screened 
against hESC lines including hES-3, hES-2, and hES-4. Secondary screening 
was performed for positive clones to determine the cross reactivity of these 
mAbs with other cells lines, namely human fibroblast (IMR90), mouse feeders 
(ΔE-MEF), mouse embryonic stem cells (mESC), human embryonic 
carcinoma (EC) cells (Ntera, 2102Ep, NCCIT), and other human cell lines 
(HEK-293, HeLa). Thus, a panel of mAbs specifically against hESC surface 
markers was shortlisted. From this panel of mAbs, mAb TAG-A1 (A1) was 
identified to selectively bind to and kill undifferentiated hESC. This property 
is similar to a previously described mAb, mAb84. However unlike mAb84 
which is an IgM, A1 is an IgG. Since mAb A1 is a mouse mAb, to avoid 
immune response when used in humans, chimeric A1 with human Fc was 
produced. The antibody genes encoding the variable region of the mAb was 
amplified by PCR and cloned into a mammalian expression vector containing 
the human IgG1 constant regions. The vector was then transfected into CHO 
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cells for expression of the chimeric mAb. For this project, all experiments 
were performed with chimeric A1. 
This chapter reports the in vitro characterization of A1 and where relevant, 
benchmarking it to mAb84. The specificity of A1 cytotoxicity was first 
determined against undifferentiated hESC, hiPSC and spontaneously 
differentiated hESC via embryoid body (EB) formation or FGF-2 starvation. 
Subsequently, the antigen target of A1 on hESC was investigated. Next, A1 
was characterized by determining its dosage efficiency, killing kinetics, 
nucleic acid and amino acid sequences in the variable regions, competitive 
binding, and penetration efficiency into EB, benchmarking to mAb84. Last but 
not the least, the binding stoichiometry between A1 and hESC, as well as the 
association between A1 cytotoxicity and its structure e.g. bivalency vs 




Figure 4-1: Generation of monoclonal antibodies against hESC surface markers by 
hybridoma formation.  
 
4.2 A1 binds to and kills undifferentiated hPSC 
To investigate the reactivity of A1 to undifferentiated hPSC, hESC or hiPSC 
were treated with A1 for 45 minutes at 4
o
C. After incubation, A1 binding and 
killing were analysed by flow cytometry analysis. A1 showed strong binding 
to both undifferentiated hESC and hiPSC derived from human fetal lung 
fibroblasts (ESIMR90) (Figure 4-2A). Cell viability was estimated via the 
uptake of a cell impermeable dye, propidium iodide (PI), which binds to 
nucleic acids in cells with compromised plasma membrane and emits a red 
fluorescence. Increased PI uptake indicates cell death (Figure 4-2B). In-house 
BAL B/C
a. 5 weekly injections of live hESC
b. Screen serum for antibodies that bind to hESC
c. Sacrifice mouse and harvest the spleen cells
d. Fusion: hybridomas
SP2/0 myeloma cells
e. Screen for Ig-producing hybridomas
f. Screen mAb against various  cell types
g. Antibodies specific to hESC
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mAb8 (IgG1) was used as an isotype control which binds to hESC without 
cytotoxicity. Upon A1 treatment, both hESC and hiPSC had a significant 
decrease in cell viability (Figure 4-2C). 
 
Figure 4-2: A1 binds to and kills both undifferentiated hESC and hiPSC.  
Either hESC or hiPSC (2 x 10
5 
in 100 μl) were treated with 5 μg of A1 or mAb8 for 45 
minutes at 4
o
C. (A) A1 showed strong binding to both hESC (HES-3) and hiPSC (ESIMR90). 
mAb8 also binds to hESC. Binding of mAbs was assessed with FITC-conjugated secondary 
antibody by flow cytometry analysis. Representative histograms are shown. Open histogram 
represents non-treated cells and shaded histogram represents A1-treated cells. Gated area 
represents positive mAb binding. (B) Upon A1 treatment, hESC viability dropped from 80.0% 
to 6.86%. mAb8 binding on hESC did not change hESC viability. Cell viability was assessed 
via PI uptake by flow cytometry analysis. Gated population represents viable cells. (C) A1 
kills both hESC (HES-3) and hiPSC (ESIMR90). Data are represented as mean ± SEM. 
4.3 A1 cytotoxicity is specific to undifferentiated hPSC 
To remove undifferentiated hPSC from differentiated cell products, the 
















































only specific to the undifferentiated phenotype, hESC were induced to 
spontaneous differentiate either by EB formation or FGF-2 starvation. 
4.3.1 A1 binding and cytotoxicity on differentiated hESC via EB formation 
EB are three-dimensional aggregates derived from undifferentiated hESC. 
Homophilic binding of highly expressed Ca
2+
-dependent adhesion molecule E-
cadherin facilitates EB formation. Cells within EB undergo spontaneous 




Human ESC-derived EB at different stages of spontaneous differentiation (day 
2, day 5, day 8, and day 15) were harvested for flow cytometry analysis. By 
co-staining undifferentiated hESC and differentiating cells with A1 and 
pluripotency marker antibody, anti-TRA-1-60, we found that A1 binding on 
cells was down-regulated along with the loss of cell pluripotency (Figure 
4-3A). At the same time, cell viability upon A1 treatment was assessed via PI 
uptake. We observed a complete loss of A1 cytotoxicity on differentiating 
cells from day 5 onwards (Figure 4-3B), indicating that A1 cytotoxicity might 
be an earlier indicator of cell differentiation than the expression level of 




Figure 4-3: A1 loss binding and cytotoxicity on hESC-derived EB.  
Cells (2 x 10
5 
in 100 μl) were treated with 5 μg of A1 for 45 minutes at 4oC. (A) Loss of A1 
binding is correlated with loss of pluripotency on spontaneously differentiated EB. Cells were 
dual-stained with A1 and antibody to pluripotency marker, anti-Tra-1-60. Representative 
scatter plots are shown. (B) A1 cytotoxicity on undifferentiated hESC and hESC-derived EB 
at different stages of spontaneously differentiated. Cell viability was assessed via PI uptake by 
flow cytometry analysis. Data are represented as mean ± SEM. 
 
 
4.3.2 A1 binding and cytotoxicity on differentiated hESC via FGF-2 
starvation 
Alternatively, since FGF-2 is important for maintaining hESC pluripotency
84
, 
hESC were induced to differentiate via FGF-2-starvation. A similar trend was 
observed though down-regulation of A1 binding and cytotoxicity was much 
slower (Figure 4-4). Taken together, we conclude that the binding and 
cytotoxicity of A1 is only specific to undifferentiated hESC. The ability of A1 
to selectively kill undifferentiated hPSC is beneficial for the use of A1 to 
remove residual undifferentiated hPSC from differentiated cell products prior 

































Figure 4-4: A1 loss binding and cytotoxicity on differentiated hESC via FGF-2 
starvation.  
Cells (2 x 10
5 
in 100 μl) were treated with 5 μg of A1 for 45 minutes at 4oC. (A) Loss of A1 
binding is correlated with loss of pluripotency on FGF-2-starved cells. Cells were dual-stained 
with A1 and antibody to pluripotency marker, anti-Tra-1-60. Representative scatter plots are 
shown. (B) A1 cytotoxicity on undifferentiated hESC and differentiated cells at different 
stages of FGF-2 starvation. Cell viability was assessed via PI uptake by flow cytometry 
analysis. Data are represented as mean ± SEM. 
 
4.4 A1 cytotoxicity on hESC is dosage-dependent 
Next, flow cytometry analysis was performed to investigate the effect of 
dosage on the cytotoxicity of A1, benchmarking to mAb84. The concentration 
of A1 was titrated over the range of 0.78-10 μg for 2 x 105 hESC in a volume 
of 100 μl for 45 minutes incubation at 4oC. Cell viability was assessed by PI 
uptake. We found that A1 has a dosage-dependent cytotoxicity towards hESC 
up to 5 µg (Figure 4-5), similar to mAb84. Further increase in mAb 
concentration (up to 10 µg) did not result in addition enhancement of 
cytotoxicity. There was no cell survived upon re-plating the cells back in CM 

































Figure 4-5: A1 cytotoxicity on hESC is dosage-dependent.  
Human ESC (2 x 10
5 
in 100 μl) were treated with different amount of A1 or mAb84 for 45 
minutes at 4
o
C. Cell viability was assessed via PI uptake. Data are represented as mean ± SEM. 
 
4.5 Kinetics of A1 killing on hESC 
Next, we examined the kinetics of A1 killing. In this time course study, cells 
(2 x 10
5 
in 100 μl) were treated with 5 μg of A1 or mAb84 at 4oC. PI uptake 
was measured after the first minute of incubation and every 5 minutes 
thereafter. A1 killing of hESC occurred rapidly with an 80% drop in hESC 
viability within 1 minute of A1 treatment (Figure 4-6). Extended incubation 
did not lead to further decrease in cell viability. There was no cell survived 
upon re-plating the cells back in CM and incubated over 48 hours, indicating 
the remaining 20% cells were dead as well. 
 
Figure 4-6: A1 kill hESC rapidly within 5 minutes of incubation.  
Human ESC (2 x 10
5 
in 100 μl) were treated with 5 μg of A1 or mAb84 for different time 
periods at 4
o















































4.6 Kinetics of A1 killing on hESC is not dosage-dependent 
Based on the result of A1 kinetics study shown in Figure 4-6, A1 killing 
occurs at a very fast rate. In an attempt to slow down the rate of cell killing to 
facilitate time-lapse imaging, we investigated if the dosage of mAb affected 
the kinetics of A1 killing. Cells were treated with various dosages of A1 and 
cell viability was estimated at 10-minute intervals. Surprisingly, regardless of 
the dosage of A1, most of the cell killing was achieved within the first 10 
minutes of incubation (Figure 4-7A). The assay was repeated however only 
focusing on the first 10 minutes with the middle three A1 dosages. Cell 
viability was assessed at 2-minute intervals. Most of the killings were still 
achieved within the first minute (Figure 4-7B). Therefore, it is difficult to slow 
down the killing process by reducing antibody dosage, as it only reduced the 
killing efficiency.  
 
Figure 4-7: kinetics of A1 cytotoxicity on hESC is not dosage-dependent.   
(A) Cells (2 x 10
5 
in 100 μl) were treated with various dosages of A1 from 0.25 μg to 4 μg at 
4
o
C and cell viability was assessed by PI uptake at every 10 minutes. (A) Cells (2 x 10
5 
in 100 
μl) were treated with various dosages of A1 from 0.5 μg to 2 μg at 4oC and cell viability was 
assessed by PI uptake at every 2 minutes. Data are represented as mean ± SEM. 
 
4.7 Identification of A1 antigen target on hESC 
Identification of the antigen target is not only important for the 

















































between the mAb and the target cell. Therefore, to characterize A1 and study 
A1-induced hPSC death, we examined its target antigen on hESC.    
4.7.1 A1 binds to glycoproteins on hESC  
Target antigens were enriched from total hESC lysate by immuno-
precipitation (IP) using A1 as the capture mAb. When the IP eluate was 
resolved on SDS-PAGE and immunoblotted with A1 after western blotting, it 
revealed a smear from 35-200 kDa (Figure 4-8A), whereas the antigen of 
mAb84 is a single protein band identified as PODXL
37
. The corresponding 
bands on a silver-stained gel were excised and analysed by mass spectrometry 
(MS). By mapping MS results with Uniprot Protein Database, strong antigen 
candidates were selected and can be divided into four protein groups (Figure 
4-8B): cell adhesion proteins, cytoskeleton-associated proteins, ATPase 
proteins and transporter proteins. Intriguingly, over 70% of the antigen 
candidates are glycoproteins.  
Glycoproteins are proteins with oligosaccharide chains (glycans) covalently 
attached to polypeptide side-chains via post-translational modification. A 
smeared antigen band and high percentage of glycoproteins in the MS result 
suggest that A1 is recognizing glycans on target antigens. Hence, to 
investigate whether A1 binding on hPSC is dependent on glycans, immuno-
precipitated antigens were resolved by gel electrophoresis, western blotted and 
treated with sodium periodate to open existing sugar rings
109
 followed by  
immunoblotting with A1. Comparing to the non-treated control, A1 binding to 
the entire smear was abolished after periodate-treatment of the blot (Figure 






Figure 4-8: A1 binds to multiple glycoproteins on hESC. 
(A) A1 binds to glycans on multiple target antigens on hESC. Affinity purified A1 antigens 
from hESC lysate were resolved on SDS-PAGE, transferred to PVDF membrane, subjected to 
sodium periodate treatment and immunoblotted with A1. (B) Protein IDs were identified by 
mapping peptides from mass spectrometry analysis against the Homo sapiens subset of the 
Uniprot database. Antigen candidates were selected with the following filter settings: match 




4.7.2 A1 recognizes O-linked glycans on target antigens 
Glycans are attached to proteins via glycosylation. In general, there are two 
major types of glycosylation, namely, N-glycosylation and O-glycosylation. 
N-glycosylation attaches glycans to the nitrogen of asparagine or arginine 
side-chains
110
, whilst O-glycosylation attaches glycans to the hydroxyl oxygen 
of serine, threonine, tyrosine, hydroxylysine, or hydroxyproline side chain
111
. 
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addition, sialic acid, a monosaccharide with nine-carbon backbone, is typically 
found to be terminating branches of N-linked glycans and O-linked glycans
112
.  
Next, the type of glycans that A1 recognizes was investigated. Affinity 
enriched A1 antigens were sequentially digested with sialidase, N-glycosidase 
F (PNGase F) and β-elimination. Sialidase can effectively hydrolyse the 
glycosidic linkage of terminal sialic residues in glycoproteins
113
. Removal of 
terminal sialic acid can expose N-linked and O-linked glycans. PNGase F 
releases N-linked glycans by cleaving the link between asparagine and N-
acetylglucosamines
114
. β-elimination removes O-linked glycans attached on 
serine and threonine residues from glycoproteins in the reduced form
115
. 
Samples were taken from each enzymatic digestion and immunoblotted with 
A1. Based on Figure 4-9, A1 recognizes non-sialylated glycans since sialidase 
treatment did not alter A1 binding (lane 1 vs lane 2). A1 did not bind to 
antigens in the size range of 35-50 kDa and 60-90 kDa upon β-elimination 
treatment alone (as highlighted in dashed gate from lane 5 to lane 8), 
indicating A1 recognizes O-linked glycans on these antigens. Upon both 
PNGase F and β-elimination treatment, A1 also did not bind to antigens in the 
size range of 90-200 kDa (as highlighted in dotted gate at lane 7 and 8). 
However, since certain O-linked glycans can only be removed upon N-
deglycosylation
115
, it was insufficient to conclude whether N-linked glycans 




Figure 4-9: A1 recognizes O-linked glycans on target antigens from hESC lysate.  
Affinity purified A1 antigens from total hESC lysate were treated sequentially with sialidase 
and PNGase F, resolved on SDS-PAGE, transferred to PVDF membrane, subjected to β-
elimination, and immunoblotted with A1. Dotted gate represents loss of A1 binding upon both 
PNGase F and β-elimination treatment; dashed gate represents loss of A1 binding upon β-
elimination treatment alone.  
 
To verify whether A1 is also recognizing N-linked glycans and whether 
binding to O-linked glycans is associated with A1 killing on hESC, two 
glycosylation inhibitors, namely tunicamycin
116
 and Benzyl-α-GalNac (B-
GalNac)
117
, were used to inhibit N-glycosylation and O-glycosylation 
respectively in hESC culture. Tunicamycin blocks the formation of protein N-
glycosidic linkages by inhibiting the transfer of N-acetylglucosamine 1-
phosphate to dolichol monophosphate
116
. B-GalNac is an O-GlcNAc (OGT) 




Four days after passaging, hESC in culture were spiked with optimized 
amount of inhibitors in CM and incubated for 24 hours. For the negative 
control, hESC were fed with CM or CM with the same volume of DMSO as 
the inhibitors. After incubation, hESC were harvested in single-cell suspension 
for flow cytometry analysis. Firstly, the removal of N-linked glycans and O-
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linked glycans upon inhibitor treatment were verified. Concanavalin A (ConA), 
a lectin which binds specifically to N-linked glycans
118
, was used to verify the 
removal of N-linked glycans from hESC upon tunicamycin treatment. Tra-1-
60 is a pluripotency marker of hESC. Since the epitope of Tra-1-60 antibody is 
attached on an O-linked glycan core, Tra-1-60 antibody was used to verify the 




Figure 4-10: Partial inhibition of N-glycosylation and O-glycosylation by tunicamycin 
and Benzyl-α-GalNac treatment.  
Benzyl-α-GalNac (4 mM, 24 hours) and tunicamycin (5 μg/ml, 24 hours) were used to inhibit 
O-glycosylation and N-glycosylation in hESC culture respectively. (A) Tunicamycin 
treatment partially blocked N-glycosylation in hESC culture. Upon tunicamycin treatment, 
down-regulation of N-glycosylation was detected by a decreased binding of Concanavalin A 
(ConA), a lectin which binds specifically to N-linked glycans
118
. (B) Benzyl-α-GalNac 
treatment partially blocked O-glycosylation in hESC culture. Upon Benzyl-α-GalNac 
treatment, down-regulation of O-glycosylation was detected by a decreased binding of anti-
Tra-1-60 antibody which binds to O-linked glycan epitopes on hESC
119
. Lectin or antibodies 
bound to cells were detected with a FITC-conjugated streptavidin or anti-mouse antibody. 
Representative histograms are shown. The shaded histogram represents staining with the 
negative control and open histograms represent staining with primary antibodies.  
 
In Figure 4-10, it was observed that both the binding of ConA and Tra-1-60 



















negative controls, suggesting both N-glycosylation and O-glycosylation were 
partially inhibited with the inhibitor treatments. 
Since there is a decrease in anti-Tra-1-60 antibody binding to hESC, we 
continued to confirm this decrease was not due to loss of hESC pluripotency 





, Oct3/4), only the antibody to 
Oct3/4 is not recognizing a glycan epitope on hESC. Therefore, the expression 
level of Oct3/4 was examined upon inhibitor treatment. There is no significant 
change in the binding of Oct3/4 antibody to either tunicamycin or B-GalNac 
treated hESC compared to the CM control or the DMSO control (Figure 4-11), 
indicating that inhibitor treatment did not inhibit pluripotency marker (Oct3/4) 
expression. 
 
Figure 4-11: Expression of pluripotency marker, Oct3/4, was verified upon inhibitors 
treatment.  
Cells in different treatment conditions were stained with mAb to Oct3/4 or PBS- control. 
Antibodies bound to cells were detected with a FITC-conjugated anti-mouse antibody. The 
shaded histogram represents staining with the negative control and open histograms represent 
staining with primary antibodies. Upon either tunicamycin treatment or B-GalNac treatment, 
the binding histograms of Oct3/4 antibody are comparable to these of negative controls, 
representing no change in hESC pluripotency upon inhibitors treatment.  
 
With successful partial inhibition of both N- and O-glycosylation on hESC 
while maintaining hESC pluripotency, we proceeded to investigate the binding 
and killing of A1 on hESC. After 24 hours of treatment with the inhibitors, 
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hESC were harvested as single-cell suspension (2 x 10
5 
in 100 μl) and treated 
with 5 μg of A1 or PBS- for 45 minutes at 4oC. A1 binding and killing on 
hESC were assessed by flow cytometry analysis. It was observed that A1 
binding to hESC was down-regulated upon B-GalNac treatment, but not 
tunicamycin treatment, indicating A1 only binds to O-linked glycans on hESC, 
but not N-linked glycans (Figure 4-12). This finding further confirmed the 
previous conclusion from PNGase and β-elimination experiment.  
 
Figure 4-12: A1 binding to hESC was down-regulated upon B-GalNac treatment 
Benzyl-α-GalNac (4 mM, 24 hours) and tunicamycin (5 μg/ml, 24 hours) were used to inhibit 
O-glycosylation and N-glycosylation in hESC culture respectively. Cells in different treatment 
conditions were incubated with A1 or PBS-. Binding of A1 was assessed with FITC-
conjugated secondary antibody by flow cytometry analysis. Representative histograms are 
shown. Open histogram represents no treatment control and shaded histogram represents 
antibody-treated cells. Upon B-GalNac treatment, the binding histograms of A1 shifted 
towards to the left compared to these of negative controls and tunicamycin treatment, 
representing A1 binding is only down-regulated when O-glycosylation is inhibited.  
 
 
At the same time, cell viability upon B-GalNac treatment was significantly 
higher than the CM-control, DMSO-control and tunicamycin treatment 
(Figure 4-13), indicating binding to O-linked glycans is essential for A1 to 
elicit cytotoxicity on hESC.  
 










Figure 4-13: A1 cytotoxicity on hESC was down-regulated upon B-GalNac treatment 
Benzyl-α-GalNac (4 mM, 24 hours) and tunicamycin (5 μg/ml, 24 hours) were used to inhibit 
O-glycosylation and N-glycosylation in hESC culture respectively. Cells in different treatment 
conditions were harvested in single-cell suspension and treated with A1 or PBS-. Viability of 
cells was estimated by PI uptake. Cell viability in different treatment conditions was 
normalized to its corresponding negative controls (no A1 treatment). Upon B-GalNac 
treatment, cell viability upon A1 treatment was significantly higher than these of negative 
controls (CM control and DMSO control) as well as tunicamycin treatment. Data are 
represented as mean ± SEM.  
 
Since maintaining hESC in a pluripotent state is crucial to the experiment, 
here we further investigated whether hESC treated with glycan inhibitor 
remained pluripotent, i.e., able to be differentiated into cells of the three germ 
layers: endoderm, mesoderm and ectoderm. To test this, hESC either treated 
with DMSO or Benzyl-α-GalNac (4 mM or 8 mM) for 24 hours were passaged 
for spontaneous differentiation as EB. Cells were harvested at two time points: 
undifferentiated hESC and EB on day 7. Total mRNA was extracted from 
harvested cells for quantitative real-time PCR (qRT-PCR) analysis. RNA 
expression levels of markers for pluripotency, endoderm, mesoderm and 
ectoderm were normalized against endogenous control, RNA levels of 




































Figure 4-14: There is no difference in the relative RNA expression level of listed markers 
between DMSO control and B-GalNac treatment.   
Relative mRNA expression levels of pluripotency markers (Oct4, Nanog) and markers for the 
three germ layers (Endoderm: AFP, GATA6, Mesoderm: Hand1, Nkx2.5; Ectoderm: Pax6, 
Msx1). Data are represented as mean ± SEM. 
 
 
According to Figure 4-14, there was no significant difference in RNA 
expression level of markers for pluripotency and markers for the three germ 
layers between DMSO treatment of B-GalNac treatment. As expected, 
undifferentiated hESC had the highest expression level of pluripotency 
markers, Oct4 and Nanog, and lowest expression levels of germ layer markers, 
indicating cells were highly pluripotent. On Day7, expression of all six germ 
layer markers significantly increased whereas expression of pluripotency 
markers decreased drastically. All these observations confirmed that B-







































































4.7.3 A1 binds to epitope containing sugar motif (Fucα1-2Galβ1-
3GlcNAcβ1-3Galβ1) on hPSC antigens 
To determine the glycan epitope that A1 recognizes on hPSC, A1 binding and 
cytotoxicity on hESC was examined after pre-incubation with nine sugars of 
the non-sialylated blood group antigens, namely, type-1 H (H1), type-2 H (H2), 
Lacto-N-fucopentaose I (LNFP1), type-1 A (bgA), type-1 B (bgB), LNFP1, 
LewisA, LewisB, LewisX, and LewisY (Figure 4-15), separately for 30 
minutes before incubation with hESC for 45 minutes.  
 
Figure 4-15: Structures of the nine sugars used in the sugar inhibition assay
121
. 
The sugar motif (Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-) that may be part of the A1 binding 
epitope in H1, LNFP1 and Lewis B is highlighted in red box. 
 
Upon pre-incubation with different sugars, A1 binding on hESC as well as 
hESC viability was assessed by flow cytometry analysis. A decrease in A1 
binding on hESC was observed upon pre-incubation with H1, LNFP1 and 
LewisB (Figure 4-16), indicating a binding competition between these three 
sugars and the epitope on hESC for A1. Among the nine sugars, H1, LNFP1 
and LewisB share a common sequence of four monosaccharide and their 
linkages (Figure 4-15), suggesting A1 recognizes this glycan motif (Fucα1-
2Galβ1-3GlcNAcβ1-3Galβ1-) on hESC antigens.  




Figure 4-16: A1 binding on hESC was blocked by LNFP1, H1 and LewisB. 
A1 (5 μg) was pre-incubated with the nine different sugars (2 mM) prior to treatment with 2 x 
10
5 
cells (100 μl) for 45 minutes at 4oC. Binding of A1 was assessed with FITC-conjugated 
secondary antibody by flow cytometry analysis. Representative histograms are shown. Open 
histogram represents no treatment control and shaded histogram represents antibody-treated 
cells. 
 
Next, the specific antigen or antigens bands that are blocked by the three 
sugars were investigated. Immuno-precipitated antigens were resolved by gel 
electrophoresis and immuno-blotted with sugar-blocked A1. As a result, most 
of the antigens in the A1 control-blotted membrane were not detected in the 
other three blots (Figure 4-17).  
 
Figure 4-17: Binding profile of sugar-blocked A1 on hESC.  
Affinity purified A1 antigens from hESC lysate were resolved on SDS-PAGE, transferred to 
PVDF membrane, and immunoblotted with A1 or sugar-blocked A1. 
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From the same sugar inhibition assay, it was further observed that upon pre-
incubation with these three sugars, A1 cytotoxicity on hESC was abolished 
(Figure 4-18), indicating that A1 cytotoxicity on hESC depends on its binding 
to the glycan motif (-Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-). Taken together, 
we conclude that A1 binds to an O-linked glycan epitope containing the sugar 
motif (-Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1) to elicit cytotoxicity on hPSC.  
 
Figure 4-18: A1 cytotoxicity on hESC was blocked by LNFP1, H1 and LewisB. 
A1 (5 μg) was pre-incubated with the nine different sugars (2 mM) prior to treatment with 2 x 
10
5 
cells (100 μl) for 45 minutes at 4oC. Cell viability was assessed via PI uptake. Data are 
represented as mean ± SEM. 
 
4.8 Amino acid sequences in A1 variable regions  
To confirm that A1 and mAb84 are different antibodies despite both mAbs 
displaying similar cytotoxic effect on hESC, the amino acid sequence of mAb 
heavy and light variable regions was deduced via nucleotide sequencing of the 
hybridomas. As expected, differences in amino acid sequences between A1 
and mAb84 were observed in the variable regions, more specifically, the 
complementarity determining regions (CDRs) (Figure 4-19). CDRs are 
hypervariable domains of antibodies that determine the specificity of antibody 
binding. In the heavy chain variable regions, there are four different amino 
























there are also four different amino acids in all three CDRs (Figure 4-19B). 
Hence, A1 and mAb84 are different antibodies.  
 
Figure 4-19: Differences in the CDRs amino acids sequences between A1 and mAb84.  
 (A) Heavy chain sequences of A1 and mAb84. (B) Light chain sequences of A1 and mAb84. 
CDRs are highlighted in red. Differences in amino acids between A1 and mAb84 were 
underlined. 
 
4.9 Competitive inhibition between mAb84 and A1  
Since both mAb84 and A1 can bind to and kill hESC in a similar manner, we 
next investigated whether they are binding to the same epitope on hESC using 
a competitive inhibition assay. Cells (2 x 10
5
 in 100 μl) were treated with 5 μg 
of A1 or mAb84 at 4
o
C simultaneous or sequentially. A1 was labelled with 
FITC and mAb84 was labelled with APC. Figure 4-20 shows the readout of 
FITC and APC signal, which represents the binding of mAbs to hESC. We 
observed that regardless whether the mAbs were added simultaneously or 
sequentially, the FITC and APC signals were as strong as their corresponding 
signals in the positive control (individual mAbs), indicating there is no 
competitive inhibition between the binding of mAb84 and A1 on hESC. Hence,  














Figure 4-20: There is no competitive inhibition between A1 and mAb84. 
(a) Double negative control without antibody treatment; (b) positive control for A1: cells were 
treated by A1 and labelled with FITC; (c) positive control for mAb84: cells were treated by 
mAb84 and labelled with APC; (d) cells were treated with A1 and mAb84 simultaneously; (e) 
cells were firstly treated with mAb84 preceding A1; (f) cells were firstly treated with A1 
preceding mAb84.  
  
4.10 A1 showed better penetration efficiency into EB than mAb84 
Since A1 is five times smaller than mAb84 (150 kDa vs 850 kDa 
respectively), A1 is expected to have better penetration into tissue mass. To 
demonstrate this, the penetration efficiency of A1 and mAb84 into EB was 
investigated. EB derived from hESC on day 5 were incubated with the same 
amount (μg) of FITC-conjugated A1 or FITC-conjugated mAb84 for 4 hours 
at 4
o
C. Subsequently, excess antibodies were washed off and the EB were 
cryo-sectioned and imaged with a ﬂuorescence microscope. As shown in 
Figure 4-21A, mAb84 was mostly localised at the periphery of EB whereas 
A1 showed better penetration and distribution throughout the EB. Penetration 
efficiency of mAbs was estimated by the percentage of mean fluorescence 











penetration efficiency over mAb84 (Figure 4-21B). Hence, A1 is 
advantageous in eliminating residual undifferentiated hESC embedded within 
3D aggregates of differentiated progenies.   
 
Figure 4-21: A1 showed better penetration efficiency into hESC-derived EB than 
mAb84. 
(A) Fluorescence and bright field images of cryo-sectioned EB exposed to either FITC-
conjugated A1 or FITC-conjugated mAb84. Arrows indicate penetrated A1. (B) Penetrated 
mAb intensity was calculated by comparing the mean fluorescence intensity within EB (about 
20 µm from the edge) to the mean fluorescence intensity of the entire EB. Fluorescence 
intensity was measured by ImageJ. A1 had a significantly higher penetrated intensity 
compared to mAb84. Data are represented as mean ± SEM. (C) Images of EB that were used 
for the quantification.  
 
4.11 Binding stoichiometry between A1 and hESC 
It is clear that binding of A1 to hESC is a prerequisite for its cytotoxicity on 
hESC. However, the threshold number of bound A1 on hESC to elicit its 
cytotoxicity is unclear. Investigation of binding stoichiometry between A1 and 
hESC may help to better understand the binding profile as well as the 




































This was achieved by estimating the number of A1 molecules that can bind to 
a single hESC upon saturation. Excess A1 was incubated with 2 x 10
5
 hESC at 
4
o
C for 45 minutes and unbound A1 was separated in the supernatant. The 
amount of unbound A1 was measured by ELISA and used to estimate the 
number of A1 present on a single hESC. A brief illustration of ELISA working 
principle is shown in Figure 4-22. At the same time, viability of the cells in the 
pellet was estimated by PI uptake. 
 
Figure 4-22: Brief illustration of the ELISA working principle.  
Excess anti-human IgG (heavy and light chain specific) was used as the coating antibody to 
capture the chimeric IgG1 A1 (human Fc). Subsequently, the secondary anti-human IgG (Fc 
specific) with peroxidase conjugated would bind to the chimeric IgG1 A1 (Fc region) and the 
absorbance of an oxidized product from peroxidase-OPD reaction is measured at 492 nm with 
reference to 620 nm.  
 
 
For ELISA, the absorbance values of all samples at 492 nm were normalized 
by their reference values at 620 nm. The relative absorbance value of the 
standard A1 was then plotted against its corresponding concentration to 
generate a standard curve (Figure 4-23). Based on the standard curve, the 
number of A1 molecules per hESC was estimated.  
Secondary antibody: goat anti-human 
IgG (Fc specific)-peroxidase conjugated
Capture antibody: goat anti-human 
IgG (heave and light chain specific) 
HRP





Figure 4-23: The standard curve of ELISA.  
The standard curve was generated from the serial diluted IgG1 A1 with known concentration. 
The equation of the regression line was then used to calculate the concentration of the 
unbound A1. The resulted concentration values were multiplied by their corresponding 
dilution factors and a mean value was taken to calculate the total amount of unbound A1 in the 
supernatant. Subsequently, the number of A1 that can bind to a single hESC was estimated 
using the equation in Figure 3-1. Data are represented as mean ± SEM. 
In Figure 4-24, the number of A1 molecules as well as A1 killing was plotted 
against the initial amount of A1. It was observed that A1 binding and killing 
on hESC was saturated at the same point, where the initial amount of A1 is 
3.64 μg, (Figure 4-24), indicating saturated binding is essential for maximum 
killing. At this point, there are about 2.93 x 10
7
 A1 molecules on a single 
hESC.  
 
Figure 4-24: A1 binding and killing on hESC at different initial concentration. 
Number of A1 molecules per hESC as well as A1 killing was plotted against the initial 
amount of A1. A1 killing was measured by PI uptake via flow cytometry. Data are represented 
as mean ± SEM. Point with saturated A1 killing and binding was highlighted in red. 
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Moreover, by comparing the amount of unbound A1 and bound A1 in the 
stoichiometry assay (Figure 4-25), it was clear that binding and killing is only 
saturated when the amount of A1 is significantly higher than the amount of 
bound A1, suggesting A1 binding is a dynamic and reversible process.  
 
Figure 4-25: The relationship between the amount of unbound A1 and bound A1 in the 
stoichiometry assay and corresponding A1 killing on hESC at different initial amount of 
A1.  
The amount of bound A1 was estimated by subtracting the difference between the initial 
amount of A1 by the amount of unbound A1. Point with saturated A1 killing was highlighted 
in red. Data are represented as mean ± SEM. 
 
4.12 A1-induced hESC plasma membrane damage  
The rapid killing effect and the PI uptake of A1-treated hESC suggest that A1 
kills hESC via oncosis, which typically results in membrane pore formation. 
Therefore, the sizes of these pores were estimated with dextran beads of 
varying molecular weight. As mAb84 was reported to induce pore formation 
in hESC, it was used as a benchmark. In addition, an in-house antibody, 
mAb85, which binds to but do not kill hESC, was used as an isotype control.  
Cells were incubated with A1, mAb84, mAb85, or PBS- followed incubation 
with fluorescent dextran beads. As a positive control, cells were fixed and 
permeabilized. The population of cells with high fluorescence was gated and 
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different sizes (40 kDa, 70 kDa, 2000 kDa) were able to diffuse into A1-
treated hESC and mAb84-treated hESC, leading to an increase in fluorescence 
level comparable to the fixed and permeabilized cells. In contrast, the 
fluorescence level of the negative control and mAb85 control is minimal, 
representing the background of dead cells. This data suggests that the pores 
formed on the plasma membrane were greater than 2,000 kDa in size, which is 
about 20 nm.  
 
Figure 4-26: Determination of pore size with 40 kDa, 70 kDa and 2000 kDa dextran 
beads respectively. 
Human ESC (2 x 10
5 
in 100 μl) were treated with 5 μg of A1, mAb84, mAb85, or PBS- at 4oC 
Increase in intracellular fluorescence is correlated with the entry of dextran beads into the cells. 
Data are represented as mean ± SEM. 
 
4.13 A1 cytotoxicity on hESC requires bivalency, but not Fc-domain  
The valency of an antibody determines the number of antigens that an 
individual antibody can bind
122
. Non-engineered antibodies have at least two 































































































made monovalent antibody available
123
. Some studies have shown that 
antibodies with bivalency or multivalency have better functionality than their 
monovalent forms
124–126
. Won et al. has reported that the cytotoxicity of the 
bivalent ([Fab-SWn-PE38]2) antibody-toxin against the CRL1739 cell line was 
18.8-fold higher than that of the monovalent (Fab-SWn-PE38) antibody-
toxins
124
. In the study on the effect of antibody valency on Fc gamma RI-
mediated ADCC, Koolwijk et al. demonstrated that monovalently bound mAb 
has a significant decrease in cytotoxicity compared to bivalently bound 
mAb
125
. Another study also reported that only bivalent antibodies are capable 
of neutralizing Herpes simplex virus (HSV) since the neutralization capacity 
of this antibody is dependent on cross-linkage of antigen trimmers on the 
virus
126
. More relevant to this study, the cytotoxicity of mAb84 fragments was 
also only recapitulated by the multivalent scFv84-HTH but not Fab84
127
. 
However, bivalency of antibodies has also been reported to impede its 
functionality. According to Cobbold et al.128, bivalent antibody binding would 
lead to antigenic modulation which allows cells to escape complement lysis or 
opsonizatioin by redistributing and eventually losing the antigen-antibody 
complexes from the cell surface
129
. Since IgG A1 is a bivalent antibody that 
binds and kills hESC, it was investigated if bivalency is essential for A1 to 
elicit its cytotoxicity on hESC.  
An IgG typically consists of two identical heavy chains (one variable domain 
and three constant domains) and two identical light chains (one variable 
domain and one constant domain)
130,131
 (Figure 4-27). Fragment antigen-
binding (Fab) consists of one constant domain and one variable domain of 
each of the heavy and the light chain from the N-terminal. Fragment 
83 
 
crystallisable region (Fc) consists of four constant domains of the heavy 
chains nearer to the C-terminal. The size of IgG is about 150 kDa, where both 
Fab and Fc are about 50 kDa. To investigate whether bivalency or the Fc-
domain is essential for A1 binding and cytotoxicity on hPSC, monovalent 
Fab_A1 was generated with papain and bivalent F(ab)2_A1 was generated 
with IdeS Protease.  
 




(A) Papain cleaves the peptide bonds linkage between the Fab fragments and Fc fragment
132
. 
(B) IdeS protease cleaves at a single site below the disulfide bond hinge region, yielding 





After papain digestion, a mixture of monovalent Fab-A1, Fc-A1 and undesired 
by-products (smaller than 30 kDa) were obtained. The mixture was then 
dialyzed through a spin column (30 kDa pore size) to remove the by-products 
and papain (23 kDa). Subsequently, the protein mixture was resolved using 
Coomassie gel. Two distinct bands at 45 kDa and 51 kDa (Figure 4-28A) 
corresponding to the size of Fab and Fc fragments were observed. Even with 
dialysis, there are still some undesired by-products in the size between 19 kDa 
to 25 kDa. These small fragments are most likely from over-digestion of Fab 




were transferred to PVDF membrane and immunoblotted with biotin-
conjugated Fc-specific antibody. Fc-A1 band was then detected at 51 kDa with 
a streptavidin-FITC secondary antibody (Figure 4-28B). Therefore, the size of 
Fab-A1 is about 45 kDa. After IdeS protease digestion, IdeS with histidine tag 
was removed with affinity spin column. F(ab)2_A1 was observed at 90 kDa, 
and Fc/2 was observed at 25 kDa (Figure 4-28).  
 
Figure 4-28: Size of digested antibody fragments.  
(A) Antibody fragments were resolved in Coomassie gel. Upon papain digestion, two distinct 
protein bands at 45 kDa and 51 kDa are either Fab-A1 or Fab-Fc. Upon IdeS digestion, 
F(ab)2_A1 was obtained at 90 kDa, Fc/2_A1 was obtained at 25 kDa; (B) Resolved proteins 
were transferred to PVDF membrane and Fc-A1 band was detected with an Fc-specific 
antibody. The size of Fc-A1 is about 51 kDa, therefore, the other protein band at 45 kDa in 
Coomassie gel would be Fab-A1.  
 
 
In the subsequent experiments, Fc_A1 or Fc/2_A1 was not removed from the 
digestion mixture due to the low yield of affinity purification. It was 
demonstrated that Fc_A1 does not bind to hESC via flow cytometry analysis 
(Figure 4-29). Therefore, with the presence of Fc_A1 or Fc/2_A1 in the 





























Figure 4-29: Fc_A1 in the digestion mixture does not bind to hESC 
Human ESC were incubated with the digested A1 or undigested A1 for 45 minutes and 
followed by staining with biotin-conjugated Fc-specific primary antibody. Antibodies bound 
to cells were detected with a FITC-conjugated streptavidin. The shaded histogram represents 
staining with the negative control and open histograms represent staining with primary 
antibodies.  
 
Next, the binding and killing of Fab_A1 and F(ab)2_A1 on hESC was assessed 
via flow cytometry analysis. Cells were incubated with IgG1_A1, F(ab)2_A1, 
or Fab_A1 for 45 minutes. The binding of antibodies to hESC was detected by 
staining with FITC-conjugated anti-Kappa light chain specific antibody. Cell 
viability was estimated by PI uptake. Both Fab_A1 and F(ab)2_A1 bound to 
hESC comparably as A1 (Figure 4-30A), suggesting neither bivalency nor Fc-
domain is essential for A1 binding on hESC. However, F(ab)2_A1 cytotoxicity 
on hESC was comparable to A1 whereas Fab_A1 did not elicit any 
cytotoxicity on hESC (Figure 4-30B). Hence, bivalency, but not the Fc-
domain, is essential for A1 cytotoxicity on hESC.  
 










Figure 4-30: Bivalency of A1 is essential for its cytotoxicity on hESC, but not binding 
Human ESC (2 x 10
5 
in 100 μl) were treated with 5 μg of A1, F(ab)2_A1 or Fab_A1 for 45 
minutes at 4
o
C. (A) Binding of F(ab)2_A1 and Fab_A1 to hESC was comparable to A1. 
Antibody binding to hESC was detected with FITC-conjugated kappa light chain specific 
antibody. Representative histograms are shown. Open histogram represents non-treated cells 
and shaded histogram represents antibody-treated cells. (B) However, only bivalent F(ab)2_A1 
can recapitulate A1 cytotoxicity on hESC. Cell viability was assessed via PI uptake. Data are 
represented as mean ± SEM. 
 
4.14 Summary  
In this chapter, in vitro characterization of A1 was discussed in detail. A1, 
generated against undifferentiated hESC, showed strong binding and 
cytotoxicity on both hESC and hiPSC. By inducing hESC to undergo 
spontaneous differentiation via EB formation and FGF-2 starvation, A1 
cytotoxicity was demonstrated to be highly specific to undifferentiated hESC, 
but not differentiating or differentiated cells. Unlike mAb84 that binds to 
glycosylated PODXL on hESC, A1 surprisingly recognizes an O-linked 
glycan epitope present on multiple antigens on hESC. The termini of this 

































glycan epitope were found to contain the sugar motif Fucα1-2Galβ1-
3GlcNAcβ1-3Galβ1. Differences in the amino acid sequences of all three 
CDRs in the variable heavy and light chain were observed between A1 and 
mAb84, which further proved that they are different antibodies. Intriguingly, 
there are no competitive inhibition of binding between A1 and mAb84 
suggesting that different epitopes are recognized by the mAbs. Being five 
times smaller than mAb84, A1 showed better penetration efficiency into EB. 
Cytotoxicity of A1 was dosage-dependent. A1 rapidly kills hESC within 5 
minutes of incubation in a dosage-independent manner. A1 binding on hESC 
is a dynamic and reversible process. Killing is most likely achieved at 
saturated binding, when there are about 3 x 10
7
 A1 molecules per hESC. A1 
induced hESC plasma membrane damage with pore size larger than 20 nm. 
Last but not the least, A1 cytotoxicity on hESC requires minimally bivalency, 
and is independent of the Fc domain.  
In conclusion, the cytotoxic antibody, A1, can be used as a cell surface marker 
for undifferentiated hESC and hiPSC. In hPSC-based therapy, A1 can be 
potentially used to eliminate residual undifferentiated hPSC from 
differentiated cell products especially in 3D aggregates to prevent teratoma 





5 CHAPTER 5 IN VIVO CHARATERIZATION OF A1 
5.1 Introduction  
The ability of A1 to kill undifferentiated hPSC in vitro is characterized in 
chapter 4. As the ultimate application of cytotoxic A1 is to eliminate residual 
undifferentiated hPSC from differentiated cells and therefore prevent teratoma 
formation, in this chapter, we determined the ability of A1 to prevent teratoma 
formation in vivo. Previously, Tan et al. showed that injection of hESC pre-
treated with mAb84 for 45 minutes in vitro successfully prevented teratoma 
formation in SCID mouse models for up to 6 months post-injection
34
. 
Leveraging on the success of mAb84, the study was extended in this thesis to 
evaluate the potential of teratoma formation if undifferentiated hESC was 
mixed with A1 just prior to injection into SCID mouse models, without further 
in vitro incubation. Additionally, we also evaluated the efficiency of in vivo 
A1 treatment to prevent teratoma formation in SCID mouse models.  
5.2 Teratoma grading system 
Teratoma formation in SCID mice was monitored visually and measured by 
caliper using a previously established grading system for the study of 
mAb84
34
: grade 0 = no visible teratoma (6.32 mm average maximal hind leg 
diameter), grade 1 = teratoma just detectable (10.55 mm average), grade 2 = 
teratoma obvious (13.2 mm average), and grade 3 = teratoma impedes 
locomotion (14.52 mm average). 
5.3 SCID mouse model: instantaneous in vitro A1 treatment 
Based on in vitro characterization, A1 showed rapid killing on undifferentiated 
hPSC within 5 minutes of incubation. Hence, we aimed to investigate whether 
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this rapid killing is efficient to prevent teratoma formation in vivo. Single-cell 
suspension of hESC (5 x 10
6
 cells/per mouse in 30 μl fresh KO media and 30 
µl matrigel) were mixed with 30 µl of IgG1 A1, or F(ab)2_A1, or IgG1 A19, or 
HEPES buffer under identical conditions, and instantaneously (without further 
incubation) injected into SCID mouse via intramuscular (IM) route. IgG1 A19 
was incorporated as an isotype control since it binds to hESC without exerting 
cytotoxicity. Treatment with F(ab)2_A1 was used to preclude the possibility of 
ADCC.  
In the first trial, teratoma formation under each condition was monitored 5 
weeks after injection (Figure 5-1A). All 3 mice in the buffer control group 
developed grade 3 teratomas by week 6 post-injection. Cells treated with the 
isotype control, IgG1 A19, also formed teratomas as early as non-treated cells 
and all reached grade 3 by week 7, indicating that antibody binding to hESC 
alone has no effect on preventing teratoma formation. In contrast, cells treated 
with IgG1 A1 did not form teratomas in 2 SCID mice after 10 weeks post-
injection. In the remaining SCID mouse injected with IgG1 A1 treated hESC, 
the onset of teratoma formation was delayed until week 8. The ability to still 
form teratomas after A1 treatment was most likely due to non-homogenous 
mixing without incubation between antibodies and undifferentiated hESC. 
Moreover, cells treated with F(ab)2_A1 also did not form teratomas in all 3 
SCID mice after 10 weeks post-injection, indicating that the prevention of 
teratoma formation in vivo is caused by the mAb directly and independent of 
ADCC. Successful prevention of teratoma formation in five out of six SCID 
mice suggested that in vitro treatment with either IgG1 A1 or F(ab)2_A1 just 




Figure 5-1: Prevented or delayed teratoma formation with in vitro A1 treatment.  
Undifferentiated hESC was mixed with antibodies or buffer control in vitro instantaneously 
prior to injection into SCID mouse models. Each condition has 3 SCID mice. (A) First trial: 
teratoma formation was monitored from week 5 post-injection. (B) Second trial: teratoma 
formation was monitored from week 2 post-injection.   
 
 
A second trial was performed to further confirm this result and to begin 
monitoring the teratoma formation in SCID mouse models from grade 1 
onwards. Consistent with the first study, cells in buffer control or treated with 
the isotype control developed grade 3 teratomas by week 6 post injection 
where palpable grade 1 tumours were observed as early as week 2 post-
injection (Figure 5-1B).  For cells treated with IgG1 A1, 2 SCID mice did not 
form teratomas after 7 weeks whilst 1 SCID mouse showed delayed teratoma 
formation with grade 1 teratoma observed only after week 7 post-injection. 

























































































the onset only occurring at either week 6 or week 7 post-injection. These 
results confirmed that instantaneous in vitro A1 treatment can prevent or delay 
teratoma formation. However, delayed onset of teratoma formation in several 
SCID mice renders further optimization to improve the efficiency of 
instantaneous in vitro A1 treatment. This could include a longer incubation in 
vitro before injection.   
5.4 SCID mouse model: In vivo A1 treatment  
A1 has been demonstrated to have better penetration efficiency over mAb84 
into EB clusters. Here, we evaluated its efficiency in preventing teratoma 
formation via in vivo treatment. Single-cell suspension of hESC were firstly 
injected into SCID mouse, and followed by the injection of IgG1 A1 or 
F(ab)2_A1 at approximately the same site under identical conditions. The 
same buffer control group from the second trial of in vitro treatment was used 
here since both experiments were performed at the same time with the same 
source of undifferentiated hESC and A1.  
Teratoma formation was monitored from week 2 post-injection. Comparing to 
non-treated mice developing teratomas at week 2, all 3 SCID mice injected 
with IgG1 A1 did not form teratomas after week 7 post-injection (Figure 5-2), 
indicating IgG1 A1 can potentially be administered directly in vivo to kill 
undifferentiated hESC and prevent teratoma formation. However, SCID mice 
injected with F(ab)2_A1 only showed a delayed onset of teratoma formation at 




Figure 5-2: Prevented or delayed teratoma formation with in vivo A1 treatment. 
Undifferentiated hESC was injected into SCID mouse models first followed by injection of 
antibodies at approximately the same site. Each condition has 3 SCID mice.  
 
 
For in vivo A1 treatment, since A1 was administered in close proximity to 
undifferentiated hESC, the more likely route for the mAbs to locate the hESC 
in vivo would be via localised diffusion rather than systemic circulation. As 
for the difference between A1 and F(ab)2_A1, we postulate that F(ab)2_A1 
may be drained from the tissue into systemic circulation more quickly and 
therefore lowering the localised concentration of F(ab)2_A1 for interaction 
with hESC-containing tissue. This is because antibody fragments without the 
Fc portion have been reported to cross the blood-tissue barrier more easily and 
are less hindered by the binding-site barrier
134
. Furthermore, F(ab)2_A1 will 
also be cleared more easily from the systemic circulation and out of the body 










































5.5 Summary  
To facilitate the use of cytotoxic A1 in hPSC-based therapy, we demonstrated 
that both in vitro and in vivo A1 treatment can prevent or delay teratoma 
formation by undifferentiated hESC in SCID mouse models. Treatment with 
isotype control did not delay or prevent teratoma formation compared to the 
buffer control group, indicating non-cytotoxic antibody binding to hESC does 
not affect teratoma formation, for example, by ADCC. Moreover, in vitro 
treatment with F(ab)2_A1 also prevented or delayed teratoma formation, 
comparable to IgG1 A1. We therefore conclude that the killing of hESC with 
A1 and prevention of teratoma formation is a direct effect of the mAb and 
independent of ADCC. These data provide a proof of concept that A1 can be 
administered both in vitro and in vivo to kill undifferentiated hESC and 






6 CHAPTER 6 ELUCIDATION OF A1-INDUCED HESC DEATH 
MECHANISM 
6.1 A1 induces hESC death via oncosis  
6.1.1 Introduction  
As discussed previously, there are two major modes of cell death in the pre-
mortal phase: apoptosis and oncosis. Apoptosis and oncosis can be 
distinguished by their respective hallmarks (Table 6-1). Based on in vitro 
characterization, A1 kills hPSC within 5 minutes of incubation and resulting in 
the formation of pores larger than 20 nm in the plasma membrane. These two 
features match well with the hallmarks of oncosis. Therefore, it was 
hypothesized that A1 kills hPSC via oncosis, not apoptosis. In this section, 
hallmarks of apoptosis and oncosis were examined in A1-induced hESC death 
to confirm the hypothesis. 




Cell death time Slow (12-24hrs) Fast (seconds to minutes) 
DNA fragmentation Increased No change 
Caspases activity Increased No change 
Volume changes 
Shrinking of cytoplasm and 
condensation of nucleus 





Cytoplasm Retained in apoptotic bodies Released 
 
 
6.1.2 A1-treated hESC does not undergo apoptosis 
First, this hypothesis was reiterated by two complimentary biochemical assays 
for apoptosis: TUNEL assay and caspase assay.  
95 
 
6.1.2.1 TUNEL assay 
TUNEL assay was used to measure the extent of DNA fragmentation upon 
cell death
107
. In TUNEL assay, 3’ end of DNA fragments are labelled with 
fluorescent-tagged dUTP catalysed by TdT enzyme. The intensity of dUTP 
and DNA size were read by flow cytometry. Increased dUTP intensity is 
correlated to DNA fragmentation and plotted in Figure 6-1. As positive control, 
confluent hESC cultures were exposed to 200 mJ of UV to induce apoptosis. 
After UV exposure, the cells were maintained at 37
o
C, 5% CO2 for 20 hours 
before harvest for apoptotic assays. A1-treated hESC did not exhibit 
significant elevation in the level of DNA fragmentation compared to the 
negative control, non-treated hESC. On the contrary, the positive control, UV-
treated hESC exhibited a significant elevation in the level of DNA 
fragmentation.  
 
Figure 6-1: Degree of DNA fragmentation measured in TUNEL assay by flow cytometry. 
Increase in dUTP fluorescence intensity was correlated to increased DNA fragmentation. UV-
treated hESC was positive control. Data are represented as mean ± SEM. 
 
6.1.2.2 Caspase assay 
Next, we compared the activity of several caspases (caspases 3, 7 and 9) 

























assay, fluorescence-labelled inhibitor of caspase reagents were used to 
specifically detected activated caspase. To correlate cell death with caspase 
activity, cells were co-stained with a cell impermeable dye, 7-AAD, to identify 
dead cells. Fluorescence intensity of caspase reagents and 7-AAD were 
displayed on a scatter plot by flow cytometry (Figure 6-2A) and gated into 
four different quadrants. The population in each quadrant was plotted in 
Figure 6-2B. Results showed that the activity of caspases measured for both 
A1-treated and non-treated hESC were comparable and at minimal basal levels. 
In contrast, UV-treated hESC exhibited significantly higher caspases activities. 
Hence, results from both apoptotic assays suggested that the A1 killing of 
hPSC was unlikely induced by apoptosis.  
 
Figure 6-2: Measured caspases activity and cell death by flow cytometry.  
(A) A representative scatter plot of detecting active caspase 3&7 and cell death. Fluorescence-
labelled inhibitor of caspase reagents were used to specifically identify active caspases. Cell 
death was determined with 7-AAD dye by measuring cell membrane integrity. UV-treated 
hESC was positive control. Bottom left quadrant represents viable cells without active 
caspase; top left quadrant represents dead cells without active caspase (oncosis); top right 
quadrant represents dead cells with active caspase (apoptosis). Population in each quadrant 
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6.1.3 Morphological and structural changes of A1-treated hESC 
Morphological changes, such as cell volume change, plasma membrane 
damage, and apoptotic bodies, are hallmarks to distinguish apoptosis and 
oncosis.  Therefore, to further elucidate the mode of A1-induced hESC death 
and investigate the lethal effect of A1 on hESC, we examined the 
morphological and structural changes under confocal microscopy for time-
lapsed dynamics, scanning electron microscopy for surface morphological and 
cell structural changes, as well as transmission electron microscopy for 
intracellular morphological changes on hESC before and after A1 treatment.  
6.1.3.1 Time-lapsed dynamics of A1-treated hESC under confocal 
microscope 
Knowing that A1 is able to induce hESC death within several minutes of 
incubation, we went on to examine the dynamic morphological changes of 
hESC in culture under time-lapsed Spinning Disk Confocal Microscope. 
Immediately after the in-situ treatment with A1, hESC started to retract from 
each other and round up on the culture plate (Figure 6-3). Cell morphology 
changed drastically over the first 10 minutes. After imaging, the mAb-
containing buffer was aspirated. Cells were washed with PBS-, topped up with 
condition media, and incubated in 37
o
C, 5% CO2 for an additional 24 hours to 
test the survival rate after A1 treatment. Almost all A1-treated hESC detached 
from the culture plate and were assessed to be dead by PI uptake assay. This is 
indicative that A1 is capable of killing hESC in culture. However, hESC 
confluency seemed to be an important factor for A1-induced morphological 
changes. No obvious morphological changes were observed if hESC 
confluency was > 80%. This could be possibly explained by the strong stress 
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fibre formed in focal adhesions as well as formation of stress fibre connection 
through cell-cell junction when cells reach confluency in culture
137,138
.     
 
Figure 6-3: Dynamics of A1-treated hESC in culture under Confocal Microscopy. 
Human ESC were cultured for 4 days prior to A1 treatment. Cell confluency was about 40%. 
A1 was added into cell culture right after the recording was started. Scale bar: 100 μm.  
 
6.1.3.2 Visualization of hESC under Transmission Electron Microscope 
(TEM) 
Previous studies on antibody-induced cell death have used TEM to investigate 
the cell death mechanism. According to Matsuoka
71
, mAb RE2 was reported 
to induce lymphocyte death. Under TEM, they observed the plasma membrane 
damage, dilation of ER and mitochondria. With these observations, they 
concluded that this antibody induces lymphocyte death via oncosis. Separately, 
a study on GA101-induced oncosis also revealed early stage intercellular 
adhesion and involvement of microvilli in intercellular adhesion under TEM
74
.  
We therefore used TEM to study the intracellular and intercellular 
morphological changes of A1-treated hESC. Cells in single cell suspension 
were treated with A1 (5 μg per 2 x 105 hESC in 100 μl) or PBS control for 45 
minutes, followed by immediate fixation. Upon fixation, cells were processed 
as described previously for TEM imaging. Non-treated cells were uniformly 
distributed with an average size of approximately 10 μm in diameter, uniform 
staining intensity, and intact plasma membrane (Figure 6-4).  





Figure 6-4: Morphology of a non-treated hESC under TEM.  
Human ESC were fixed with paraformaldehyde and glutaraldehyde, embedded in resin, 
sectioned into ultra-thin sections, stained with uranyl acetate and lead citrate to be viewed 
under TEM. Non-treated hESC had uniform cell shape and intact membrane. Mitochondria 
were marked with white arrows. 
 
 
Upon A1 treatment, distinct morphological alterations were observed. In 
general, there was no formation of apoptotic bodies in A1-treated hESC. 
Instead, significant enrichment of mitochondria was observed (Figure 6-5A). 
These mitochondria had well-developed cristae suggesting that they were in an 
energy-producing phase. This feature has not been reported in other similar 
modes of cell death. Figure 6-5B showed an example of intercellular adhesion 
formed by four A1-treated hESC. Different staining intensities were observed 
among these cells. One possible reason could be that they were at different 
stages of cell death and thus the amount of proteins being stained was different. 
The cell at the bottom right was least stained and it had lost its membrane 
integrity and cell morphology, suggesting this cell was undergoing post-mortal 
oncotic necrosis. The cell in the middle had lower staining intensity than the 
two cells at the top. However, this cell has the most apparent cell swelling and 
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mitochondria swelling, which suggest that swelling occurred at later stage than 
protein degradation in A1-induced hESC death. Moreover, peripheral re-
localisation of mitochondria in this cell towards cell-cell adhesion sites was 
also observed (Figure 6-5B). These observations further proved our hypothesis 
that A1 kills hESC via oncosis, and it may also imply that A1-induced cell 
death may be associated with mitochondria, ATP and adhesion proteins.  
  
 
Figure 6-5: Morphological changes of A1-treated hESC under TEM.   
Human ESC were treated with A1, fixed with paraformaldehyde and glutaraldehyde, 
embedded in resin, sectioned into ultra-thin sections, stained with uranyl acetate and lead 
citrate to be viewed under TEM. (A) Significantly enriched mitochondria (highlighted with 
red circle) were observed in A1-treated hESC. These mitochondria had well-develop cristae, 
suggesting the cell was at energy producing stage. (C) An example of intercellular adhesions 
formed by 4 cells. Cells were not uniformly stained and lost different degrees of membrane 
and cell integrity. Peripheral re-localisation of mitochondria towards cell-cell adhesion sites 





6.1.3.3 Visualization of hESC under Scanning Electron Microscope (SEM) 
Next, we examined hESC for cell surface morphological changes and cell 
structural changes under scanning electron microscopy (SEM). Cells in single 
cell suspension were treated with A1 (5 μg per 2 x 105 hESC in 100 μl) or PBS 
control for 45 minutes, followed by immediate fixation. Upon fixation, cells 
were processed as described previously for SEM imaging. In general, non-
treated hESC had uniform shape, rich microvilli and intact plasma membrane 
(Figure 6-6). 
 
Figure 6-6: Morphology of non-treated hESC under SEM.  




Upon A1 treatment, there was a loss of cell surface microvilli and membrane 
integrity. Pores were formed on the plasma membrane with convoluted 
surface, which were usually covered by debris networks of fused microvilli or 
damaged plasma membrane. A 5-staged pattern of hESC morphological 
changes triggered by A1 treatment was summarized. At stage 1, A1-treated 
hESC typically displayed partially degraded or shortened microvilli and 
enlarged cell volume, whereas the membrane integrity was still relatively 
102 
 
intact (Figure 6-7). Some fused microvilli at certain membrane area should be 
the transition from stage 1 to stage 2. 
 
Figure 6-7: Morphological changes of A1-treated hESC at stage 1 under SEM.  
Left: overview of a single hESC; right: highlighted area in higher magnification. A1-treated 
hESC at stage 1: relatively intact membrane, but degraded/shortened microvilli and cell 
swelling. Fused microvilli are likely to be the transition from stage 1 to stage 2. 
 
At stage 2, numerous membrane pores in varied sizes were formed (Figure 
6-8). Another feature at stage 2 was the appearance of one or more circular 
shaped areas of ~2 μm that were always surrounded by fused microvilli. 
Within this area, microvilli were absent but there was the presence of 
cytoskeleton-like structures. 
 
Figure 6-8: Morphological changes of A1-treated hESC at stage 2 under SEM. 
Left: overview of a single hESC; right: highlighted area in higher magnification. A1-treated 
hESC at stage 2: formation of membrane pore in varied sizes (indicated by arrows) and 





At stage 3, microvilli further shortened or even completely disappeared 
(Figure 6-9). Different from stage 2, in the circular area, both the surrounding 
fused microvilli and the centred cytoskeleton-like structures disappeared. 
Moreover, larger membrane pores were formed.  
 
Figure 6-9: Morphological changes of A1-treated hESC at stage 3 under SEM. 
Left: overview of a single hESC; right: highlighted area in higher magnification. A1-treated 
hESC at stage 3: Microvilli further shortened or even completely disappeared. Larger 
membrane pores formed as indicated by arrows. In highlighted area, fused microvilli around 
the circular area as well as the cytoskeleton-like structures in the centre disappeared.  
 
At stage 4, membrane damage was more pronounced and likely from the 
damaged circular area of stage 3 revealing the cytoskeleton structure and 
nucleus (Figure 6-10A). Lastly, at stage 5, severely damaged membrane 
peeled off from the nucleus leaving the nucleus uncovered (Figure 6-10B). 
Among these observed morphological changes, cell swelling, plasma 
membrane pore formation and subsequent severe plasma membrane damage 
are all previously reported hallmarks of oncosis. The progress of 
morphological changes also suggested that A1-induced hESC death is likely 




Figure 6-10: Morphological changes of A1-treated hESC at stage 2 under SEM.  
Left: overview of a single hESC; right: highlighted area in higher magnification. (A) A1-
treated hESC at stage 4: massive membrane damage; Membrane damage was worsen from the 
damaged circular area of stage 3 and visible nucleus covered by massive cytoskeleton 
structures; (B) A1-treated hESC at stage 5: damaged membrane peeling off from the nucleus.  
 
 
6.1.4 Summary  
In this section, effort was made to determine the mode of A1-induced hESC 
death. In two apoptosis assays, it was proved that A1-treated hESC did not 
have significant increase in the level of DNA fragmentation as well as 
caspases activity. Therefore, A1 was unlikely killing hESC via apoptosis. 
Furthermore, under confocal microscope, TEM and SEM, features that are 





apoptotic bodies, cell swelling, plasma membrane pore formation, and severe 
plasma membrane damage. Taking together all the features, we concluded that 
A1 kills hESC via oncosis. Intriguingly, we also observed mitochondria 
enrichment and peripheral re-localisation, microvilli shortening or 
degradation, as well as massive destruction of actin cytoskeleton structures. 
These events were hypothesized to be associated with the mechanism of A1-
induced hESC death, which will be discussed in detail later in this thesis.  
6.2 A1 binds uniformly on hESC surface 
Next, to better understand how A1 binding to hESC leads to cell death, we 
examined the distribution pattern of A1 on hESC surface under scanning 
electron microscope aided with gold-conjugated secondary antibodies to 
reveal the distribution. Briefly, hESC were treated with A1 or PBS- control, 
fixed with glutaraldehyde and paraformaldehyde, incubated with gold-
conjugated secondary antibodies, dehydrated, critical point dried and viewed 
under SEM.  
Samples were viewed under three different modes: cell morphology was 
detected under secondary electron mode while gold particle-labelled A1 were 
detected under backscattering mode. Overlay between cell morphology and 
A1 binding was viewed under combined mode. No non-specific binding of 
secondary antibodies was observed in non-treated control (Figure 6-11). 
Consistent with previous observation under normal SEM, the cell membrane 




Figure 6-11: Non-treated hESC under immuno-SEM.  
Cell morphology was detected under secondary electron mode (upper left) while gold particle-
labelled A1 were detected under backscattering mode (upper right). Overlay between cell 
morphology and A1 binding was viewed under combined mode (bottom). Representative 




In A1-treated hESC, A1 particles were uniformly distributed across the cell 
surface (Figure 6-12). Previously, in mAb84-induced hESC death, gold-
labelled antibody clusters were observed under backscattering mode
34
. 
Without the combined mode, this clustering effect was interpreted as antibody 
clustering antigens to form pores throughout the plasma membrane. However, 
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in our study, under combined mode, it was clear that there was no correlation 
between A1 binding pattern and plasma membrane damage. 
 
Figure 6-12: A1 binding pattern was not correlated with plasma membrane damage.  
Cell morphology was detected under secondary electron mode (upper left) while gold particle-
labelled A1 were detected under backscattering mode (upper right). Overlay between cell 
morphology and A1 binding was viewed under combined mode (bottom). Representative 
images are shown. A1 binding on hESC is uniform. Arrow indicates an example of plasma 
membrane damage that was not correlated with A1 binding pattern.   
 
 
On the contrary, observed clusters of gold particle were more likely resulting 
from fusion of microvilli and damaged plasma membrane (Figure 6-13). These 
observations suggest that the formation of membrane pores was not the result 
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of external mechanical force from A1 binding, but more likely through A1 
binding initiated signalling cascade.  
 
Figure 6-13: Correlation between A1 aggregates and membrane debris. 
Arrows indicates the correlation between A1 (gold particles) aggregates and debris of fused 
microvilli or damaged plasma membrane. 
 
 
Surprisingly, we also observed that the majority of A1 binding was on surface 
microvilli, both elongated and shortened (Figure 6-14), suggesting that A1-





Figure 6-14: A1 bound to surface microvilli of hESC.  
Representative images are shown in combined mode. (A) A1 bound to elongated hESC 
microvilli. (B) A1 bound to shortened hESC microvilli.  
 
6.3 Bivalent A1 binding elicits hESC homotypic adhesion 
Upon A1 binding, we also observed formation of hESC aggregates (Figure 
6-15). Formation of cell aggregate or homotypic adhesion has been reported in 





To investigate the cause of homotypic adhesion, we first used an in-house 







. Binding of bivalent antibodies alone to hESC was 
previously shown not to sufficient to elicit homotypic adhesion (data not 
shown). Moreover, the difference in the ability of F(ab)2_A1 and Fab_A1 to 
induce homotypic adhesion was observed (Figure 6-15). Intriguingly, this 
difference coincided with the difference in their cytotoxicity on hESC, 
indicating homotypic adhesion and cell death is functionally related.   
 
Figure 6-15: Bivalent A1 and F(ab)2_A1 can induce hESC homotypic adhesion. 
Human ESC (2 x 10
5 
in 100 μl) were treated with 5 μg of A1, F(ab)2_A1, or Fab_A1 for 45 
minutes at 4
o
C in 96-well plates. After incubation, cells were viewed under bright field light 
microscopy. Homotypic adhesion were formed upon A1 or F(ab)2_A1 treatment, not 
monovalent Fab_A1. Representative images are shown. 
 
6.4 A1-induced hESC death is associated with actin re-organization 
Homotypic adhesion, microvilli degradation and plasma membrane damage all 
implied the involvement of actin cytoskeleton in A1-induced hESC death. 
Actin cytoskeleton undergoes constant formation and remodelling, which 
contributes to its roles in cell motility, cell signalling and the establishment 
and maintenance of cell junctions and cell shape. Here, different assays were 





6.4.1 A1 treatment induces reduction of actin-association proteins 
Firstly, similar to mAb84-induced hESC oncosis
34
, significant reduction of 
four actin-associated proteins in A1-treated hESC compared to non-treated 
hESC was observed, namely, α-actinin, paxillin, talin and vinculin (Figure 
6-16). 
 
Figure 6-16: A1 treatment induced reduction of actin-associated proteins.  
Human ESC were harvested in single-cell suspension, treated with A1 or PBS- control for 45 
minutes. After incubation, cells were washed and lysed in 2% Triton/PBS-. Reduction of 
actin-associated proteins, namely, talin, vinculin, α-actinin and paxillin, after A1 treatment 
was detected. GAPDH was used as an endogenous control. Representative data are shown. 
 
 
6.4.2 Inhibitors of actin polymerization can partially block A1 cytotoxicity 
A previous study on mAb RE2-mediated T cells oncosis identified that 
treatment with Cytochalasin B/D completely blocks the cytotoxicity of mAb 
RE2 towards T cells
71
. We therefore investigated the effect of Cytochalasin B, 
Cytochalasin D and Latrunculin A on A1-induced hESC death. In general, 
Cytochalasin B/D inhibits actin polymerization by blocking the fast growing 
end of actin polymer
142
, whereas Latrunculin A binds to G actin and prevents 
polymerization of actin monomers
143
. Briefly, hESC was pre-incubated with 
optimized amount of Cytochalasin B/D or Latrunculin A for 5 minutes and the 
cell-inhibitor mixture were incubated with A1 for another 45 minutes. As 









DMSO as that of the inhibitors. Cell viability was assessed by PI uptake. In 
Figure 6-17, upon A1 treatment, inhibitors-treated hESC had a reduction in 
cell death compared to the non-treated controls, suggesting a functional link 
between actin polymerization and A1-induced hESC death.  
 
Figure 6-17: Association between actin polymerization and A1 cytotoxicity on hESC.  
Human ESC (2 x 10
5 
cells in 100 μl) were pre-incubated with the actin inhibitors: Latrunculin 
A (4 μg), cytochalasin B (4 μg), and cytochalasin D (4 μg) for 5 minutes before A1 treatment. 
Cell viability was assessed with PI uptake. A1 cytotoxicity on hESC was partially inhibited 
upon actin inhibitors (latrunculin A, Cytochalasin B, and Cytochalasin D) treatment. Data are 
represented as mean ± SEM. P values for t-test: * < .05, ** < .01, *** < .001. 
 
6.4.3 A1 induces F-actin enrichment and G-actin re-localisation in hESC 
Studies by Alduaij et al. on GA101, an mAb targeting type II CD20 showed 
that peripheral relocalization of actin cytoskeleton is critical for GA101-
induced lymphoma oncosis and homotypic adhesion
75
. Hence, we investigated 
whether there is alteration of F-actin and G-actin in hESC upon A1 treatment. 
Briefly, hESC were harvested as a single-cell suspension and incubated with 
A1 for 45 minutes. After incubation, excess A1 were washed off and cells 
were fixed before loading onto poly-L-lysine-coated plates. As a negative 
control, hESC were treated with PBS-. Immuno-staining of F-actin and G-
actin revealed that A1 treatment evoked the relocalization of G-actin from the 


































(Figure 6-18). Enrichment of F-actin upon A1 treatment further confirmed that 
actin polymerization is involved in A1-induced hESC death. Moreover, 
enrichment at cell-cell adhesion sites could be associated with homotypic 
adhesion.  
 
Figure 6-18: Re-distribution of F-actin and G-actin in A1-treated hESC.  
A1 treatment led to enrichment of F-actin at cell-cell adhesion cites and G-actin translocation 
from nucleus to cytoplasm. Representative images are shown. F-actin was labelled with Alexa 
Fluor 488 Phalloidin, nucleus was stained with Hoechst blue, and G-actin was labelled with 




In this section, the role of actin cytoskeleton in A1-induced hESC death was 
studied. Upon A1 treatment, reduction of four actin-associated proteins (talin, 
vinculin, α-actinin, and paxillin) was observed. Moreover, inhibitors of actin 
polymerization partially blocked A1 cytotoxicity on hESC, which was further 
supported by the enrichment of F-actin at cell-cell adhesion sites and the re-
localisation of G-actin from nucleus to cytoplasm. Taken together, these 
results demonstrated a close association between actin re-organization and A1-







6.5 A1-induced hESC death is mediated by excess reactive oxygen 
species (ROS) production from NADPH oxidase  
6.5.1 Introduction   
ROS are chemically highly reactive molecules containing oxygen, such as 
superoxide, hydrogen peroxide, hydroxyl radicals and peroxynitrite. Under 
normal conditions, ROS can perform multiple functions in living organism, 
such as signalling cell growth/differentiation and maintaining cell 
homeostasis
144,145
. However, ROS level can increase drastically upon 






 and integrin 
signalling
149
. Excessive amount of ROS would lead to irreversible oxidative 
damages to DNA, lipids, proteins and enzymes
150–152
. ROS production has 







, though it is still unclear whether the 
production of ROS is always an essential component. Several studies have 
reported the excess production of ROS in mAb-induced cell death
76,157–160
.The 
modes of mAb-induced cell death involving ROS production are either 
apoptosis or oncosis. Studies involving mAb GA101 targeting human B-
lymphoma cells, demonstrated that by depleting ROS with scavengers, 
GA101-induced cell death can be partially inhibited
76
. They have also 
demonstrated that GA101 kills human B-lymphoma cells via a non-apoptotic 
pathway with features of homotypic adhesion and plasma membrane 
damage
74,75
, which are also observed in A1-induced hESC death. Therefore, 
we hypothesized that ROS might also play an essential role in A1-induced 
hESC death.  
6.5.2 A1 induces excess ROS production in hESC 
First, we investigated whether ROS is produced in A1-treated hESC. After A1 
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treatment, cells are incubated with dihydroethidium (HE) staining which when 
oxidized by ROS emits red fluorescence. From Figure 6-19, there was a 
distinct population of cells with higher fluorescence in the A1 treated 
condition thus suggesting that A1 treatment led to a significant increase in the 
level of ROS.   
 
Figure 6-19: A1-induced ROS production measured via HE staining by flow cytometry. 
Human ESC (2 x 10
5 
in 100 μl) were treated with 5 μg of A1 or PBS- control for 45 minutes at 
4
o
C. ROS production was then determined 30 minutes after incubation with HE (25 μM). In 
the presence of ROS, HE is oxidized to emit red fluorescence. (A) The amount of ROS 
production as measured via HE staining was quantified by flow cytometry analysis. Gated 
population represents increased level of ROS production. Representative histograms are 
shown. (B) A1 treatment induced excess ROS production (measured by HE staining) in hESC. 
Data are represented as mean ± SEM.  
 
Alternatively, ROS production was determined using carboxy-H2DCFDA 
staining under light microscopy. In the presence of ROS, carboxy-H2DCFDA 
is oxidized to carboxy-DCF that emits green fluorescence. Similar to HE 
staining, there was an increased level of carboxy-DCF green fluorescence 
detected after A1 treatment (Figure 6-20) indicative of elevated ROS 
































Figure 6-20: A1-induced ROS production measured via carboxy-H2DCFDA staining by 
fluorescence microscopy. 
A1 (5 μg) was directly added to the 96-well flat-bottomed plate with 2 x 105 hESC which 
were pre-incubated with carboxy-H2DCFDA. In the presence of ROS, carboxy-H2DCFDA is 
oxidized to carboxy-DCF that emits green fluorescence. Images were taken 30 minutes after 
A1 treatment.  
 
6.5.3 A1-induced hESC death correlates with ROS production 
To examine the relationship between ROS production and cell death, hESC 
were dual stained with Sytox green to identify dead cells and HE for ROS 
production (Figure 6-21). After A1 treatment, there was a significant increase 
in the cell population localised in the upper right quadrant of the scatter plot 
(Fig 6-21) which represents dead cells with high level of ROS production. 
Hence, ROS production directly correlates with hESC death upon A1 
treatment.  
 
Figure 6-21: A1-induced hESC death and ROS production were directly correlated. 
Human ESC (2 x 10
5 
in 100 μl) were treated with 5 μg of A1 or PBS- control for 45 minutes at 
4
o
C. Cell death (Sytox Green uptake) and ROS production (HE intensity) was quantified by 



















6.5.4 ROS production is essential for A1-induced hESC death 
Having established a direct correlation between A1-induced hESC death and 
ROS production, we investigated whether ROS production is an essential step 
in A1-induced hESC death. Using ROS scavengers: Tiron and Tempol, which 
are well-characterized superoxide dismutase (SOD) mimetic
161–163
, the extent 
of cell killing by A1 was compared. Briefly, hESC were pre-incubated with 
Tiron or Tempol for 1 hour before treatment with A1. Cell viability after A1 
treatment was estimated by PI uptake. It was clear that pre-treatment of hESC 
with both Tiron and Tempol significantly inhibited A1-induced hESC death 
(Figure 6-22), indicating that excess ROS production is required for A1 killing 
of hESC.  
 
Figure 6-22: ROS scavengers partially blocked A1-induced hESC death. 
Before A1 treatment, cells were treated with PBS- or the ROS scavengers (Tiron 50mM or 
Tempol 120mM) for 1 hour. Cell viability was assessed via PI uptake by flow cytometry 




By dual staining hESC with Sytox green and HE, we proved that depletion of 
ROS by Tiron correlated with a decrease in A1-induced cell death (Figure 
6-23), which clearly establishes the essential role of ROS in A1-induced hESC 







































) to hydrogen peroxide
163
, suggesting that the superoxide is the 
form of ROS responsible for A1-induced hESC death. 
 
Figure 6-23: Depletion of ROS production was directly correlated with decreased A1-
induced hESC death. 
Before A1 treatment, cells were treated with PBS- or Tiron (50mM) for 1 hour. Cell death 
(Sytox Green uptake) and ROS production (HE intensity) was quantified by flow cytometry 
analysis. Representative scatter plots are shown. Population in upper right quadrant represents 
dead cells with excess ROS production.  
 
 
6.5.5 Source of A1-induced ROS production in hESC 
Knowing ROS production is essential for A1-induced hESC death, we went on 
to explore the upstream source of A1-induced ROS production in hESC. In 
living cells, ROS can be produced by several sources including endothelial 
nitric oxide synthases, mitochondria (complex I and complex III), xanthine 
oxidase, 5-lipoxygenase and nicotinamide adenine dinucleotide phosphate-
oxidase (NADPH oxidases)
164
. However, the sources of superoxide 
production, which are most dominant and relevant to cell death, would be 
mitochondria and NADPH oxidases. Mitochondria O
2- 
was commonly 


































involved in both apoptosis and oncosis
166
. Another study also reported that an 
initial generation of ROS by NADPH oxidases is needed to trigger the release 
of ROS by other enzymes
167
. Moreover, NADPH oxidase has been reported to 
be the source of GA101-induced ROS production in human B-lymphoma 
cells
76
. Since we have demonstrated that A1 induces hESC death via oncosis, 
we hypothesized that A1 induces ROS production and eventually hESC death 
via the activation of NADPH oxidase.  
NADPH oxidase is a membrane-bound enzyme complex which transfers 
electrons across biological membranes to free oxygen and generate ROS, more 




. There are seven NOX homologues of 
NADPH oxidase, namely Nox1-Nox5, Duox1 and Duox2. Some structural 
properties have been highly conserved among all seven NOX homologues 
(Figure 6-24A): six membrane-spanning domains, four heme-binding 
domains, NADPH-binding sites and FAD binding sites
168
. Despite their 
similarities in structural properties and enzymatic function, NOX homologues 
differ in their mechanism of assembly or activation
169,170
 (Figure 6-24B).  
 
Figure 6-24: Isoforms of NADPH oxidases
168
.  
(A) Conserved structural properties of all seven Nox isoforms of NADPH oxidase; (B) 




The first identified and most thoroughly studied isoform of NADPH oxidase is 
Nox2, or gp91phox. Nox2-NADPH oxidase consists of two membrane-bound 
subunits: Nox2 (glycoprotein, 91 kDa) and p22phox (22 kDa) and at least 
three cytoplasmic subunits: the small GTPase Rac2, p47phox and p67phox
168–
170
. Later studies also identified two more proteins involved in the complex 






Figure 6-25: Assembly and activation of Nox2-NADPH oxidase
164
  
(Left) Before activation: cytosolic components (p67phox, p40phox, p47phox, and Rac-GDP), 
transmembrane components (gp91phox/Nox2, p22phox, and rap1). (Right): After activation: 






Nox2 constitutively interacts with p22phox to form a cytochrome b558 
complex, which is essential for its oxidase activity (Figure 6-25). Activation 
stimuli lead to phosphorylation of p47phox and its subsequent conformational 
change allowing its interaction with p22phox. As an “organizer subunit”, 
localised p47phox then brings the “activator subunit” p67phox into contact 
with Nox2 as well as the small subunit p40phox to the complex. Activation 
stimuli also lead to the activation Rac-GDP to Rac-GTP, allowing 
translocation of Rac-GTP to the plasma membrane to interact with Nox2 and 
p67phox. Upon successful assembly, the active NADPH oxidase complex 
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would transport electrons from cytoplasmic NADPH to extracellular oxygen 
to generate superoxide (O
2-
).  
6.5.5.1 Activity of NADPH oxidase increases upon A1 treatment 
To investigate the involvement of NADPH oxidase in A1-treated hESC death, 
the activity of NADPH oxidase was estimated by measuring NADP/NADPH 
ratio. Upon activation of NADPH oxidase, NADPH will be oxidized to 
NADP
+
 with the production of superoxide. Briefly, hESC were treated with 
A1 or PBS- control and lysed for the extraction of NADPH and NADP
+
. A1-
treated hESC has significantly higher NADP/NADPH ratio than that of non-
treated hESC (Figure 6-26), indicating NADPH oxidase in A1-treated hESC 
are highly active.  
 
Figure 6-26: Increased NADPH oxidase activity in A1-treated hESC.  
Activity of NADPH oxidase as measured via NADP
+
/NADPH ratio in hESC significantly 
increase upon A1 treatment. Data are represented as mean ± SEM. 
 
 
6.5.5.2 Inhibitor of NADPH oxidase partially blocks A1-induced hESC death 
Next, to confirm that NADPH oxidase is responsible for the production of 
superoxide in hESC, three inhibitors of NADPH oxidase, 
Diphenyleneiodonium chloride (DPI), Mycophenolic acid (MPA), and 






















electron from the redox centre of NADPH oxidase and forming a radical 
which then inhibits electron transfer from NADPH to oxygen
175
. MPA 
depletes cellular GTP and consequently inhibits Rac activation
176
. Apocynin 
prevents the assembly of the NADPH oxidase subunits by inhibiting the 
translocation of cytosolic components to plasma membrane
177
. Briefly, cells 
were pre-incubated with inhibitors for 1 hour prior to the addition of A1. For 
the negative control, cells were pre-incubated with the same volume of 
DMSO. After A1 treatment, cell viability in different treatment conditions was 
estimated by PI uptake and normalized to their respective non-A1-treatment 
controls. Pre-treatment with these inhibitors significantly attenuated A1 killing 
on hESC (Figure 6-27).  
 
Figure 6-27: Inhibitors of NADPH oxidase can partially block A1-induced hESC death. 
Before A1 treatment, cells were treated with DMSO or inhibitors of NADPH oxidase (DPI 
240 mM, or Apo 40 mM, or MPA 3.12 mM) for 1 hour. Cell viability in different treatment 
conditions was estimated by PI uptake and normalized to their respective non-A1-treatment 




To confirm that the inhibitors are blocking A1 cytotoxicity on hESC via 
inhibiting NADPH oxidase, hESC were dual stained with Sytox green to 
identify dead cells and HE for ROS production. Decrease in cell death 






































NADPH oxidase is the source of A1-induced ROS production and it is 
essential for A1 to elicit cytotoxicity on hESC. 
 
Figure 6-28: Inhibition of ROS production was directly correlated with decreased A1-
induced hESC death. 
Before A1 treatment, cells were treated with DMSO or inhibitors of NADPH oxidase (DPI 
240 mM, or Apo 40 mM) for 1 hour. Human ESC were dual stained with Sytox green and HE 
to detect cell death and ROS production respectively. Representative scatter plots are shown. 
Population in upper right quadrant represents dead cells with excess ROS production. After 
A1 treatment, hESC with inhibitors treatment have a significant decrease in ROS production 
and cell death. 
 
6.5.5.3 Nox2 is the mediator of A1-induced ROS production and hESC death 
As discussed previously, there are seven isoforms of NADPH oxidase. We 
next explored which isoform or isoforms are responsible for A1-induced ROS 
production. Among the seven isoforms, activation of Nox1, Nox2, and Nox3 
requires the assembly of cytoplasmic and membrane-bound subunits as well as 
Rac activation (Figure 6-24B). On the contrary, activation of other isoforms 
does not involve any cytoplasmic subunits as well as Rac activation. 
Therefore, since both APO and MPA can inhibit ROS production and A1 
killing, their target isoforms are likely to be Nox1-Nox3. Since there is lack of 






























reported to produce ROS in GA101-treated lymphocytes
76
, we first 
investigated whether Nox2 is responsible for A1-induced ROS production.  
Two different siRNAs (siNox2_s3787 and siNox2_s3788) were used to down-
regulate Nox2 expression in hESC. Briefly, prior to transfection, cells were 
pre-incubated with ROCK inhibitor to preserve cell viability. After incubation, 
cells were then dissociated into single-cell suspension and incubated in siNox2 
or scramble siRNA. After 10-15 minutes incubation, the suspension was 
seeded on matrigel-coated plates, maintained with daily fresh mTeSR and 
harvested 4-5 days after transfection for various assays. Firstly, transfection 
efficiency was verified using qRT-PCR and western blotting. Upon siNox2 
transfection, the RNA expression of Nox2 in transfected hESC decreased by 
about 50% compared to hESC transfected with scramble siRNA control 
(Figure 6-29A). Significant reduction of Nox2 protein expression was also 
observed in western blotting (Figure 6-29B).  
 
Figure 6-29: Nox2 expression was partially down-regulated with siNox2.  
(A) Knockdown of Nox2 was confirmed via measured Nox2 RNA expression level by qRT-
PCR. Data are represented as mean ± SEM. (B) Knockdown of Nox2 was confirmed by 


































The expression of pluripotency marker, Tra-1-60, after transfection was also 
determined. There was no difference in the binding of anti-Tra-1-60 antibody 
between siNox2-transfected and scramble control transfected hESC (Figure 
6-30), indicating that expression of pluripotency marker, Tra-1-60, was not 
affected by the knockdown of Nox2.  
 
Figure 6-30: Expression of pluripotency marker Tra-1-60 of hESC was maintained upon 
siNox2 transfection.  
Pluripotency marker expression of hESC (Tra-1-60) upon Nox2 knockdown was confirmed 
via flow cytometry analysis. Representative histograms are shown. Open histogram represents 




Similarly, there was no significant difference observed in A1 binding between 
the two conditions (Figure 6-31), indicating that Nox2 is not an antigen target 
of A1 on hESC.  
 
Figure 6-31: A1 binding was not affected upon Nox2 knockdown.  
2 x 10
5 
siNox2-transfected hESC or hESC with scramble control (100 μl) were treated with 5 
μg of A1 or PBS- control for 45 minutes at 4oC. Binding of A1 was assessed with FITC-
conjugated secondary antibody by flow cytometry analysis. Representative histograms are 



















However, with down-regulation of Nox2 expression, A1-induced hESC death 
was significantly attenuated (Figure 6-32). Increase in the viable cell 
population correlated to the percentage of siNox2-knockdown cells, 
suggesting Nox2 is responsible for A1-induced ROS production and hESC 
death.  
 
Figure 6-32: A1 cytotoxicity on hESC was down-regulated upon Nox2 knockdown.  
siNox2-transfected hESC or scramble control transfected hESC (2 x 10
5 
in 100 μl) were 
treated with 5 μg of A1 or PBS- control for 45 minutes at 4oC. Cell viability was assessed via 
PI uptake by flow cytometry analysis. Data are represented as mean ± SEM. 
 
 
As neither Nox2 knockdown nor inhibition of A1-induced hESC death was 
complete, it is still unclear whether Nox2 is the only mediator of A1-induced 
hESC death. We continued to assess the expression of Nox1 and Nox3 in 
hESC by western blotting and immuno-staining. Nox1 expression was not 
detected in western blotting whereas Nox3 was detected around the predicted 
molecular weight of 51 kDa (Figure 6-33A) and distributed in the cytoplasm 





































Figure 6-33: Expression of Nox1 and Nox3 in hESC.  
(A) Nox3 expression in hESC was detected at 51kDa by western blotting. However, Nox1 
was not detected. (B) Nox3 expression in hESC was detected at cell cytoplasm and plasma 
membrane by immuno-staining, but not Nox1. Nucleus was stained with Hoechst blue. Nox 
proteins were stained with Alexa Fluor-488. 
 
 
To investigate the role of Nox3 in A1-induced hESC death, Nox3 expression 
was down-regulated with siRNA. Transfection efficiency was verified using 
western blotting (Figure 6-34A) and pluripotency (Tra-1-60 expression) of 
hESC after transfection was confirmed using flow cytometry analysis (Figure 
6-34B).  
 
Figure 6-34: Nox3 was partially knockdown in hESC while hESC pluripotency was 
maintained.  
(A) Knockdown of Nox3 was confirmed by western blotting. (B) Pluripotency of hESC (Tra-
1-60) upon Nox2 knockdown was confirmed via flow cytometry analysis. Representative 
histograms are shown. Open histogram represents non-primary antibody control. Shaded 






















Though with similar transfection efficiency as Nox2, down-regulation of Nox3 
did not significantly affect A1 killing on hESC (Figure 6-35), suggesting Nox3 
is not a mediator of A1-induced hESC death.  
 
Figure 6-35: A1 cytotoxicity on hESC was not affected upon Nox3 knockdown.  
siNox3-transfected hESC or scramble control transfected hESC (2 x 10
5 
in 100 μl) were 
treated with 5 μg of A1 or PBS- control for 45 minutes at 4oC. Cell viability after A1 
treatment was assessed via PI uptake. Data are represented as mean ± SEM. 
 
 
6.5.6 Mitochondrial depolarization is a consequence of A1-induced ROS 
production. 
Since NADPH oxidase activity was not completely blocked by either 
inhibitors or siNox2 knockdown, we were unable to prove that Nox2-NADPH 
oxidase is the only source of A1-induced superoxide production. Besides 
NADPH oxidase, excess production of superoxide from mitochondrial after 
mitochondrial membrane permeabilization has been reported in apoptosis
178
. 
Moreover, mitochondrial impairment was also observed in GA101-induced 
lymphocytes death
76
. Therefore, we used potentiometric dye JC-1 to assess 
mitochondrial impairment by measuring mitochondrial depolarization. JC-1 
exhibits potential-dependent accumulation. JC-1 monomers emit green 
fluorescence (~529 nm) whist JC-1 aggregates emit red fluorescence 






























red/green fluorescence intensity ratio. Upon A1 treatment, an increase in 
mitochondrial depolarization was observed (Figure 6-36), indicating A1 
treatment can induce hESC mitochondrial impairment. 
 
Figure 6-36: A1 induced hESC mitochondrial impairment.  
Human ESC (2 x 10
5 
in 100 μl) were treated with 5 μg of A1 or PBS- control for 45 minutes at 
4
o
C. Mitochondrial permeabilization was estimated with JC-1 dye by flow cytometry analysis. 
JC-1 exhibits potential-dependent accumulation. JC-1 monomers emit green fluorescence 
(~529 nm) whist JC-1 aggregates emit red fluorescence (~590 nm). Mitochondrial 
depolarization is indicated by a decrease in the red/green fluorescence intensity ratio. 
Representative scatter plot was shown. Gated population represents cells with mitochondrial 
membrane depolarization.  
 
 
We therefore wanted to know whether mitochondrial membrane 
permeabilization is another source of A1-induced superoxide production. 
However, by down-regulating Nox2 expression in hESC, JC-1 measured 
mitochondrial depolarization was reduced correlating to the attenuation in cell 
death (Figure 6-37), suggesting mitochondrial depolarization is a consequence 
of A1-induced Nox2 activation. Therefore, the mitochondrion is unlikely an 

















Figure 6-37: Mitochondrial depolarization was down-regulated upon Nox2 knockdown. 
Upon A1 treatment, mitochondrial depolarization and cell death (PI uptake) were measured in 
scramble and Nox2-knockdown hESC. JC-1 dye exhibits potential-dependent accumulation in 
mitochondria. JC-1 aggregates emit red fluorescence whereas JC-1 monomers emit green 
fluorescence. Mitochondrial depolarization is indicated by a decrease in the red/green 
fluorescence intensity ratio. Data are represented as mean ± SEM. 
 
 
6.5.7 Summary  
In this section, the role of excess reactive oxygen species (ROS) production in 
A1-induced hESC was studied. First, excess ROS production was detected via 
HE staining by flow cytometry analysis and H2DCFDA staining by 
fluorescent microscopy. By using two ROS scavengers (Tiron and Tempol) 
targeting superoxide, the essential role of excess superoxide production was 
identified. Significant increase in NADPH oxidase activity as well as partially 
inhibited A1 cytotoxicity by NADPH oxidase inhibitors implied that NADPH 
oxidase was the source of A1-induced ROS production, which was 
subsequently confirmed by the knockdown of Nox2 isoform. Moreover, 
mitochondrial impairment was shown to be a consequence of A1-induced 
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6.6 What is the sequence of observed events? 
So far, several events have been observed during A1-induced hPSC death 
including microvilli degradation, homotypic adhesion, actin cytoskeleton re-
organization, plasma membrane damage and ROS production. To have a 
clearer understanding of the killing mechanism, we therefore aimed to 
delineate the order of these observed events. Given the functional significance 
of ROS production in A1-induced hESC death, we were interested to 
investigate where along the oncolytic cell death pathway is ROS production 
effecting.  
6.6.1 A1-induced ROS production occurs downstream of microvilli 
degradation, and upstream of plasma membrane damage  
The effect of ROS depletion on A1-induced morphological changes was 
assessed by SEM. Similar to hESC in PBS- control, Tiron-treated hESC also 
resulted in microvilli degradation upon A1 treatment (Figure 6-38). However, 
Tiron-treated hESC retained a uniform cell size and morphology without 
plasma membrane damage (Figure 6-38), indicating that ROS production lies 





Figure 6-38: ROS production occurs downstream of microvilli degradation, but 
upstream of severe plasma membrane damage.  
Before A1 treatment, 2 x 10
5 
cells (100 μl) were treated with PBS- or Tiron (50 mM) for 1 
hour. Cell morphology was observed under SEM. Representative images are shown. ROS 
depletion by Tiron did not prevent microvilli degradation, but plasma membrane damage after 
A1 treatment.  
 
 
6.6.2 A1-induced ROS production occurs downstream of homotypic 
adhesion 
Next, the effect of ROS depletion by Tiron on A1-induced homotypic 
adhesion was assessed. Tiron treatment did not inhibit homotypic adhesion 
induced by A1 (Figure 6-39), suggesting ROS production occurs down-stream 




















Figure 6-39: ROS depletion by Tiron did not prevent A1-induced homotypic adhesion. 
Before A1 treatment, 2 x 10
5 
cells (100 μl) were treated with PBS- or Tiron (50 mM) for 1 
hour. Homotypic adhesion was viewed under light microscopy. Representative images 
(original magnification x10) are shown. 
 
 
6.6.3 A1-induced ROS production occurs upstream of actin-reorganization 
We then assessed how Tiron and actin inhibitors together would affect A1-
induced ROS production and hESC death. In the presence of Tiron, actin 
inhibitors treatment did not show significant inhibition effect on A1 
cytotoxicity (Figure 6-40).  
 
Figure 6-40: Actin inhibitors treatment did not prevent A1 cytotoxicity on hESC in 
addition to Tiron treatment.  
Human ESC (2 x 10
5 
in 100 μl) were pre-incubated with PBS- or Tiron (50 mM) for 1 hour 
and subsequently the three actin inhibitors: Latrunculin A (4 μg), cytochalasin B (4 μg), or 
cytochalasin D (4 μg) for 5 minutes before A1 treatment. Cell viability was assessed with PI 


















































More importantly, regardless of Tiron, treatment with actin inhibitor did not 
change the amount of ROS production induced by A1 (Figure 6-41), 
indicating ROS production occurs upstream of actin re-organization.  
 
Figure 6-41: Treatment with actin inhibitors did not affect A1-induced ROS production. 
Human ESC (2 x 10
5 
in 100 μl) were pre-incubated with PBS- or Tiron (50 mM) for 1 hour 
and subsequently the three actin inhibitors: Latrunculin A (4 μg), cytochalasin B (4 μg), or 
cytochalasin D (4 μg) for 5 minutes before A1 treatment. ROS production was estimated with 
HE staining by flow cytometry analysis. Data are represented as mean ± SEM. 
 
6.7 Summary 
In this chapter, we elucidated the mechanism of A1-induced hESC death. 
Firstly, in the absence of four apoptosis hallmarks, namely slow killing rate, 
significant DNA fragmentation and elevated activity of caspases and the 
formation of apoptotic bodies, A1-induced hESC death was unlikely the result 
of apoptosis. On the contrary, rapid killing rate, and morphological changes 
such as cell and mitochondria swelling, plasma membrane damage, all pointed 
to oncosis as the cause of hESC killing by A1.  
A1-induced oncosis was initiated by the binding of A1 on hESC surface. 
There was no correlation between A1 distribution and plasma membrane pore 
formation, whilst the A1 aggregates were shown to localize predominantly on 
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formation is not caused by external mechanical forces exerted by A1 binding, 
but more likely to be a result of A1-initiated signalling pathway. The 
minimally required bivalency of A1 (Figure 4-30B) might contribute to the 
signalling pathway by ligating receptors on hESC. Microvilli are likely to be 
the signal initiating sites since the majority of A1 binding was observed on 
surface microvilli.  
In addition, A1-treated hESC exhibited microvilli degradation and homotypic 
adhesion. A close association between A1-induced cell death and actin re-
organization was also unravelled. More importantly, we demonstrated that 
excess reactive oxygen species (ROS), more specifically superoxide, was 
produced upon A1 treatment and it was critical for A1-induced hESC death. 
The source of A1-induced ROS was nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase, most likely Nox2 isoform.  
Moreover, A1-induced ROS production occurs downstream of microvilli 
degradation and homotypic adhesion, but upstream of massive actin re-
organization, mitochondria impairment and plasma membrane damage.  
Taken together, we proposed a mechanistic model of A1-induced hESC death 
(Figure 6-42). Briefly, bivalent A1 binds to surface microvilli of hESC and 
ligates certain antigen receptors to initiate the death signal, which leads to 
microvilli degradation and hESC homotypic adhesion. NADPH oxidase is 
subsequently activated to produce excess ROS (O
2-
). Highly oxidized 
environment leads to massive actin re-organization, mitochondria membrane 
permeabilization and plasma membrane damage. Eventually, cells undergo 
oncosis due to severe cellular damage. To our knowledge, this is the first 




Figure 6-42: Mechanistic model of A1-induced hESC death.  
Ligation of antigen receptors upon A1 binding initiates death signalling which firstly resulted 
in microvilli degradation and homotypic adhesion. Subsequently, excess ROS was produced 
upon the activation of NADPH oxidase, which leads to plasma membrane damage, actin re-
organization, and mitochondrial membrane permeabilization. Eventually, cells undergo 
oncosis due to severe cellular damage. 
  
Bivalent A1 binds and ligates certain antigen receptors to initiate death signal 
Homotypic adhesion (HA)
Elevated ROS (O2-) production by NADPH oxidase
Plasma membrane damage
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7 CHAPTER 7 CONCLUSION, DISCUSSION AND FUTURE 
WORKS 
7.1 Conclusion 
A panel of monoclonal antibodies (mAbs) was raised against hESC to identify 
novel cell surface markers for characterization, enrichment or isolation of 
undifferentiated hESC from differentiated cells.  Interestingly, apart from 
binding, one of our mAbs, mAb84 was also reported to exert a direct cytotoxic 
effect on undifferentiated hESC which can be exploited to eliminate residual 
teratoma-forming hESC after differentiation
34
. Leveraging on this initial 
finding, our group in BTI continued to generate new mAbs and another mAb 
exhibiting this hESC killing property is mAb TAG-A1 (A1). Thus the 
objectives of this thesis were to focus on characterizing mAb A1 in vitro and 
in vivo, and elucidated the mechanism of A1-induced hPSC death.  
In vitro characterization of A1 found that A1 binds to and kills both hESC and 
hiPSC. A1 cytotoxicity is specific to undifferentiated hESC as A1 is unable to 
kill spontaneously differentiated cells via EB formation or FGF-2 starvation. 
This corresponds to the down-regulation of the A1 epitope during 
differentiation. Based on stoichiometry assay, saturated A1 binding (over 3 x 
10
7
 A1 molecules on a single hESC) is essential for maximum killing. The 
minimum valency required for cell killing is 2 (either IgG or F(ab)2)  and the 
Fc region of the mAb do not contribute to cell killing. A1 kills hPSC within 1 
minute in a dosage-dependent manner, which is comparable to mAb84. 
Nevertheless, being five times smaller in size than mAb84, A1 showed better 
penetration efficiency into EB. Therefore, A1 may be a better alternative for 
the removal of residual undifferentiated hPSC in cell aggregates. Although 
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both A1 and mAb84 show strong reactivity to hPSC, there is no competitive 
inhibition between the binding of A1 and mAb84 on hESC. Unlike mAb84 
that binds to glycosylated PODXL, A1 recognizes an O-linked glycan epitope 
expressed on multiple antigens on hESC surface. By inhibition studies, the 
glycan epitope was determined to contain the sugar motif Fucα1-2Galβ1-
3GlcNAcβ1-3Galβ1. This difference in antigen specificity can be explained 
because there are differences in the amino acid sequence of the 6 CDR (3 each 
for variable heavy and variable light chain) which is responsible for antigen 
recognition.  
From in vivo characterization, it was demonstrated that in vitro treatment of 
undifferentiated hESC with A1 just prior to injection into SCID mice was able 
to prevent or delay the onset of teratoma formation in SCID mouse models. 
Extending the study to F(ab)2_A1 and a hESC-binding isotype control, further 
showed that the prevention of teratoma formation in vivo is caused by the 
mAb directly and is independent of ADCC. The in vivo characterization was 
also extended to evaluate the efficiency of in vivo A1 treatment. Here, IgG1 A1 
was directly administered in vivo separate from hESC injection. Like before, 
A1 was able to prevent teratoma formation. Therefore, A1 can potentially be 
administrated either in vitro or in vivo to kill undifferentiated hPSC and 
prevent in vivo teratoma formation in hPSC-based therapy. 
Functional studies were carried out to elucidate the mechanism of A1-induced 
hPSC death. In the absence of the four hallmarks of apoptosis, including slow 
killing rate, formation of apoptotic bodies, DNA fragmentation and elevated 
activity of caspases, it was concluded that A1 was not killing hPSC via 
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apoptosis. Instead, A1 was killing hPSC via oncosis with hallmarks that 
include rapid cell death, cell swelling and plasma membrane damage.  
A1-induced oncosis was initiated by bivalent A1 binding to and ligating 
antigen receptors on hPSC surface. Ligation of antigen receptors does not 
directly form pores throughout the plasma membrane since there was no 
correlation between A1 distribution and plasma membrane pore formation, 
whilst A1 aggregates were found to localize predominantly on fused debris of 
microvilli and damaged plasma membrane. Hence, receptor dimerization was 
more likely initiating a signalling pathway leading to cell death where 
microvilli are likely the signal initiating sites since A1 binding was 
predominantly observed on surface microvilli.  
Upon activation of death signalling, A1-treated hESC undergo microvilli 
degradation and homotypic adhesion at the early stage, followed by excess 
ROS production, which is upstream of massive actin re-organization, 
mitochondrial membrane permeabilization, and severe plasma membrane 
damage. The elevated ROS production is essential for A1-induced hESC 
death, which is produced by NADPH oxidase, most likely Nox2 isoform.  
Taken together, A1 can be utilized in vitro to eliminate undifferentiated hPSC 
from differentiated cell products prior to transplantation, or as a subsequent in 
vivo enhancement, to prevent teratoma formation in vivo. We believe that 
development of stringent removal procedures with A1 alone or in combination 
with other marker-specific antibodies will greatly improve the safety of hPSC-
based therapeutics. Moreover, the first mechanistic model for antibody-
induced hESC oncosis is proposed, which also uncovers the essential role of 
NADPH oxidase-mediated ROS production in A1-induced hESC oncosis. 
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Understanding of A1-induced hESC death pathway will also be helpful in 
optimizing the efficacy of antibody-based elimination of undifferentiated 
hPSC. 
7.2 Discussion and future works 
Despite the increasing success of differentiating hPSC into various lineage-
specific cells and increased clinical trials for the transplantation of hPSC-
derived progenies, the safety concerns of teratoma formation by residual 
undifferentiated hPSC remains to be solved. Prospective approaches, including 
cell sorting with marker-specific antibodies and recently emerged cytotoxic 
agents, are superior to retrospective approaches, as the latter would introduce 
unknown risks by genetic modification and metastatic transformation.  
Following the discovery of cytotoxic mAb84 by our group
32
, Ben-David et 
al.
62
 identified the small molecule, PluriSIn#1, which can selectively kill hPSC 
by inhibiting oleic acid biosynthesis from stearoyl-coA desaturase (SCD1). 
However, based on its mechanism of action, cytotoxicity of PluriSIn#1 may 
not be restricted to hPSC. Although in vitro treatment with PluriSIn#1 
prevented teratoma formation in SCID mouse models, prolonged exposure to 
PluriSIn#1 (~48 hours) may compromise the viability of differentiated cells. 
Moreover, the effectiveness of in vivo treatment with PluriSIn#1 was not 
investigated.  
A1 holds three advantages over PluriSIn#1 in hPSC-based therapy including: 
specific targeting of hPSC, rapid killing rate, and efficiency in preventing or 
delaying tumour formation after in vivo treatment. A1 is also advantageous 
over mAb84 for any hPSC-derived transplants in the form of cell layers or cell 
aggregates. Moreover, to provide the highest level of safety, A1 can be used 
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in combination with other marker-specific antibodies in vitro, or as a 
subsequent dose in vivo. Nevertheless, further optimization is still needed for 
both in vitro treatment and in vivo treatment since a complete elimination of 
teratoma formation was not observed in all the A1 treated SCID mice. For in 
vitro A1 treatment, instead of instantaneous injection after mixing, a longer 
mixing and/or incubation time (around 5 minutes) may increase the efficiency. 
Titration of the antibody dosage may also improve hESC killing. For in vivo 
A1 treatment, IgG1 A1 should be preferred over F(ab)2_A1 to provide a longer 
half-life post-injection and higher local concentration around hESC-containing 
tissue. To improve efficiency, one or more subsequent doses can be injected 
since A1 has no side effects on differentiated cells. Moreover, a combination 
of in vitro and in vivo treatment can also be adopted. 
For the future work, we are aiming to evaluate the efficiency of A1 in 
preventing teratoma formation in 3 different SCID mouse models. First, since 
the ultimate goal is to eliminate undifferentiated hESC from differentiated cell 
products, a differentiated model, which contains a heterogeneous population 
of both differentiated and undifferentiated hESC, would be investigated. 
Differentiation of hESC could either be spontaneous or directed. In vivo A1 
treatment via intramuscular route would be adopted as it has been 
demonstrated to work on the undifferentiated model. Second, as not all the 
undifferentiated hESC can be targeted locally by intramuscular route, we 
would also evaluate the efficiency of delivering A1 via the intravenous (IV) 
route, which is the most commonly adopted route of administration for 
antibody drugs in the market. Comparing to local treatment via IM, a 
significantly larger amount of mAbs is required by IV to achieve similar local 
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concentration upon systemic circulation and diffusion
136
. Moreover, as mAb 
distribution from systemic circulation to the site of cell injection depends on 
the vascularization of the localised area, the timing of antibody administration 
and injection of undifferentiated hESC should be optimized. Third, in addition 
to hESC, in vivo characterization of A1 can be extended to hiPSC to 
demonstrate equivalence in A1 efficacy since the in vitro killing data was 
comparable for both sources of hPSC.  The outcome will greatly benefit the 
field of regenerative medicine because hiPSC is not only an alternate source of 
hPSC, it has a wider applicability catering to patient-specific hiPSC-based 
therapy.  
So far, most of our findings on A1-induced hESC death are consistent with 
previous work carried out on type II anti-CD20 antibody, GA101-induced 
lymphoma cell death
74–76
 (Table 7-1). However, different from A1-induced 
hESC death, GA101 kills lymphoma cell at a slower rate (~4 hours). 
Moreover, actin re-organization in GA101-induced cell death occurs upstream 





Table 7-1: Similarities and differences between GA101 and A1. 
 
Characteristic GA101 A1 
Target cells B-lymphoma cells hESC and hiPSC 
Bivalency-dependent -- 





F(ab)2_A1 kills hESC 
Not apoptosis 
No DNA fragmentation; 
Low caspases activity ; 
Bcl-2 overexpression does 
not affect killing. 
No DNA fragmentation; 
Low caspases activity. 
Antigen(s) CD20 
O-linked glycan epitope on 
multiple proteins 
Killing kinetics Within 4 hours Within 5 minutes 
Increased membrane 
permeability 
PI, 7-AAD, Annexin V, 
FITC 
PI, 7-AAD, Sytox green 
Microvilli degradation -- Observed under SEM 
Homotypic adhesion 
Observed under light 
microscopy 
Observed under light 
microscopy 
Actin re-organization 
F-actin redistribution;  
Inhibitors of actin 
polymerization partially 
blocks GA101 killing. 




F-actin and G-actin 
redistribution;  
Inhibitors of actin 
polymerization partially 
blocks A1 killing.  
Downstream of ROS 
production 
Plasma membrane damage Observed under SEM 
Measured by dextran beads;  
Observed under SEM and 
TEM. 
Mitochondrial impairment 
Measure with JC-1 dye and 
DiOC6 
Measure with JC-1 dye 
Excess ROS production by 
NADPH oxidase 
Excess superoxide 
production from NADPH 
oxidase 
Excess superoxide 






The differences in killing rate and order of actin re-organization might be 
explained by the difference in microvilli characteristics between hESC and 
lymphoma cells. Lymphoma cells have a median microvillar length and 
surface density ranging from 0.3 to 0.4 μm and 2 to 4 microvilli/ μm2,179. 
However, based on our SEM images, microvilli on hESC are generally 2 times 
longer and denser than lymphoma cells. Microvilli have been reported to 
initiate signalling pathways through surface receptors such as receptor-
tyrosine kinase
180
 or G-protein coupled receptors
181
. In A1-induced hESC 
death, binding of the antibody was predominantly observed on surface 
microvilli, suggesting that A1-induced death signalling might be initiated 
through microvilli. Similarly, GA101 might induce death signalling through 
microvilli on lymphoma cells.  
In fact, latrunculin treatment on lymphoma cells was found to result in 
shortening or even disappearance of microvilli
179
. Therefore, in GA101 
studies, prevention of homotypic adhesion, ROS production and eventual 
lymphoma cell death by latrunculin B treatment could possibly be due to the 
lack of microvilli to initiate death-signalling pathway. However, in the case of 
A1, with longer and denser microvilli on hESC, actin inhibitors within a non-
toxic range may not be able to affect signalling through shortening hESC 
microvilli. Therefore, future work could be carried out to investigate how to 
control hESC microvilli structure and hence control A1-induced cell death.  
This hypothesis about signalling through microvilli might also explain the 
difference in the time required for antibody-induced cell death (GA101-
induced lymphoma cell death: 4 hours vs A1-induced hPSC death: 5 minutes) 
145 
 
since theoretically longer and denser microvilli would provide more receptors 
and therefore faster signal amplification.  
Moreover, microvilli are abundant in cellular adhesion proteins. Microvilli 
structure was also shown to be associated with homotypic adhesion of 
lymphoma cells
182
. Therefore, A1-induced re-structuring of microvilli is likely 
to be the cause for the subsequent homotypic adhesion.  
Unlike antibody-dependent cell-mediated cytotoxicity (ADCC), complement-
dependent cytotoxicity (CDC), and antibody-induced apoptosis, antibody-
induced oncosis is a relatively new paradigm. There is still no clear 
understanding on the mechanism of action for different antibodies to induce 
oncosis on different cell types. Therefore, understanding the mechanism of 
A1-induced hESC oncosis would be insightful for the understanding of 
antibody-induced oncosis in general. 
Based on the current findings, we have proposed a model to elucidate the 
mechanism of A1-induced hESC death. This model revealed a previously 
unrecognized role for NADPH oxidase-derived ROS in mediating oncotic 
hESC death. Together with previously reported role of NADPH oxidase-
derived ROS in GA101-induced lymphoma death, it might suggest that 
NADPH oxidase-derived ROS plays a central role in mediating antibody-
induced oncosis in various types of cells. Therefore, combination of A1 with 
ROS–generating reagents could be explored to provide synergistic cell killing. 
Further investigation of this cell death pathway might be helpful in optimizing 
the efficacy of antibody-based elimination of undifferentiated hESC.  
The molecular basis underlying the activation of Nox2-NADPH oxidase upon 
A1 binding to hESC remains to be elucidated. Studies have shown that 
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NADPH oxidase can be activated via different signalling pathways by various 
stimuli, such as growth factors, cytokines, physical stimuli and lipids
183–185
. 
However, all pathways eventually converge at a common passage with the 
phosphorylation of p47phox and the activation of Rac. Therefore, we could 
start the investigation retrospectively by finding out the responsible kinase and 
guanine nucleotide exchange factors (GEFs) in A1-induced Nox2 activation. 
This common passage might also explain why different antibodies targeting 
different cell types can induce ROS production and eventually lead to oncosis.  
Alternatively, we could start the investigation from A1 binding. Based on 
three well-studied pathways of Nox2-NADPH oxidase activation, G-protein 
coupled receptor (GPCR) or receptor tyrosine kinase (RTK) are responsible 
for the signalling transduction across the plasma membrane
172
 (Figure 7-1). 
 
Figure 7-1: Three well-studied pathways of Nox2-NADPH oxidase activation.  
 
  
Activation of GPCR or RTK requires ligand binding mediated conformational 
change or dimerization. Although we have demonstrated that membrane pore 
is not directly formed by antigen oligomerization, bivalency-dependent 
cytotoxicity of A1 might be associated with antigen conformational change or 
dimerization. In the support of this hypothesis, bivalent antibody-induced 
activation of GPCR
186
 and RTK have been reported
187
. A previous study has 
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reported that neutralization of Herpes simplex virus (HSV) is dependent on 
bivalent antibody crosslinking antigen trimmers on the virus
126
. Moreover, 
based on our previous study on engineered mAb84 fragments, antibody 
cytotoxicity appears to depend not only on bivalency, but also on the specific 
interaction between mAb and target, since bivalent scFv84-HTH was able to 
recapitulate the cytotoxicity of mAb84 on hESC whereas scFv84-diabody was 
not cytotoxic
33
. The specificity of antibody-antigen interaction was also 
observed in anti-CD20 antibodies as demonstrated that even with overlapping 
epitope, type I and II anti-CD20 mAbs evoke different modes of lymphoma 
cell death
188
. The same study suggested that the specificity is caused by 
differences in the orientation of antibody-antigen binding and the resultant 
membrane compartmentalization of antigen dimers. Therefore, it is imperative 
to identify the complete epitope that A1 recognizes so as to further understand 
how the signalling cascade is triggered. Since A1 recognizes glycans on 
multiple proteins, we also need to delineate whether one or multiple types of 
receptors trigger the signalling cascade.  
NADPH oxidases are membrane-bound and can be found at different 
subcellular locations. The 2 major sites of Nox2-NADPH oxidases are plasma 
membrane
189,190
 and lysosomal/endosomal membrane
191–193
. Since targeting to 
specific subcellular site is required for localised ROS production, knowing the 
site of A1-induced ROS production could provide us an insight to understand 
the activation pathway of NADPH oxidase as well. Plasma membrane-bound 
NADPH oxidases orientate in the way that the electron transfers from 
cytoplasmic NADPH to oxygen on the extracellular side of the plasma 
membrane (Figure 6-25). Superoxide generated in the extracellular domain 
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requires time to diffuse into intracellular space and would also be instantly 
diluted with a much larger assay volume, therefore unlikely can induce a rapid 
and drastic killing. Moreover, superoxide released into the extracellular 
domain would result in a homogeneously oxidized environment for all cells in 
the assay, which contradicts to the direct correlation between cell death and 
ROS production. To achieve direct and rapid cell killing, superoxide is more 
likely produced in an intracellular compartment, such as lysosomal membrane 
or endosomal membrane. Since lysosomal/endosomal membrane is formed 
from phagocytosis/endocytosis of plasma membrane (Figure 7-2), NADPH 
oxidase orients in the opposite way so that superoxide is produced into the 
lumen of lysosome and endosome.  
 






Lysosomal-produced ROS has been implicated in different cell death 
pathways, including apoptosis, oncosis and autophagic cell death
195,196
. 
Studies have also reported the link between superoxide production and 
lysosome membrane permeabilization (LMP), though it appears that 





whether there is LMP in A1-treated hESC and how is LMP linked to A1-
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